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A B S T R A C T
Background
Chronic obstructive pulmonary disease (COPD) is associated with cough, sputum production or dyspnoea, and a reduction in lung
function, quality of life, and life expectancy. Apart from smoking cessation, no other treatments that slow lung function decline are
available. Roflumilast and cilomilast are oral phosphodiesterase-4 (PDE4) inhibitors proposed to reduce the airway inflammation and
bronchoconstriction seen in COPD. This Cochrane Review was first published in 2011, and was updated in 2017 and 2020.
Objectives
To evaluate the eKicacy and safety of oral PDE4 inhibitors for management of stable COPD.
Search methods
We identified randomised controlled trials (RCTs) from the Cochrane Airways Trials Register (date of last search 9 March 2020). We found
other trials at web-based clinical trials registers.
Selection criteria
We included RCTs if they compared oral PDE4 inhibitors with placebo in people with COPD. We allowed co-administration of standard COPD
therapy.
Data collection and analysis
We used standard Cochrane methods. Two independent review authors selected trials for inclusion, extracted data, and assessed risk
of bias. We resolved discrepancies by involving a third review author. We assessed our confidence in the evidence by using GRADE
recommendations. Primary outcomes were change in lung function (minimally important diKerence (MID) = 100 mL) and quality of life
(scale 0 to 100; higher score indicates more limitations).
Main results
We found 42 RCTs that met the inclusion criteria and were included in the analyses for roflumilast (28 trials with 18,046 participants) or
cilomilast (14 trials with 6457 participants) or tetomilast (1 trial with 84 participants), with a duration between six weeks and one year or
longer. These trials included people across international study centres with moderate to very severe COPD (Global Initiative for Chronic
Obstructive Lung Disease (GOLD) grades II to IV), with mean age of 64 years.
We judged risks of selection bias, performance bias, and attrition bias as low overall amongst the 39 published and unpublished trials.
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)
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Lung function
Treatment with a PDE4 inhibitor was associated with a small, clinically insignificant improvement in forced expiratory volume in one second
(FEV1) over a mean of 40 weeks compared with placebo (mean diKerence (MD) 49.33 mL, 95% confidence interval (CI) 44.17 to 54.49;
participants = 20,815; studies = 29; moderate-certainty evidence). Forced vital capacity (FVC) and peak expiratory flow (PEF) were also
improved over 40 weeks (FVC: MD 86.98 mL, 95% CI 74.65 to 99.31; participants = 22,108; studies = 17; high-certainty evidence; PEF: MD
6.54 L/min, 95% CI 3.95 to 9.13; participants = 4245; studies = 6; low-certainty evidence).
Quality of life
Trials reported improvements in quality of life over a mean of 33 weeks (St George's Respiratory Questionnaire (SGRQ) MD -1.06 units, 95%
CI -1.68 to -0.43; participants = 7645 ; moderate-certainty evidence).
Incidence of exacerbations
Treatment with a PDE4 inhibitor was associated with a reduced likelihood of COPD exacerbation over a mean of 40 weeks (odds ratio
(OR) 0.78, 95% CI 0.73 to 0.84; participants = 20,382; studies = 27; high-certainty evidence), that is, for every 100 people treated with PDE4
inhibitors, five more remained exacerbation-free during the study period compared with those given placebo (number needed to treat for
an additional beneficial outcome (NNTB) 20, 95% CI 16 to 27). No change in COPD-related symptoms nor in exercise tolerance was found.
Adverse events
More participants in the treatment groups experienced an adverse eKect compared with control participants over a mean of 39 weeks (OR
1.30, 95% CI 1.22 to 1.38; participants = 21,310; studies = 30; low-certainty evidence). Participants experienced a range of gastrointestinal
symptoms such as diarrhoea, nausea, vomiting, or dyspepsia. Diarrhoea was more commonly reported with PDE4 inhibitor treatment
(OR 3.20, 95% CI 2.74 to 3.50; participants = 20,623; studies = 29; high-certainty evidence), that is, for every 100 people treated with PDE4
inhibitors, seven more suKered from diarrhoea during the study period compared with those given placebo (number needed to treat for
an additional harmful outcome (NNTH) 15, 95% CI 13 to 17). The likelihood of psychiatric adverse events was higher with roflumilast 500
µg than with placebo (OR 2.13, 95% CI 1.79 to 2.54; participants = 11,168; studies = 15 (COPD pool data); moderate-certainty evidence).
Roflumilast in particular was associated with weight loss during the trial period and with an increase in insomnia and depressive mood
symptoms.
Participants treated with PDE4 inhibitors were more likely to withdraw from trial participation; on average, 14% in the treatment groups
withdrew compared with 8% in the control groups.
Mortality
No eKect on mortality was found (OR 0.98, 95% CI 0.77 to 1.24; participants = 19,786; studies = 27; moderate-certainty evidence), although
mortality was a rare event during these trials.
Authors' conclusions
For this current update, five new studies from the 2020 search contributed to existing findings but made little impact on outcomes
described in earlier versions of this review.
PDE4 inhibitors oKered a small benefit over placebo in improving lung function and reducing the likelihood of exacerbations in people with
COPD; however, they had little impact on quality of life or on symptoms. Gastrointestinal adverse eKects and weight loss were common,
and the likelihood of psychiatric symptoms was higher, with roflumilast 500 µg.
The findings of this review provide cautious support for the use of PDE4 inhibitors in COPD. In accordance with GOLD 2020 guidelines,
they may have a place as add-on therapy for a subgroup of people with persistent symptoms or exacerbations despite optimal COPD
management (e.g. people whose condition is not controlled by fixed-dose long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS)
combinations). More longer-term trials are needed to determine whether or not PDE4 inhibitors modify FEV1 decline, hospitalisation, or
mortality in COPD.
P L A I N   L A N G U A G E   S U M M A R Y
Phosphodiesterase-4 inhibitors for people with chronic obstructive pulmonary disease (COPD)
Background
COPD is a progressive lung condition caused by damage from harmful chemicals breathed in and is predominantly seen in people who
smoke tobacco. These chemicals cause inflammation and lung damage and increase mucus production in the lungs. This leads to periods
of breathlessness and coughing called exacerbations (or flare-ups). Exacerbations make it harder for people to do their day-to-day tasks.
Exacerbations become more frequent and severe over time. People vary in terms of how they are aKected by COPD. This is related in part to
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
the severity of the disease but also to diKerences in response to medicines, as well as fitness and co-existent conditions. For most people,
the only way to prevent further lung damage is to stop smoking.
Medicines prescribed to manage COPD generally aim to improve symptoms, reduce exacerbations, or both. In early stages, taking
bronchodilators makes breathing easier by relaxing muscles in the lungs and widening airways, allowing more air to move freely into and
out of the lungs.
Some long-acting agents may reduce exacerbations. For example, steroid inhalers reduce inflammation in the lungs and thus modestly
reduce the number of exacerbations.
Phosphodiesterase-4 (PDE4) inhibitors are a relatively new class of medicines marketed to improve COPD. They have both bronchodilator
and anti-inflammatory eKects. Two currently available medicines - roflumilast and cilomilast - are taken as a tablet. We collated and
analysed results of existing trials to define the benefits and risks of PDE4 inhibitors in COPD.
Key results
Data analysis included 42 studies in 24,587 adults with moderate to very severe disease who discontinued other regular COPD medications.
Some trials allowed people to carry on using their usual COPD medicines. Most trials were funded by manufacturers of PDE4 inhibitors.
PDE4 inhibitors provided a small benefit in improving lung function measurements (forced expiratory volume in one second (FEV1), forced
vital capacity (FVC), and peak expiratory flow (PEF)). PDE4 inhibitors also reduced the likelihood of COPD-related exacerbations. We found
that 28 out of 100 people taking PDE4 inhibitors every day for a year would experience at least one exacerbation, which was five fewer than
for people who did not receive these medicines.
PDE4 inhibitors provided a small benefit in reducing breathlessness and improving quality of life. Around 5% to 10% of people who received
roflumilast or cilomilast reported side eKects such as diarrhoea, nausea, and vomiting. We expected that 11 out of 100 people taking PDE4
inhibitors every day for 39 weeks would experience an episode of diarrhoea, which was seven more than for those not receiving PDE4
inhibitors. We found that 7 people out of 100 were likely to experience a psychiatric event with roflumilast 500 µg. A two- to three-fold
increase in risk of sleep or mood disturbance was found with roflumilast 500 μg, although overall the total number of reported incidents
was low. There was no eKect on death rates. EKects were the same regardless of the severity of COPD, or whether other medicines for
COPD were being taken.
Quality of the evidence
We were moderately certain about data for lung function and quality of life. We were highly certain of evidence for side eKects such as
diarrhoea and of data for exacerbations.
Results seen in trials published in journals by pharmaceutical companies show greater benefit of these medicines than those that were
unpublished. Psychiatric adverse eKects data remain unpublished.
Conclusions
We support the use of PDE4 inhibitors for COPD, but with caution. PDE4 inhibitors provided a small benefit in improving lung function and
reducing the likelihood of COPD exacerbations, but they had little impact on quality of life and COPD symptoms. Side eKects including
diarrhoea and weight loss were common.
PDE4 inhibitors may be best used as add-on therapy for a subgroup of people with persistent symptoms or exacerbations despite otherwise
optimal COPD management (e.g. people whose condition was not controlled on fixed-dose long-acting beta2-agonist (LABA) and inhaled
corticosteroid (ICS) combinations). This is in accordance with GOLD 2020 guidelines. Longer-term trials are necessary to get a more accurate
estimate of the benefits and safety of these medicines over time, including determining whether they slow COPD disease progression.
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)



















































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Phosphodiesterase-4 inhibitors compared to placebo for chronic obstructive pulmonary disease
Phosphodiesterase-4 inhibitors compared to placebo for chronic obstructive pulmonary disease
Patient or population: people with stable chronic obstructive pulmonary disease
Setting: community-based, randomised, parallel, double-blind, placebo-controlled trials
































This is an overall analysis of the outcome that
includes roflumilast 250 µg, roflumilast 500 µg,
cilomilast 15 mg, and tetomilast 50 µg
MID for FEV1 is 100 mL
Change in FVC











This is an overall analysis of the outcome that
includes roflumilast and cilomilast studies
Change in PEF











This is an overall analysis of the outcome that
includes roflumilast and cilomilast studies
Change in SGRQ total score














This is an overall analysis of the outcome that
includes roflumilast 500 µg, roflumilast 250
µg, and cilomilast 15 mg. Lower scores on the
SGRQ represent improved quality of life. The
MID for this scale is a change of 4 units. This re-
sult does not reach the MID for this scale (0 to
100; higher scores indicate more limitations)
Number of participants with 1
or more exacerbations
Follow-up: weighted mean 40
weeks








This is an overall analysis of the outcome that
includes roflumilast 500 µg, cilomilast 15 mg,













































































































































Number of participants expe-
riencing an adverse event
Follow-up: weighted mean 39
weeks








This is an overall analysis of the outcome that
includes roflumilast 500 µg, cilomilast 15 mg,
and tetomilast 50 µg, and participants who




Follow-up: weighted mean 39
weeks








This is an overall analysis of the outcome that
includes roflumilast 500 µg, cilomilast 15 mg,
and tetomilast 50 µg. Diarrhoea was the most
commonly reported gastrointestinal side ef-
fect. See Figure 4. Weight loss was more com-
mon and may be a result of diarrhoea
Psychiatric adverse effects
(roflumilast 500 µg)
Follow-up: 6 to 52 weeks








Pooled data from FDA website, not individual
trial reports
Mortality
Follow-up: weighted mean 40
weeks








This is an overall analysis of the outcome that
includes roflumilast 500 µg, cilomilast 15 mg,
and tetomilast 50 µg
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; COPD: chronic obstructive pulmonary disease; FDA: US Food and Drug Administration; FEV1: forced expiratory volume in 1 second; FVC: forced vital
capacity; MD: mean difference; MID: minimally important difference; OR: odds ratio; PEF: peak expiratory flow; PDE4: phosphodiesterase-4 inhibitor; RCT: randomised con-
trolled trial; RR: risk ratio; SGRQ: St George's Respiratory Questionnaire.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aThe outcome was downgraded by 1 point due to moderate heterogeneity across studies (I2 = 30% to 60%).
bAlthough some publication bias was found on further investigation through a sensitivity analysis, we did not consider the removal of studies suspected of publication bias to
have a large enough impact on the overall eKect estimate and CIs. Therefore, we did not downgrade for publication bias.
cThe outcome was downgraded by 2 points due to substantial heterogeneity across studies (I2 = 50% to 90%).
dBased on data from the combined COPD safety pool. Individual study data not obtained.















































































































































Figure 4.   Funnel plot of comparison: 1 PDE4 inhibitor versus placebo (2020 update), outcome: 1.1 FEV1 (by drug) [mL].
















































































Cochrane Database of Systematic Reviews
B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is one of the leading
causes of global morbidity and mortality, resulting in a growing
social and economic burden (GOLD 2020). In 2002, COPD was
estimated to be the fiWh leading cause of death, responsible for
approximately 4.8% of total deaths worldwide, and it is projected
to rise to fourth position by the year 2030 (Mathers 2005).
COPD is an overarching term that includes two lung conditions:
chronic bronchitis and emphysema. These lung conditions cause
narrowing of the airways and overinflation of the alveoli, leading
to diKiculty in breathing. Diagnosis of COPD by the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) says that
it is a "heterogeneous disease that is characterized by persistent
respiratory symptoms and airflow limitation that is due to
airway and/or alveolar abnormalities usually caused by exposure
to noxious particles or gases and influenced by host factors
including abnormal lung development" (GOLD 2020). COPD may
be punctuated by periods of acute worsening of respiratory
symptoms, called exacerbations. Besides exposures, host factors
predispose individuals to develop COPD. Comorbidities contribute
to overall severity and mortality in individual people (GOLD
2020). Diagnosis is based on a history of exposure to risk
factors for this disease and symptoms of cough and sputum
production or dyspnoea (shortness of breath). Spirometry is
required for diagnosis, with airflow obstruction confirmed by
a post-bronchodilator forced expiratory volume in one second
(FEV1)/forced vital capacity (FVC) of 0.7 or lower (Celli 2004). Life
expectancy is reduced among people diagnosed with COPD, and
although prognosis is variable, age and FEV1 are the strongest
predictors of mortality.
The predominant risk factor for COPD is tobacco smoking, with
other environmental pollutants also known to contribute. Cigarette
smoke leads to activation of macrophages and CD8 T lymphocytes
that release inflammatory mediators and cytokines. The process
also involves neutrophil attraction and cell apoptosis (Barnes
2000). To date, smoking cessation is the only intervention known
to slow the decline in lung function associated with COPD (GOLD
2020).
Pharmacotherapy is commonly used to treat people with COPD,
with eKects on symptoms, quality of life, or frequency and severity
of exacerbations (Celli 2004; GOLD 2020). Mainstays of treatment
include short- and long-acting inhaled beta2-agonists (LABAs)
and anticholinergics, corticosteroids, and methylxanthines. Triple
therapy with inhaled corticosteroids, LABAs, and long-acting
muscarinic antagonists (LAMAs) can improve FEV1, reduce
exacerbations, and improve patient-reported outcomes (GOLD
2020). New approaches to treatment are needed, as no individual
agent slows the decline in lung function or survival. In the TORCH
study (Calverley 2007), a combination of salmeterol 50 μg and
fluticasone 500 μg twice daily reduced the risk of death by 17%
compared with placebo over the three-year trial period; however,
this finding did not reach the pre-defined level of statistical
significance for the study.
An exacerbation of COPD is an acute and sustained increase in
symptoms that results in the need for additional therapy (GOLD
2020). Risk of exacerbation is significantly increased in more severe
cases of COPD. Exacerbations have a negative impact on quality of
life and lead to more rapid COPD progression, as well as to higher
healthcare utilisation and associated costs. A greater impact on
health is seen in a subgroup of people with COPD who are more
susceptible to exacerbations (defined as "frequent exacerbators"),
who have at least two treated exacerbations per year (Le Rouzic
2018).
Common triggers are respiratory viral infection, bacterial infection,
and air pollution (Wedzicha 2007; White 2003), which may lead
to increased airway inflammation, production of mucus, acute
deterioration in lung function, hyperinflation from gas trapping,
or a combination of these symptoms (Van GeKen 2015). These
processes contribute to symptoms of increased dyspnoea and
cough, as well as to changes in the character or volume of sputum.
Description of the intervention
The intervention is an oral medicine that is a selective inhibitor
of the isoenzyme phosphodiesterase-4 (PDE4). This isoenzyme has
a role in airway inflammation and bronchoconstriction, both of
which are pathological features of COPD (Boswell-Smith 2006). Two
medicines in this class that have been studied are roflumilast and
cilomilast.
How the intervention might work
Cyclic adenosine monophosphate  (cAMP) is a secondary
messenger that suppresses the activity of inflammatory cells
and mediates the process of smooth muscle relaxation in the
airways. Phosphodiesterases, in turn, hydrolyse and turn oK
the biological activity of cAMP (Boswell-Smith 2006). Therefore,
inhibitors of phosphodiesterase action should theoretically provide
improvements in the extent of airway narrowing and damage from
inflammation.
Non-selective phosphodiesterase (PDE) inhibitors such as
theophylline, a methylxanthine, have been used for years for
treatment of people with COPD. These are recommended by
current international guidelines as part of adjunctive therapy
to long-acting bronchodilators (GOLD 2020). Limitations to their
use include a narrow therapeutic margin and the frequency of
adverse eKects, which may occur even when the plasma level
is within the therapeutic range (Boswell-Smith 2006). Common
adverse eKects associated with theophylline include headache,
nausea, vomiting, diarrhoea, restlessness, nervousness, insomnia,
and gastrointestinal eKects (Barnes 2003). Less common, but
more serious, are increased risks of cardiac arrhythmia and
seizure (Barnes 2003). Some of the adverse eKects associated
with theophylline have been attributed to its non-selective PDE
inhibition and concurrent adenosine receptor antagonism (Barnes
2005).
The isoenzyme PDE4 is the predominant isoenzyme involved in
metabolising cAMP in immune and inflammatory immune cells,
such as neutrophils, macrophages, T cells, and endothelial cells
in COPD; and in airway smooth muscle and pulmonary nerves
(Agusti 2005; Boswell-Smith 2006; Torphy 1998; Vignola 2004).
Inhibition of PDE4 leads to elevation of cAMP in inflammatory and
immunomodulatory cells, resulting in suppression of inflammatory
cell function, relaxation of airways smooth muscle, and modulation
of pulmonary nerves (Boswell-Smith 2006; Essayan 2001; Torphy
1999). Thus, PDE4 is an attractive target for inhibition in COPD.
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Furthermore, central nervous system (CNS) and cardiovascular
adverse eKects experienced by patients treated with the non-
selective PDE inhibitor, theophylline, are the result of adenosine
receptor antagonism. This feature is not present with PDE4-specific
inhibitors (Vignola 2004).
Why it is important to do this review
The development of selective PDE4 inhibitors oKers new hope
for therapy oKering both anti-inflammatory and bronchodilatory
eKects in COPD, with fewer of the adverse eKects encountered with
non-selective inhibitors. Additionally, PDE4 inhibitors may be easier
to use because they provide less pharmacokinetic variability and
lower potential for drug interactions compared with theophylline
(Barnes 2005).
Several PDE4 inhibitors have been developed, with some
progressing to phase 3 clinical trials. These include the second-
generation PDE4 inhibitors roflumilast (Nycomed, formerly Altana)
and cilomilast (GlaxoSmithKline).
Earlier studies of roflumilast have shown significant improvement
in pre-bronchodilator FEV1 and reduced annual rates of
exacerbation among people with severe to very severe COPD who
also have chronic bronchitis (Calverley 2009). Roflumilast may
be considered in people taking triple inhaled therapy who still
have exacerbations, FEV1 less than 50% predicted, and chronic
bronchitis, especially if they have had a hospitalisation in the last
year (GOLD 2020).
This review update focuses on eKects of PDE4 inhibitors for
treatment of people with stable COPD, using clinically important
outcomes. Collating this evidence into a systematic review allows
an assessment as to whether or not the theoretical benefits of
PDE4 inhibitors translate into useful clinical eKects, and may
suggest the potential place of PDE4 inhibitors within the increasing
pharmacopoeia of COPD treatments.
O B J E C T I V E S
To evaluate the eKicacy and safety of oral PDE4 inhibitors for
management of stable COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) that compared
orally administered PDE4 inhibitors with placebo. We included any
long-term treatment trials but excluded single-dose trials, as well
as trials in acute exacerbations of COPD. We also excluded cross-
over trials to reduce non-random sources of bias between studies.
Types of participants
Adults (over 18 years of age) with COPD, as defined by the American
Thoracic Society, the European Respiratory Society, or GOLD, with
airflow obstruction evident by spirometry with post-bronchodilator
FEV1/FVC of 0.7 or less (GOLD 2020). We considered trials that
included participants with both COPD and asthma only if data from
participants with COPD could be extracted separately from the
study report or through correspondence with the study authors. We
excluded ex vivo experiments and trials with participants requiring
mechanical ventilation on presentation.
Types of interventions
We included trials if they compared outcomes for participants
who received an orally administered PDE4 inhibitor with those for
control participants who received placebo.
Types of outcome measures
Primary outcomes
• Changes in lung function from baseline including forced
expiratory volume in one second (FEV1), forced vital capacity
(FVC), or peak expiratory flow (PEF)
• Quality of life (e.g. total score on St George's Respiratory
Questionnaire (SGRQ))
Secondary outcomes
• Incidence of COPD exacerbations
• Symptoms (breathlessness on Borg and other scales and
Shortness of Breath Questionnaire; composite measures
(summary symptom score))
• Exercise tolerance (six-minute walk test)
• Adverse events (number of participants experiencing one or
more adverse event, e.g. gastrointestinal, central nervous
system (CNS), and cardiovascular adverse events; change in
weight; withdrawal rates)
• Serious adverse events
• Mortality
Search methods for identification of studies
Electronic searches
The previously published version included searches up to October
2016. We updated the search for this version from 2016 to 9 March
2020.
We identified trials from the Cochrane Airways Trials Register
(Cochrane Airways 2019), which is maintained by the Information
Specialist for the Group. The Cochrane Airways Specialised Register
contains studies identified from several sources.
• Monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL), in the Cochrane Library, through the Cochrane
Register of Studies Online (crso.cochrane.org).
• Weekly searches of MEDLINE Ovid SP 2016 to March 2020.
• Weekly searches of Embase Ovid SP 2016 to March 2020.
• Monthly searches of PsycINFO Ovid SP 2016 to March 2020.
• Monthly searches of the Cumulative Index to Nursing and Allied
Health Literature (CINAHL) EBSCO 2016 to March 2020.
• Monthly searches of the Allied and Complementary Medicine
Database (AMED) EBSCO.
• Handsearches of proceedings of major respiratory conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference
proceedings, are provided in Appendix 1. See Appendix 2 for search
terms used to identify studies for this review.
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We also searched the following trials registries.
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov/).
• World Health Organization International Clinical Trials Registry
Platform (apps.who.int/trialsearch/).
We searched the Cochrane Airways Trials Register and additional
sources to March 2020, with no restriction on language or type of
publication. The original strategy for this review, which was more
sensitive but less specific, is provided in Appendix 3.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references and the websites of clinical
trials registries for unpublished trial data. We searched relevant
manufacturers' websites for study information and PubMed for
errata or retractions from included studies published in full text
(www.ncbi.nlm.gov/pubmed).
Data collection and analysis
Selection of studies
Two review authors (SJ, RF) independently screened the titles and
abstracts of search results and coded them as 'retrieved' (eligible
or potentially eligible/unclear) or 'did not retrieve'. We retrieved
the full-text study reports of all potentially eligible studies, and two
review authors (SJ, RF) independently screened them for inclusion,
recording reasons for exclusion of ineligible studies. We resolved
any disagreements through discussion. We identified and excluded
duplicates and collated multiple reports of the same study, so that
each study, rather than each report, was the unit of interest in the
review. We recorded the selection process in suKicient detail to
complete a PRISMA flow diagram and Characteristics of excluded
studies table (Moher 2009). We categorised references according to
trial name (by drug name and number, or by author and year).
Data extraction and management
For the current update, we used an Excel spreadsheet to extract
data and assess risk of bias for each included study. One review
author (SJ) extracted data on characteristics of included studies
(methods, participants, interventions, outcomes) and results of the
included studies. We contacted sponsors of the included studies for
unpublished data and searched the sponsor's website for further
details of outcomes if needed.
We extracted the following data.
• Methods: study design, total duration of study, details of any
'run-in' period, number of study centres and locations, study
setting, withdrawals, and date of study.
• Participants: N, mean age, severity of condition, baseline lung
function, inclusion criteria, and exclusion criteria.
• Interventions: intervention, comparison, concomitant
medications, and excluded medications.
• Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
• Notes: funding for studies and notable conflicts of interest of trial
authors.
Two review authors (SJ, RF) independently extracted outcome
data from the included studies. We noted in the Characteristics
of included studies table if outcome data were not reported in a
useable way. We resolved any disagreements by consensus. One
review author (SJ) transferred data into the Review Manager 5
file (RevMan 2014). We double-checked that data were entered
correctly by comparing data presented in the systematic review
against the study reports. A third review author (PP) spot-checked
study characteristics for accuracy against the study report.
Assessment of risk of bias in included studies
Two review authors (SJ, RF) independently assessed risk of bias for
each study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2019). We resolved
disagreements by discussion. We assessed risk of bias according to
the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We judged each potential source of bias as high, low, or unclear,
and we provided a quote from the study report together with
a justification for our judgement in the 'Risk of bias' table. We
summarised 'Risk of bias' judgements across diKerent studies for
each of the domains listed. We considered blinding separately for
diKerent key outcomes when necessary. When information on risk
of bias related to unpublished data or correspondence with trialists,
we noted this in the 'Risk of bias' table.
When considering treatment eKects, we took into account the risk
of bias for studies that contributed to that outcome.
Assessment of bias in conducting the systematic review
We conducted the review according to the published protocol and
justified any deviations from it in the DiKerences between protocol
and review section of this systematic review.
Measures of treatment e:ect
The outcomes included in this review were either dichotomous or
continuous. For dichotomous outcomes, we recorded the number
of participants with one or more outcome events by allocated
treatment group.
We undertook meta-analyses only when this was meaningful,
that is, when treatments, participants, and the underlying clinical
question were similar enough for pooling to make sense. We
expressed results for pooled outcomes with dichotomous variables
using a fixed-eKect odds ratio (OR) with 95% confidence interval
(CI). Results for continuous variables were expressed as mean
diKerences (MDs) using a fixed-eKect or standardised mean
diKerence (SMD), with 95% CI. We considered a P value less than
0.05 statistically significant. We combined rate ratios on a natural
logarithm scale and weighted them by the inverse of the variance
of the log rate ratio. We used intention-to-treat or 'full analysis set'
analyses when they were reported (i.e. analyses for which data had
been imputed for participants who were randomly assigned but
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did not complete the study) instead of completer or per-protocol
analyses.
For change in FEV1, we used 100 mL as the minimally important
diKerence (MID). For SGRQ, the scale was measured from 0 to 100,
with higher scores indicating more limitations. A change in score of
4 units was considered as the MID.
We presented the data as forest plots when possible to show size
and direction of eKect for treatments with 95% CIs (certainty) using
Review Manager 5 (RevMan 2014).
When a single study reported multiple trial arms, we included only
the relevant arms. We reported details of the additional arms in the
Characteristics of included studies table. When two comparisons
(e.g. intervention A versus placebo and intervention B versus
placebo) are combined in the same meta-analysis, we will combine
the active arms or will halve the control group to avoid double-
counting.
If adjusted analyses were available (ANOVA or ANCOVA), we used
these as a preference in our meta-analyses. If both change from
baseline and endpoint scores were available for continuous data,
we used change from baseline unless there was low correlation
between measurements among participants. If a study reported
outcomes at multiple time points, we used the latest time point.
If studies reported post-treatment follow-up, we extracted this
information and reported it narratively.
Unit of analysis issues
For dichotomous outcomes, we used participants, rather than
events, as the unit of analysis (e.g. number of participants
experiencing an adverse event rather than the number of adverse
events). However, if a study reported rate ratios, we analysed them
on this basis.
Dealing with missing data
We contacted the respective pharmaceutical companies for missing
trial data. In particular, Nycomed and Forest Laboratories provided
us with some study details and results extracted from published
articles and abstracts that were not identified in our initial search.
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study was identified as an abstract
only). When this was not possible, and missing data were thought
to introduce serious bias, we took this into consideration when
performing the GRADE assessment for aKected outcomes.
Assessment of heterogeneity
We used the I2 statistic, along with P values (Higgins 2003), to
measure heterogeneity among the trials in each analysis. For I2, we
employed the following criteria.
• 0% to 40%: might not be important.
• 30% to 60%: may represent moderate heterogeneity.
• 50% to 90%: may represent substantial heterogeneity.
• 75% to 100%: considerable heterogeneity.
In the case of substantial heterogeneity, we reported it and
explored possible causes by conducting pre-specified subgroup
analysis.
Assessment of reporting biases
We compared available published outcomes with prescribed
methods and, when available, original study protocols. If we were
able to pool more than 10 studies, we created and examined a
funnel plot to explore possible small-study and publication biases.
Data synthesis
We used a fixed-eKect model and performed a sensitivity analysis
by using a random-eKects model.
'Summary of findings' tables
We assessed the certainty of evidence for change in FEV1
lung function, change in quality of life, COPD exacerbations,
adverse events, diarrhoea, and all-cause mortality. We conducted
assessments according to recommendations put forth by the
GRADE Working Group (Guyatt 2008) and presented in Summary
of findings 1 . We used the five GRADE considerations (risk of bias,
consistency of eKect, imprecision, indirectness, and publication
bias) to assess the quality of a body of evidence related to studies
that contributed data for the pre-specified outcomes. We used
the methods and recommendations described in Higgins 2019,
employing GRADEpro GDT soWware (GRADEpro GDT 2015). We
justified all decisions to downgrade the certainty of evidence
by using footnotes and made comments to aid the reader's
understanding of the review when necessary. We applied the
clinical importance of results using published minimal important
diKerences (MIDs), when available (e.g. SGRQ has well-established
MIDs in the literature).
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
• Severity of airflow obstruction at baseline (FEV1 % predicted
GOLD grade II 50% to 80%, grade III 30% to 50%, grade IV < 30%)
(GOLD 2020).
• Drug (e.g. roflumilast, cilomilast).
• Dose (e.g. roflumilast 250 μg or 500 μg).
• Duration of therapy (≤ 12 weeks; 24 to 26 weeks; 52 weeks; > 52
weeks).
• Concomitant therapy (inhaled or oral corticosteroids, inhaled
long-acting beta2-agonists, or anticholinergics, or both).
We used the formal test for subgroup interactions in Review
Manager 5 (RevMan 2014).
Sensitivity analysis
We planned to carry out the following sensitivity analyses,
removing the following from the primary outcome analyses.
• Studies with high risk of bias in one or more domains.
We planned to compare results from a fixed-eKect model by using
a random-eKects model.
We did not anticipate the large number of unpublished trials at the
protocol stage. Consequently, we undertook a sensitivity analysis
of eKect sizes for the primary outcomes reported in published and
unpublished trials.
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R E S U L T S
Description of studies
Results of the search
See Figure 1 for study flow diagram (Moher 2009).
 
Figure 1.   Flow diagram.
 
From the previous updates (2011 to 2016), 37 studies were included
in the review (reference to 2011, 2013, and 2016 reviews). From the
current database update search (2016-2020), 261 abstracts were
identified, one of which was a duplicate and was removed. Full texts
for 42 relevant references were assessed further for inclusion (Table
1). Of 27 references that were selected for inclusion, 18 references
were new additional references to already included studies, one
of which was a new additional reference to an ongoing study
that had already been identified previously. Four unpublished
trials met the inclusion criteria; however, the data for these trials
were not available (NCT01595750; NCT00671073; NCT01701934;
EUCTR2004-004442-40-GB). Five new trials were identified that
met the inclusion criteria and were included in the analyses
(Kavitha 2018; Liu 2018; NCT00874497 (EMPHASIS); RO-2455-402-
RD (ROBERT); Urban 2018 (ELASTIC)).
Included studies
Details of the 42 studies included in this review are described in
detail in the Characteristics of included studies section.
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Of the 42 studies, 27 studies examined roflumilast (COPD
safety pool; Kavitha 2018; Liu 2018; RO-2455-301-RD (ACROSS);
RO-2455-402-RD (ROBERT); RO-2455-404-RD (REACT); Roflumilast
DAL-MD-01; Roflumilast FK1 101; Roflumilast FK1 103; Roflumilast
FLUI-2011-77; Roflumilast IN-108; Roflumilast JP-706; Roflumilast
M2-107; Roflumilast M2-110; Roflumilast M2-111; Roflumilast
M2-111+M2-112; Roflumilast M2-112; Roflumilast M2-118;
Roflumilast M2-119; Roflumilast M2-121; Roflumilast M2-124;
Roflumilast M2-124+M2-125; Roflumilast M2-125; Roflumilast
M2-127; Roflumilast M2-128; Roflumilast ROF-MD-07(RE2SPOND);
Urban 2018 (ELASTIC)), 14 trials studied cilomilast (Cilomilast
039; Cilomilast 042; Cilomilast 076; Cilomilast 091; Cilomilast
103657; Cilomilast 110; Cilomilast 111; Cilomilast 121; Cilomilast
156; Cilomilast 157; Cilomilast 168; Cilomilast 180; Cilomilast 181;
Compton 2001), and one trial explored the use of tetomilast
(NCT00874497 (EMPHASIS)).
Most of the roflumilast trials were funded by pharmaceutical
companies including AstraZeneca and GlaxoSmithKline. Three
trials did not report funding information (Kavitha 2018; Liu 2018;
Roflumilast FK1 103). One study was funded by Ludwig Boltzmann
Institute (Urban 2018 (ELASTIC)). All cilomilast studies were funded
by GlaxoSmithKline, and one tetomilast study was funded by
Otsuka Pharmaceutical Development & Commercialization, Inc
(NCT00874497 (EMPHASIS)).
Almost all studies used inclusion criteria of spirometry and a
history of smoking. Only 6 of the 39 studies mandated a history
of exacerbation in the previous year (Cilomilast 103657; Cilomilast
121; NCT00874497 (EMPHASIS); Roflumilast M2-124; Roflumilast
M2-125; Urban 2018 (ELASTIC)).
The mean age of participants in these trials ranged from 60 to 70
years, with the proportion of male participants between 49% and
96%. Mean FEV1 (% predicted) in trials that reported it ranged from
33% to 51%. Most trials included participants at all stages of COPD;
however limitation to those with severe and very severe COPD
occurred in RO-2455-301-RD (ACROSS), RO-2455-404-RD (REACT),
Roflumilast DAL-MD-01, Roflumilast M2-111, Roflumilast M2-112,
Roflumilast M2-124, Roflumilast M2-125, and Roflumilast ROF-
MD-07(RE2SPOND).
Roflumilast studies
Most of the trials were designed as randomised, double-blind,
placebo-controlled studies, apart from Urban 2018 (ELASTIC),
which was triple-blinded, and Kavitha 2018, which was assumed to
have no blinding. All studies before 2013, apart from Roflumilast
JP-706, were included in combined safety figures for roflumilast
that have been made available through publications on the
FDA website (https://www.accessdata.fda.gov/drugsatfda_docs/
nda/2011/022522Orig1s000MedR.pdf). Combined safety figures
also include participants in two other 24-week studies (Roflumilast
M2-110; Roflumilast M2-121), for which results have not been
published (roflumilast 500 µg: 5970; roflumilast 250 µg: 1002;
placebo: 5682).
All studies compared 500 µg of roflumilast in the intervention
group with placebo, with the exception of one study, which was an
early-dose selection study comparing participants who were given
roflumilast 250 µg and 500 µg for 24 weeks (Roflumilast M2-107).
The duration of roflumilast treatment in studies ranged from 12 to
52 weeks.
The history of roflumilast studies can be explained in order of
publication. The first published PDE4 inhibitor study for COPD
treatment was 52 weeks in duration and allowed concomitant
corticosteroid use (Roflumilast M2-112). Subsequently, results of a
replicate study were published (Roflumilast M2-111). Another two
studies were completed that investigated the eKects of roflumilast
for 52 weeks in participants with severe to very severe COPD with
associated chronic bronchitis who were at risk of exacerbations
(Roflumilast M2-124; Roflumilast M2-125).
Two studies evaluated the add-on use of roflumilast with long-
acting bronchodilator agents (Roflumilast M2-127; Roflumilast
M2-128), the first with salmeterol and the second with tiotropium.
Both studies ran for 24 weeks. A further two studies - RO-2455-404-
RD (REACT) and Roflumilast ROF-MD-07(RE2SPOND) - added
roflumilast or placebo to a fixed-dose ICS/LABA combination.
Roflumilast M2-118 was a 12-week study that focused on airway
physiology during rest and exercise in participants with moderate
to severe disease. Roflumilast M2-119 investigated pulmonary
function and safety in a group of participants recruited at centres
across the Asia-Pacific regions. Roflumilast DAL-MD-01 was mainly
aimed at investigating eKects on sputum and other biomarkers.
Roflumilast FLUI-2011-77 explored the airway architecture using
imaging techniques.
Three more large RCTs were completed - RO-2455-301-
RD (ACROSS), RO-2455-404-RD (REACT), and Roflumilast ROF-
MD-07(RE2SPOND). RO-2455-301-RD (ACROSS) was carried out
across three centres in mainland China, Hong Kong, and Singapore
and investigated the eKects and safety of roflumilast over
24 weeks. Both RO-2455-404-RD (REACT) and Roflumilast ROF-
MD-07(RE2SPOND) were 52-week multi-centre trials investigating
eKects on rates of moderate and severe exacerbations.
Four additional trials were completed in 2017 and 2018 -
Kavitha 2018, Liu 2018 RO-2455-402-RD (ROBERT), RO-2455-402-RD
(ROBERT), and Urban 2018 (ELASTIC). RO-2455-402-RD (ROBERT)
was a multi-centre study carried out across Denmark, Germany,
Poland, Sweden, and United Kingdom for 16 weeks. The primary
aim of this study was to investigate eKects on inflammatory
markers and changes in lung function. Urban 2018 (ELASTIC) was
an Austrian study carried out over 26 weeks, primarily to assess
eKects of subclinical atherosclerosis and markers of inflammation,
but also lung function, exercise, and health impact, in participants
with stable COPD. Kavitha 2018, a 12-week single-centre study in
India investigating eKects of roflumilast on change in pulmonary
function of participants with moderate to severe disease taking a
combined LABA and tiotropium metered-dose inhaler. Liu 2018 was
a 52-week single-centre study in China that primarily investigated
change in lung function among participants with moderate to
severe disease.
Two trials were reported only as conference posters: Roflumilast
FK1 101 and Roflumilast FK1 103. The first compared roflumilast
500 µg, roflumilast 250 µg, and placebo for 26 weeks; the
second compared roflumilast 500 µg once daily for 24 weeks with
roflumilast 500 µg once daily for 12 weeks, then with placebo once
daily for the following 12 weeks.
Unpublished results were identified for two other studies:
Roflumilast IN-108 compared the safety and eKicacy of roflumilast
250 μg and 500 μg in participants recruited from five centres across
India; however, no inclusion criteria were stated, concomitant
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medications were poorly described, and only 15 participants in
the placebo group completed the protocol. Roflumilast JP-706 was
a 24-week study sponsored by a diKerent collaborator that, in
addition to treatment eKects, monitored pharmacokinetic levels of
roflumilast and its metabolite roflumilast-N-oxide.
In the three studies that compared 500 µg or 250 µg with
placebo, the placebo group was halved to avoid double counting
(Roflumilast FK1 101; Roflumilast IN-108; Roflumilast M2-107).
NCT02671942 2016 was identified as an ongoing trial - a Chinese
study designed to assess whether altering the standard 500-µg
dose improved tolerability of roflumilast. NCT02451540 (reported
as ongoing in the 2016 update) was carried out in Belgium to assess
eKects of roflumilast on lung function (as measured by functional
respiratory imaging) in COPD patients taking LABA/LAMA therapy.
This study was reported in the trials registry as being terminated
early as no new investigational product could be delivered to the
study site.
Further information for three unpublished trials could not be
found upon contact with authors (NCT00671073; NCT01595750;
NCT01701934).
Cilomilast studies
No new studies were identified for the current update.
Data were derived mainly from phase 3 clinical trials and from one
phase 2/3 trial. These included unpublished studies. All used a 15-
mg dose twice daily, except for Compton 2001.
Compton 2001 was a parallel, six-week, dose-ranging study
comparing placebo with 5 mg, 10 mg, and 15 mg of cilomilast,
with FEV1 as the primary outcome. Pivotal eKicacy studies included
Cilomilast 039, Cilomilast 042, Cilomilast 091, and Cilomilast 156,
all of which were 24 weeks in duration. Cilomilast 121 (phase 2/3, 24
weeks), Cilomilast 157 (52 weeks), and Cilomilast 103657 (24 weeks)
followed the pivotal eKicacy studies and were smaller in sample
size.
Cilomilast 039 and Cilomilast 156 were conducted in North America,
and Cilomilast 042 and Cilomilast 091 were conducted in the
European Union. Here, primary study outcomes were change in
FEV1, lung function, and SGRQ quality of life score. Cilomilast 076,
Cilomilast 110, Cilomilast 111, and Cilomilast 168 were supporting
studies, all of which lasted less than 24 weeks, with average trial
duration of 10.8 weeks, for which neither FEV1 lung function nor
SGRQ was the primary outcome. Cilomilast 180 (18 weeks) had
a primary lung function endpoint - functional residual capacity;
Cilomilast 181 (13 weeks) assessed the number of inflammatory
cells in a bronchial biopsy.
Tetomilast studies
One new tetomilast study was identified - a phase 2a multi-
centre, randomised, double-blind, placebo-controlled study that
assessed eKicacy and safety in patients with emphysema who had
at least one previous exacerbation (NCT00874497 (EMPHASIS)).
Study duration was 104 weeks, and the dose of tetomilast was
50 µg. The primary outcome was change in FEV1 (NCT00874497
(EMPHASIS)).
One unpublished study on oglemilast was identified by the search
(NCT00671073); however, no further information could be obtained
from trial authors on contact.
Excluded studies
We excluded 15 additional references from the 2020 update at full-
text review, as they did not meet the inclusion criteria. We have
provided reasons for exclusion of these 15 studies (see Excluded
studies).
Risk of bias in included studies
An overview of risk of bias in individual studies is provided in Figure
2; support for judgements for individual studies is provided under
Characteristics of included studies.
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Figure 2.   Methodological quality summary: review authors' judgements about each methodological quality item





























































































































































Cilomilast 039 + + + ? + + +
Cilomilast 042 + + + ? + + ?
Cilomilast 076 + + ? ? + + ?
Cilomilast 091 + + + ? + ? ?
Cilomilast 103657 + + ? + + + ?
Cilomilast 110 + + + + + + ?
Cilomilast 111 + + + ? + + ?
Cilomilast 121 + + + ? + + +
Cilomilast 156 + + + + + + +
Cilomilast 157 + + + ? + + +
Cilomilast 168 + ? + ? + + +
Cilomilast 180 + ? + ? + + +
Cilomilast 181 + + + ? + + +
Compton 2001 + + + ? + ? +
COPD safety pool + ? + ? ? ? ?
Kavitha 2018 - ? - - + - +
Liu 2018 + ? + + + - +
NCT00874497 (EMPHASIS) + + ? + - + ?
RO-2455-301-RD (ACROSS) + + + + + ? +
RO-2455-402-RD (ROBERT) + + + + + + +
RO-2455-404-RD (REACT) + + + + + + ?
Roflumilast DAL-MD-01 ? + + + + + ?
Roflumilast FK1 101 ? ? + ? ? ? +
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Figure 2.   (Continued)
Roflumilast DAL-MD-01 ? + + + + + ?
Roflumilast FK1 101 ? ? + ? ? ? +
Roflumilast FK1 103 ? ? + ? ? ? +
Roflumilast FLUI-2011-77 ? ? + + ? + +
Roflumilast IN-108 ? ? + ? + ? ?
Roflumilast JP-706 ? ? + ? ? - +
Roflumilast M2-107 + ? + + + - +
Roflumilast M2-110 + + + ? ? +
Roflumilast M2-111 + + + ? + + +
Roflumilast M2-111+M2-112 + + + + + + +
Roflumilast M2-112 + + + ? + + +
Roflumilast M2-118 + ? + ? + ? +
Roflumilast M2-119 + ? + ? - + +
Roflumilast M2-121 + ? + ? + ? +
Roflumilast M2-124 + + + ? + + -
Roflumilast M2-124+M2-125 ? + ? ? ? ? ?
Roflumilast M2-125 + + ? ? + -
Roflumilast M2-127 + ? + + + + +
Roflumilast M2-128 + + + + + ? +
Roflumilast ROF-MD-07(RE2SPOND) + ? + + ? ? ?
Urban 2018 (ELASTIC) ? ? + + + + ?
 
Allocation
We assessed 12 out of 24 roflumilast studies as having low risk
of bias for allocation concealment. Information about allocation
concealment for cilomilast studies was limited in publications, but
we have considered that this is unlikely to be a source of bias
because these studies were sponsored, and standard methods
would have been used to minimise the risk of selection bias.
We therefore judged the risk of selection bias as low, although
allocation concealment is marked as unclear in many of these
studies. We considered the only study for tetomilast as having low
risk of bias for this domain.
Blinding
All studies included in this review were double-blind RCTs, with
the exception of Kavitha 2018, which failed to report blinding. We
regarded overall risk of performance bias and detection bias as low.
Incomplete outcome data
The rate of withdrawal and dropout was reported in 28 of the 39
studies and was generally less than 20% for randomly assigned
participants. However, two studies reported higher rates of attrition
(NCT00874497 (EMPHASIS); Roflumilast M2-119). NCT00874497
(EMPHASIS) reported that 54% of participants in both tetomilast
and placebo groups did not complete treatments. In addition, five
more participants in the tetomilast group than in the placebo
group discontinued treatment due to adverse events. Similarly, in
Roflumilast M2-119, more participants in the roflumilast group than
in the placebo group discontinued (20% versus 8%). We judged
these two studies to be at high risk of bias. We judged the remaining
nine studies as having unclear risk of bias due to lack of information
about the flow of participants throughout the duration of these
studies.
Selective reporting
We identified 27 published and 12 unpublished trials. We
performed analyses of diKerences in treatment eKect between
published and unpublished treatment groups for primary
outcomes and reported this information in the subgroup and
sensitivity analyses below.
Other potential sources of bias
We did not consider sponsorship as necessarily increasing the risk
of bias when studies were well designed.
For some trials, we noted minor diKerences in baseline
characteristics such as age, gender, FEV1, and smoking history.
E:ects of interventions
See: Summary of findings 1 Phosphodiesterase-4 inhibitors
compared to placebo for chronic obstructive pulmonary disease
Primary outcomes
Change in FEV1
We included 32 studies in the main analysis (participants =
20,815). Eighteen studies compared roflumilast 500 µg with
placebo (RO-2455-301-RD (ACROSS); RO-2455-402-RD (ROBERT);
RO-2455-404-RD (REACT); Roflumilast DAL-MD-01; Roflumilast
FK1 101; Roflumilast FK1 103; Roflumilast FLUI-2011-77;
Roflumilast IN-108; Roflumilast M2-107; Roflumilast M2-111;
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Roflumilast M2-112; Roflumilast M2-118; Roflumilast M2-119;
Roflumilast M2-124; Roflumilast M2-125; Roflumilast M2-127;
Roflumilast M2-128; Roflumilast ROF-MD-07(RE2SPOND), three
studies compared roflumilast 250 µg with placebo (Roflumilast FK1
101; Roflumilast IN-108; Roflumilast M2-107), 10 studies compared
cilomilast 15 mg with placebo (Cilomilast 039; Cilomilast 042;
Cilomilast 076; Cilomilast 091; Cilomilast 103657; Cilomilast 110;
Cilomilast 121; Cilomilast 156; Cilomilast 157; Compton 2001), and
one study compared tetomilast 50 µg with placebo (NCT00874497
(EMPHASIS)).
For RO-2455-402-RD (ROBERT), we calculated standard deviations
(SDs) using the RevMan calculator and the number of participants
in each treatment group. We did not have change from baseline
data for each treatment group; therefore, we used the reported
mean diKerence value between groups (0.063) as the MD for the
roflumilast group and an MD of zero for the placebo group.
Urban 2018 (ELASTIC) was not included in the meta-analysis as the
data were skewed and were analysed on a log-scale as a percentage
diKerence. Similarly, Liu 2018 could not be included in the analysis
because reporting of standard errors was unclear, and we received
no further correspondence from trial authors on request. Kavitha
2018 reported the outcome separately as endpoint data.
Main analysis
Note that an increase in FEV1 represents an improvement in lung
function.
Based on the 32 trials that reported this outcome, results showed
improvement in FEV1 from baseline among PDE4 inhibitor-treated
participants compared with controls at a mean of 40.17 weeks'
duration (mean diKerence (MD) 49.33 mL, 95% confidence interval
(CI) 44.17 to 54.49; participants = 20,815; studies = 32; I2 = 45%;
moderate-certainty evidence) (Analysis 1.1; Figure 3; Summary of
findings 1). EKects on FEV1 with 500 µg or 250 µg roflumilast,
respectively, were improved (roflumilast 500 µg: MD 55.18 mL, 95%
CI 48.65 to 61.71; participants = 14,384; studies = 18; I2 = 21%;
studies = 17; I2 = 26%) (roflumilast 250 µg: MD 56.88 mL, 95% CI
24.38 to 89.38; participants = 1033; studies = 3; I2 = 0%). Similar
improvement was observed with cilomilast 15 mg (MD 38.15 mL,
95% CI 29.41 to 46.90; participants = 5322; studies = 10; I2 = 62%).
There was only one small study, with wide uncertainty about eKects
with tetomilast (MD 82.00 mL, 95% CI -50.84 to 214.84; participants
= 76) (Analysis 1.1).
 
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Figure 3.   Forest plot of comparison: 1 PDE4 inhibitor versus placebo (2020 update), outcome: 1.1 FEV1 (by drug)
[mL].
Study or Subgroup




Test for overall effect: Z = 1.21 (P = 0.23)




















Heterogeneity: Chi² = 21.53, df = 17 (P = 0.20); I² = 21%
Test for overall effect: Z = 16.56 (P < 0.00001)
1.1.3 Roflumilast 250 µg




Heterogeneity: Chi² = 1.08, df = 2 (P = 0.58); I² = 0%
Test for overall effect: Z = 3.43 (P = 0.0006)












Heterogeneity: Chi² = 23.75, df = 9 (P = 0.005); I² = 62%
Test for overall effect: Z = 8.55 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 56.15, df = 31 (P = 0.004); I² = 45%
Test for overall effect: Z = 18.73 (P < 0.00001)


























































































































































































































































IV, Fixed, 95% CI [mL]
82.00 [-50.84 , 214.84]
82.00 [-50.84 , 214.84]
71.00 [46.00 , 96.00]
63.00 [-208.97 , 334.97]
56.00 [38.26 , 73.74]
13.00 [-120.78 , 146.78]
52.00 [-9.00 , 113.00]
39.00 [-9.44 , 87.44]
125.00 [64.96 , 185.04]
152.00 [-64.52 , 368.52]
88.00 [48.83 , 127.17]
42.00 [21.08 , 62.92]
36.00 [5.52 , 66.48]
82.00 [8.34 , 155.66]
96.00 [37.74 , 154.26]
38.00 [15.86 , 60.14]
58.00 [38.59 , 77.41]
49.00 [24.07 , 73.93]
81.00 [47.75 , 114.25]
53.00 [40.00 , 66.00]
55.18 [48.65 , 61.71]
36.00 [-24.52 , 96.52]
137.00 [-79.38 , 353.38]
63.00 [23.84 , 102.16]
56.88 [24.38 , 89.38]
40.00 [12.30 , 67.70]
30.00 [-13.04 , 73.04]
20.00 [-90.83 , 130.83]
30.00 [-25.40 , 85.40]
44.00 [30.13 , 57.87]
70.00 [-40.92 , 180.92]
20.00 [-3.93 , 43.93]
24.00 [1.82 , 46.18]
34.00 [7.70 , 60.30]
160.00 [104.53 , 215.47]
38.15 [29.41 , 46.90]
49.33 [44.17 , 54.49]
Mean Difference
IV, Fixed, 95% CI [mL]
-200 -100 0 100 200
Favours placebo Favours PDE4i
Footnotes
(1) Units converted from L to mL, standard deviations obtained by imputing participant number in each group in the calculator from GIV analysis. Mean differences for each treatment group were not available, placebo imputed as zero, and roflumilast imputed as 0.063
(2) The participant number in the placebo group was halved to avoid double counting
 
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Moderate and high levels of heterogeneity seen amongst
roflumilast 500 µg and cilomilast studies, respectively, can be
explained in part by investigation of diKerences between these two
PDE4 inhibitors (for subgroup analyses, see below).
We investigated publication bias amongst the studies included
in the analysis (Figure 4). Four studies were outliers and were
investigated further (roflumilast 500 µg: Roflumilast FLUI-2011-77;
Roflumilast IN-108; roflumilast 250 µg: Roflumilast IN-108;
cilomilast 15 mg: Compton 2001). These studies were small in
population size and contributed very little weight to the overall
analysis. In addition, removing these studies from the sensitivity
analysis did not have a large impact on the overall eKect estimate.
We did not downgrade the outcome in our GRADE assessment for
this reason (Summary of findings 1).
Studies not included in the main analysis
Kavitha 2018 reported FEV1 at endpoint but did not report
the units. It is unclear whether the outcome was reported as
litres or millilitres, and trial authors reported much greater
improvement compared to authors of another study, which
reported improvement of 60 mL (see Kavitha 2018 risk of bias
assessment for explanation). Trial authors did not respond when
contacted for further information.
Change in FVC from baseline
We included 17 trials in the analysis (Cilomilast 039; Cilomilast
042; Cilomilast 091; Cilomilast 103657; Cilomilast 156; Compton
2001; RO-2455-301-RD (ACROSS); RO-2455-402-RD (ROBERT);
RO-2455-404-RD (REACT); Roflumilast M2-107; Roflumilast M2-112;
Roflumilast M2-119; Roflumilast M2-124; Roflumilast M2-125;
Roflumilast M2-127; Roflumilast M2-128; Roflumilast ROF-
MD-07(RE2SPOND)).
Treatment with a PDE4 inhibitor was associated with greater change
in FVC from baseline compared to placebo (MD 86.98, 95% CI 74.65
to 99.31; participants = 22,108; studies = 17; I2 = 0%; high-certainty
evidence) with no heterogeneity amongst the 17 trials (Analysis 1.2;
Summary of findings 1).
Studies not included in the main analysis
Kavitha 2018 reported FVC at endpoint but did not report the
units. It is unclear whether the outcome was reported as litres
or millilitres; therefore, we did not include this study in the
analysis. Trial authors did not respond when contacted for further
information.
Change in PEF from baseline
We included six studies in the analysis (Compton 2001; Roflumilast
FK1 101 (250 µg); Roflumilast FK1 101 (500 µg); Roflumilast M2-119;
Roflumilast M2-124; Roflumilast M2-125). Roflumilast FK1 101
compared one placebo group with roflumilast 250 µg or 500 µg;
therefore, the number of participants in the placebo group was
halved to avoid double counting, and the study was added to the
analysis twice to represent higher and lower doses of roflumilast.
Change in PEF was greater with roflumilast treatment overall than
with placebo (MD 6.54 L/min, 95% CI 3.95 to 9.13; participants
= 4245; studies = 6; I2 = 74; low-certainty evidence) (Analysis
1.3; Summary of findings 1). On further analysis of doses, we
noted improvement in PEF with roflumilast 500 µg but not with
roflumilast 250 µg when compared with placebo. Upon further
investigation, when Compton 2001 was taken out of the analysis,
the heterogeneity was zero.
Change in quality of life
St George's Respiratory Questionnaire (SGRQ)
Note that a decrease in SGRQ total score represents improvement
in quality of life.
We included 12 studies in the analysis for this outcome
(participants = 7645) (Cilomilast 039; Cilomilast 042; Cilomilast 091;
Cilomilast 103657; Cilomilast 121; Cilomilast 156; Cilomilast 157;
Compton 2001; Roflumilast DAL-MD-01; Roflumilast M2-107 (250
µg); Roflumilast M2-107 (500 µg); Roflumilast M2-112).
Roflumilast M2-107 reported data for 250 µg and for 500 µg
roflumilast compared to one placebo group; therefore, the number
of participants in the placebo group was halved to avoid double
counting, and the study was included in the analysis twice (Analysis
1.4).
We noted a small decrease in total score on the SGRQ from baseline
to mean 33 weeks' duration among participants treated with PDE4
inhibitors compared with those given the control intervention (MD
-1.06 units, 95% CI -1.68 to -0.43; participants = 7645; studies =
13; I2 = 47%; moderate-certainty evidence (Analysis 1.4; Figure 5;
Summary of findings 1). Moderate levels of heterogeneity amongst
roflumilast and cilomilast studies can be explained further by
subgroup analysis (see below).
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Figure 5.   Forest plot of comparison: 1 PDE4 inhibitor versus placebo (2020 update), outcome: 1.4 SGRQ total score.
Study or Subgroup




Heterogeneity: Chi² = 0.83, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 1.89 (P = 0.06)
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Test for overall effect: Z = 0.91 (P = 0.36)
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IV, Fixed, 95% CI
-6.70 [-17.29 , 3.89]
-1.70 [-3.66 , 0.26]
-1.87 [-3.80 , 0.06]
-1.60 [-3.56 , 0.36]
0.30 [-1.64 , 2.24]
-0.64 [-2.02 , 0.74]
-4.10 [-6.18 , -2.02]
0.70 [-1.81 , 3.21]
-0.40 [-3.58 , 2.78]
0.04 [-1.57 , 1.65]
-0.30 [-2.31 , 1.71]
-1.90 [-3.57 , -0.23]
0.20 [-1.95 , 2.35]
-3.90 [-7.50 , -0.30]
-1.06 [-1.81 , -0.31]
-1.06 [-1.68 , -0.43]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PDE4i Favours placebo
 
Improvement in symptoms (reported as SGRQ symptom score)
was uncertain amongst two studies (Roflumilast M2-107; Compton
2001) (MD -1.53 units, 95% CI -4.11 to 1.06; participants = 1048;
studies = 2; Analysis 1.5).
We did not include outcome data for Roflumilast M2-111, as data
were provided in the form of a 'repeated measures analysis', and
pooled data did not equal the sum of numbers in each of the
individual studies. Liu 2018 was also not included in the analysis
due to unclear reporting of standard errors and no response from
trial authors.
Secondary outcomes
Incidence of COPD exacerbations
We included 27 trials in the analysis (participants =
20,382) (Cilomilast 039; Cilomilast 042; Cilomilast 076;
Cilomilast 091; Cilomilast 111; Cilomilast 121; Cilomilast
156; Cilomilast 157; Cilomilast 168; Cilomilast 180; Liu
2018; NCT00874497 (EMPHASIS); RO-2455-301-RD (ACROSS);
RO-2455-402-RD (ROBERT); RO-2455-404-RD (REACT); Roflumilast
FK1 101 (500 µg); Roflumilast IN-108; Roflumilast JP-706;
Roflumilast M2-107; Roflumilast M2-111+M2-112; Roflumilast
M2-119; Roflumilast M2-124; Roflumilast M2-125; Roflumilast
M2-127; Roflumilast M2-128; Roflumilast ROF-MD-07(RE2SPOND);
Urban 2018 (ELASTIC); .
Use of PDE4 inhibitors was associated with a reduction in
the numbers of participants experiencing one or more COPD
exacerbations at a mean duration of 40 weeks (odds ratio (OR)
0.78, 95% CI 0.73 to 0.84; high-certainty evidence; Analysis 1.6;
Summary of findings 1). This is a relative reduction of more than
20% from a representative risk of 33 per 100 on placebo to 27 per
100 on PDE4 inhibitors over a weighted mean of 40 weeks (Summary
of findings 1), and the number needed to treat for an additional
beneficial outcome (NNTB) was 20 (95% CI 16 to 27) (Figure 6). There
was little heterogeneity among trials (I2 = 6%), and a reduction
in people experiencing COPD exacerbations was seen with both
roflumilast and cilomilast. Tetomilast revealed wide uncertainty
about the number of participants experiencing one or more COPD
exacerbations; only one study contributed to this result (Analysis
1.6).
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Figure 6.   In the control group, 33 out of 100 people had an exacerbation of COPD over 40 weeks of treatment,
compared to 27 (95% CI 26 to 29) out of 100 people in the active treatment group.
 
Exacerbation rates
Nine studies reported exacerbation rates and the number
of exacerbations experienced on average per participant per
year (Cilomilast 157; RO-2455-402-RD (ROBERT); Roflumilast
M2-111; Roflumilast M2-112; Roflumilast M2-124; Roflumilast
M2-125; Roflumilast M2-127; Roflumilast M2-128; Roflumilast ROF-
MD-07(RE2SPOND)) (Analysis 1.7). We observed a small benefit with
treatment, representing a 12% reduction in the exacerbation rate
(0.88, 95% CI 0.83 to 0.93).
Roflumilast FK1 101 reported that the probability of experiencing
an exacerbation was reduced by 8% with 250 μg of roflumilast and
by 48% with 500 μg, although the absolute value was not reported
and it was not stated whether this result was significant.
Four studies reported reduction in severe exacerbation rates
per participant per year with PDE4 inhibitor compared with
placebo (Cilomilast 039; RO-2455-404-RD (REACT); Roflumilast
M2-124+M2-125; Roflumilast ROF-MD-07(RE2SPOND)). Cilomilast
15 mg resulted in a 45% reduction in severe exacerbations (P =
0.001) (Cilomilast 039). In studies using roflumilast 500 µg, the
reduction in the rate of severe exacerbations ranged from 8.5% to
24.3% across studies (Table 2).
Symptoms (breathlessness on Borg or other symptom scales)
We included a total of 14 studies (participants = 10,701)
that reported results on the Borg Scale (Analysis 1.8),
the Shortness of Breath Questionnaire (Analysis 1.9), the
Summary Symptom Scale (Analysis 1.10), or the Breathlessness,
Cough, and Sputum Scale (BCSS) (Analysis 1.11) (Borg Scale:
Cilomilast 039; Cilomilast 042; Cilomilast 091; Cilomilast 111;
Cilomilast 156; Cilomilast 180; Shortness of Breath Questionnaire:
Roflumilast M2-127; Roflumilast M2-128; Summary Symptom Scale:
Cilomilast 039; Cilomilast 042; Cilomilast 091; RO-2455-404-RD
(REACT); Roflumilast ROF-MD-07(RE2SPOND); BCSS: NCT00874497
(EMPHASIS)).
Overall, the mean diKerence in change from baseline with PDE4
inhibitor treatment compared with the control intervention on
COPD-related symptoms at mean duration of 21 weeks was small,
regardless of the scale used to measure it. The only eKect was
seen in one trial of cilomilast - for breathlessness scored on a Borg
Scale (MD -0.19, 95% CI -0.33 to -0.05) (Analysis 1.8). This is a small
absolute diKerence so is of doubtful clinical relevance. Results
showed no diKerence with PDE4 inhibitor in eKects on the Summary
Symptom Scale (standardised mean diKerence (SMD) -0.02, 95%
CI -0.07 to 0.03; participants = 6186; studies = 5; I2 = 19%), the
Shortness of Breath Questionnaire (MD -1.09, 95% CI -2.47 to 0.28;
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participants = 1633; studies = 2; I2 = 81%), or the BCSS (Analysis
1.11).
Exercise tolerance (six-minute walk test)
We included six studies that reported the six-minute walk test
(6MWT) (participants = 2055) (Cilomilast 039; Cilomilast 042;
Cilomilast 091; Cilomilast 111; Roflumilast DAL-MD-01; Urban 2018
(ELASTIC)).
Exercise tolerance was measured on the 6MWT in six trials (two
roflumilast and four cilomilast trials). We found uncertainty in
walk test distance at a mean duration of 21 weeks between PDE4
inhibitor and placebo groups (MD 3.50; 95% CI -5.84 to 12.85)
(Analysis 1.12).
Adverse events
We included 30 studies in the overall analysis (participants
= 21,310) (Cilomilast 039; Cilomilast 042; Cilomilast
076; Cilomilast 091; Cilomilast 103657; Cilomilast 110;
Cilomilast 111; Cilomilast 121; Cilomilast 156; Cilomilast
157; Cilomilast 168; Cilomilast 180; Cilomilast 181; Compton
2001; NCT00874497 (EMPHASIS); RO-2455-301-RD (ACROSS);
RO-2455-402-RD (ROBERT); RO-2455-404-RD (REACT); Roflumilast
DAL-MD-01; Roflumilast FK1 101; Roflumilast IN-108; Roflumilast
JP-706; Roflumilast M2-107; Roflumilast M2-111+M2-112;
Roflumilast M2-119; Roflumilast M2-124+M2-125; Roflumilast
M2-127; Roflumilast M2-128; Roflumilast ROF-MD-07(RE2SPOND);
Urban 2018 (ELASTIC)).
Overall, the likelihood of a participant experiencing an adverse
event at a mean duration of 38 weeks was higher with PDE4
inhibitor treatment than with placebo (OR 1.30, 95% CI 1.22 to 1.38;
participants = 21,310; studies = 30; I2 = 64%; low certainty evidence)
(Analysis 1.13; Summary of findings 1). This eKect was seen for both
roflumilast and cilomilast but not for tetomilast, as we found only
one study for this PDE4 inhibitor.
Adverse events: roflumilast 500 µg versus roflumilast 250 µg
The higher dose of roflumilast (500 μg) was associated with more
adverse events than the lower dose (250 μg); however, this finding
was based on only four trials and confidence intervals were wide
(OR 1.21, 95% CI 1.01 to 1.46) (Analysis 1.14).
We found a range of adverse eKects that occurred more frequently
in PDE4 inhibitor-treated participants, which are described below.
Gastrointestinal adverse e:ects (diarrhoea, nausea, vomiting,
dyspepsia, weight loss)
Diarrhoea was more commonly experienced in PDE4 inhibitor-
treated groups than in placebo groups (OR 3.10, 95% CI 2.74 to
3.50; participants = 20,623; studies = 29; I2 = 12%; high-certainty
evidence) (Analysis 1.15; Summary of findings 1).
Nausea was also reported as an increased side eKect (OR 3.79, 95%
CI 3.24 to 4.43; participants = 20,949; studies = 28; I2 = 24%) (Analysis
1.16), as were vomiting (OR 3.95, 95% CI 2.78 to 5.60; participants
= 5986; studies = 12; I2 = 0%) (Analysis 1.17) and dyspepsia (OR
3.17, 95% CI 2.33 to 4.30; participants = 6247; studies = 13; I2 = 0%)
(Analysis 1.18). Weight loss was commonly reported and was an
increased adverse eKect (OR 3.72, 95% CI 3.09 to 4.47; participants
= 12,462; studies = 12; I2 = 24%) (Analysis 1.19).
More than 10% of participants in the PDE4 inhibitor group
experienced gastrointestinal side eKects; diarrhoea was the most
frequently reported symptom (Figure 7) (number needed to treat
for an additional harmful outcome (NNTH) 14, 95% CI 12 to 17).
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Figure 7.   In the control group, 4 out of 100 people had a diarrhoea episode over 39 weeks of treatment, compared
to 11 (95% CI 10 to 12) out of 100 people in the active treatment group.
 
Withdrawals
An increase in withdrawals attributed to adverse events was
recorded for both roflumilast and cilomilast treatment groups (OR
1.89, 95% CI 1.73 to 2.07; participants = 21,358; studies = 31; I2 =
21%) (Analysis 1.20).
Headache
We found 23 studies that reported a higher proportion of
participants experiencing headache as an adverse eKect when
taking a PDE4 inhibitor (OR 1.69, 95% CI 1.46 to 1.94; participants =
19,215; I2 = 23%) (Analysis 1.21). Participants in the roflumilast 500
µg treatment group were more likely to experience headache than
those given placebo (OR 2.13, 95% CI 1.74 to 2.59; participants =
13,565; studies = 12; I2 = 0%) (Analysis 1.21).
Abdominal pain
FiWeen studies reported abdominal pain as an adverse eKect in
the PDE4 inhibitor treatment group (OR 2.02, 95% CI 1.62 to 2.52;
participants = 8329; studies = 15; I2 = 0%) (Analysis 1.22). A greater
likelihood of abdominal pain was noted for participants in the
roflumilast treatment group compared with the placebo group
(OR 2.77, 95% CI 1.38 to 5.56; participants = 2641; studies = 3).
Participants were also more likely to experience abdominal pain
with cilomilast than with placebo (OR 1.97, 95% CI 1.55 to 2.49;
participants = 5604; studies = 11), although the magnitude of eKect
was smaller compared to that seen with roflumilast (Analysis 1.22).
Influenza-like symptoms
There was uncertainty in the incidence of influenza-like symptoms
between PDE4 inhibitors (OR 1.09, 95% CI 0.87 to 1.36; participants
= 11,460; studies = 10), as confidence intervals crossed the line of
no eKect (Analysis 1.23).
Upper respiratory tract infection
There was uncertainty in the incidence of upper respiratory tract
infection between PDE4 inhibitor and placebo treatment groups
(OR 0.91, 95% CI 0.81 to 1.04; participants = 17,022; studies = 23), as
confidence intervals crossed the line of no eKect (Analysis 1.24).
Psychiatric adverse e:ects: COPD safety pool
We recorded the number of psychiatric adverse events from
pooled data derived from all parallel-design, double-blind studies
investigating roflumilast collated and presented to the FDA. This
included data from the 15 fully published trials but excluded
results from Roflumilast JP-706, which was conducted by a diKerent
study collaborator. These results reported symptoms of depression
separately from depressed mood, depressive symptoms, or major
depression. The likelihood of experiencing a psychiatric adverse
event was greater in the roflumilast 500 μg treatment group than
in the placebo group (OR 2.13, 95% CI 1.79 to 2.54) (Analysis 1.25;
Summary of findings 1). This was reported in three out of 100
people in the placebo group compared to seven out of 100 in the
PDE4 inhibitor-treated group (95% CI 6 to 8) (NNTH 28, 95% CI 21
to 39). The likelihood of experiencing a psychiatric adverse event
was uncertain with 250 µg roflumilast compared with placebo, as
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
the confidence interval crossed the line of no eKect (OR 0.87, 95%
CI 0.56 to 1.33) (Analysis 1.25).
An increase in symptoms of anxiety (OR 1.81, 95% CI 1.26 to
2.62) (Analysis 1.26) and depression (OR 1.59, 95% CI 1.11 to 2.27)
(Analysis 1.27) was associated with roflumilast 500 µg compared
with placebo. Uncertainty about symptoms of anxiety (OR 0.94,
95% CI 0.40 to 2.21) or depression (OR 0.56, 95% CI 0.20 to 1.56)
was greater with roflumilast 250 µg compared with placebo, as
confidence intervals crossed the line of no eKect in both analyses
(Analysis 1.26; Analysis 1.27).
Three reports described completed suicides and two suicide
attempts in roflumilast-treated participants compared to none in
participants given placebo (roflumilast COPD safety database, n =
12,054).
In more recent roflumilast trials, the numbers of participants
experiencing insomnia and sleep disorders taking roflumilast 500
µg were greater than among those taking placebo (OR 2.67, 95% CI
2.11 to 3.38) (Analysis 1.28), but results with 250 µg roflumilast were
uncertain, as the confidence interval crossed the line of no eKect
(Analysis 1.28).
Serious adverse events
Treatment was found to have no eKect on serious adverse events
(OR 0.99, 95% CI 0.91 to 1.07; participants = 19,191; studies = 29; I2
= 54%) (Analysis 1.29).
Mortality
Mortality was a relatively rare event during these trials, results
showed no eKect of treatment for this outcome (OR 0.98, 95% CI
0.77 to 1.24; participants = 19,786; studies = 27; I2 = 0%; moderate-
certainty evidence) (Analysis 1.30; Summary of findings 1).
Subgroup and sensitivity analyses
Primary outcome: FEV1
A moderate but significant level of heterogeneity was evidence
for the change in FEV1 outcome when all trials were pooled (I2 =
45%). We analysed the data further by performing subgroup and
sensitivity analyses.
Subgroup analysis: COPD severity
To see whether the size of the treatment eKect varied with COPD
severity, we conducted subgroup analyses of trials for which the
mean per cent predicted FEV1 at baseline was available (Analysis
1.31). EKects seen in both old GOLD grade I or II (FEV1 ≥ 50%)
predicted and old GOLD grade III or IV (FEV1 < 50%) were statistically
significant and of similar magnitude (MD 52.78, 95% CI 46.73 to
58.83; test for subgroup diKerences: Chi2 = 0.03, df = 1 (P = 0.87)).
Subgroup analysis: dose (roflumilast 500 µg versus roflumilast 250 µg)
For dose eKects of roflumilast, both roflumilast 500 µg and
roflumilast 250 µg were associated with a similar change in FEV1
(roflumilast 500 µg: MD 55.18, 95% CI 48.65 to 61.71; participants
= 14,384; studies = 18; I2 = 21%; roflumilast 250 µg: MD 56.88, 95%
CI 24.38 to 89.38; participants = 1033; studies = 3; I2 = 0%) (test for
subgroup diKerences: Chi2 = 0.01, df = 2 (P = 0.92)) (Analysis 1.1;
Figure 3).
Subgroup analysis: duration of treatment
For FEV1, the size of the treatment eKect, that is, the mean
diKerence between PDE4 and placebo groups, was numerically
greater in short studies of 6 to 12 weeks (MD 101.71, 95% CI 70.96 to
132.46; participants = 1191; studies = 8) than in studies of 24 to 26
weeks (MD 46.14, 95% CI 38.44 to 53.84; participants = 8086; studies
= 13) and studies of 52 weeks (MD 48.77, 95% CI 41.44 to 56.10;
participants = 10,662; studies = 7). However this diKerence between
subgroups may be a chance finding (test for subgroup diKerences:
Chi2 = 5.11, df = 6 (P = 0.53)) (Analysis 1.33).
Subgroup analysis: concomitant therapies (roflumilast versus
cilomilast)
With respect to PDE4 inhibitor use with concomitant therapies
(Analysis 1.34), the largest increases in FEV1 were seen in
two trials where participants were taking regular, long-acting
bronchodilators: in one trial, salmeterol (Roflumilast M2-127),
and in the other, tiotropium (Roflumilast M2-128) (MD 60.52 mL,
95% CI 40.57 to 80.46). The next largest improvements were
seen in trials for which all concomitant medications (including
long-acting bronchodilators if previously received) were continued
(RO-2455-301-RD (ACROSS); RO-2455-404-RD (REACT); Roflumilast
ROF-MD-07(RE2SPOND) (MD 56.58 mL, 95% CI 46.91 to 66.25)
(Analysis 1.34). A similar improvement in FEV1 was seen when
participants were taking corticosteroids (MD 42.26 mL, 95% CI 25.46
to 59.05) (Analysis 1.34). Improvements in FEV1 were also noted
in trials where only a PDE4 inhibitor was taken (apart from short-
acting beta2 agonists) (MD 44.80 mL, 95% CI 37.69 to 51.91) (test for
subgroup diKerences: Chi2 = 5.61, df = 3 (P = 0.13) (Analysis 1.34).
Sensitivity analysis
Using a random-eKects model made no diKerence in levels of
statistical significance nor degree of heterogeneity for the change
in FEV1 (MD 51.49, 95% CI 42.87 to 60.10; Analysis 1.35). Too many
'Risk of bias' domains were judged to be at 'unclear' risk of bias
for subgroup analysis to be conducted according to study quality.
Of note, some eKect sizes were greater in the published trials, for
example, the treatment eKect on FEV1 was MD 55.75 mL (95% CI
49.45 to 62.06) in the 20 published trials, and MD 35.05 (95% CI 25.70
to 44.40) in the nine unpublished trials (Analysis 1.36), which was
significantly diKerent (test for subgroup diKerences: Chi2 = 12.94,
df = 1 (P = 0.0003)). This is illustrated in the funnel plot, with more
unpublished studies showing a smaller treatment eKect (Figure 8).
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Figure 8.   Funnel plot of comparison: 2 PDE4 inhibitor versus placebo (2020 update), outcome: 2.36 FEV1 (published
versus unpublished).











By visual analysis of the forest plot and sequential elimination, we
identified the six-week Compton 2001 cilomilast trial as a major
contributor to the heterogeneity of pooled FEV1 results. When this
trial was removed, the overall I2 statistic decreased from 45% to
26%, and in the cilomilast subgroup from 62% to 0%. It is notable
that this study had the shortest treatment duration (six weeks)
and showed the greatest improvement from baseline in FEV1 lung
function in the treatment group across all studies.
Primary outcome: SGRQ
Subgroup analysis: COPD severity
Although quality of life was improved in participants with GOLD
grade I or II COPD severity, and with GOLD grade III or IV COPD
severity (MD -1.56 units, 95% CI -2.39 to -0.74; participants = 4851;
studies = 8) (test for subgroup diKerences: Chi2 = 0.02, df = 1 (P
= 0.89)) (Analysis 1.37), overall heterogeneity was high (I2 = 55%).
Studies in which participants had grade I or II COPD severity were
similar (I2 = 0%), but variation was observed amongst studies in
which participants had grade III or IV COPD severity (I2 = 73%)
(Analysis 1.37).
Subgroup analysis: duration of treatment
It is notable that in two trials with a duration of one year that
reported total SGRQ, the change in quality of life seen with
treatment compared with control was uncertain (MD 0.26, 95% CI
-1.18 to 1.69) (Analysis 1.38). However, quality of life was improved
among participants taking a PDE4 inhibitor for less than 12 weeks
(MD -4.19, 95% CI -7.60 to -0.78) and for 24 to 26 weeks (MD -1.18,
95% CI -1.94 to -0.42). A significantly greater treatment eKect was
noted in short studies (6 to 12 weeks) compared with studies of 24
to 52 weeks. A high level of heterogeneity (I2 = 57%) was observed
amongst studies providing 24 to 26 weeks of treatment (test for
subgroup diKerences: Chi2 = 6.50, df = 2 (P = 0.04)) (Analysis 1.38).
Sensitivity analysis
Analysis revealed a diKerence in eKect size of the total SGRQ score
between published and unpublished trials (MD -1.98, 95% CI -3.07
to -0.89 versus MD -0.43, 95% CI -1.26 to 0.40) (test for subgroup
diKerences: Chi2 = 4.94, df = 1 (P = 0.03)) (Analysis 1.39).
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Secondary outcome: exacerbations
Subgroup analysis: additional medications
When investigating whether other additional medication made
any diKerence, we found similar eKicacy for both roflumilast
and cilomilast, specifically when use of concomitant long-acting
bronchodilators was permitted (OR 0.79, 95% CI 0.73 to 0.85) (test
for subgroup diKerences: Chi2 = 1.53, df = 3 (P = 0.67)) (Analysis 1.40).
D I S C U S S I O N
Summary of main results
This systematic review evaluated randomised controlled
trials (RCTs) that assessed the eKicacy and safety of oral
phosphodiesterase 4 (PDE4) inhibitors in people with chronic
obstructive pulmonary disease (COPD). The conclusions of this
review remain unchanged following the addition of new studies for
the 2020 update, reporting small improvements in lung function
and quality of life and decreased exacerbations.
Lung function
Based on data from 32 trials (low-certainty evidence), we found that
both roflumilast and cilomilast led to greater improvements in lung
function from baseline, as measured by forced expiratory volume
in one second (FEV1), forced vital capacity (FVC), or peak expiratory
flow rate (PEF), compared with placebo (Summary of findings 1).
Furthermore, improvement in lung function was seen regardless of
the severity of the disease. This improvement in FEV1 lung function
occurred whether or not PDE4 inhibitor treatment was given in
addition to other COPD treatments, such as long-acting beta2-
agonists (LABAs) or anticholinergics or inhaled corticosteroids
(ICSs).
Greater improvement in FEV1 was observed in studies of shorter
duration (Analysis 1.33); this could be due to a limited short-
term response to PDE4 inhibitor treatment, as might be seen with
tachyphylaxis, and needs further investigation.
The mean change in FEV1 was less than what is usually considered a
minimum clinically important diKerence (MCID) (100 mL; Donohue
2005), but it was comparable to that seen with other COPD
treatments in recent large RCTs. For example, mean improvement
in FEV1 of 49 mL with treatment, as seen in moderate to severe
COPD in this review, is of similar magnitude to that seen with
fluticasone (47 mL), salmeterol (42 mL), and fluticasone and
salmeterol combined (92 mL) in the TORCH 2007 study among
people with severe COPD.
Quality of life
Data show only a small improvement in quality of life as assessed by
St George's Respiratory Questionnaire (SGRQ) total score. Quality
of life had been chosen as a primary outcome because of concerns
as to whether or not the adverse eKects of PDE4 inhibitors might
outweigh any beneficial COPD-related events. The average change
in SGRQ total score was 1.06 units (over a duration between 6 and
12 months) (Summary of findings 1) and was of similar magnitude
among trials of participants with milder or more severe COPD.
Although this improvement was statistically significant, a change of
greater than four units is usually regarded as the MCID (Jones 2005).
Although symptom scores were marginally better in the treatment
groups, no change was seen in exercise tolerance, suggesting
that improvements in respiratory symptoms may not necessarily
translate into enhanced physical functioning. Fewer trials were
assessable for these outcomes, raising the possibility of type 1 or
type 2 error.
Exacerbations
A second major finding, based on data from 27 trials (moderate-
certainty evidence; Summary of findings 1), was that participants
were more likely to be exacerbation-free while being treated with
PDE4 inhibitors compared with those given control interventions.
Overall, participants were 22% less likely to have an exacerbation,
translating to a number needed to treat for an additional beneficial
outcome (NNTB) of around 20 (95% confidence interval (CI) 16
to 26) for one person to be exacerbation-free in the study period
(Figure 6; Summary of findings 1). Although the likelihood of
an individual experiencing an exacerbation was lowered with
PDE4 inhibitor treatment, the decrease in the overall rate of
exacerbations was less marked, with a relative reduction of 13%.
Taken together, results for lung function and exacerbations
suggest that PDE4 inhibitors in people with COPD are acting
independently of other treatments, particularly bronchodilators.
This is an encouraging finding that could be consistent with
a broad anti-inflammatory eKect (Fabbri 2009). On the other
hand, short-duration studies showed more favourable results
than longer studies, but the reasons for this are unclear.
Significant heterogeneity was noted among trials, suggesting that
unmeasured diKerences between trials may be having an impact.
Adverse events
Adverse events were more likely among roflumilast- and cilomilast-
treated participants than among those receiving placebo (very
low-certainty evidence; Summary of findings 1), particularly
gastrointestinal eKects such as diarrhoea, nausea, vomiting, and
dyspepsia.
Participants in treatment groups were more likely to withdraw
from trials because of adverse events; on average, 14% in the
treatment groups withdrew compared with 8% in the control
groups. Similarly, there was a slight excess in the total numbers
of participants in the treatment groups experiencing any adverse
event compared with numbers in the control groups (Analysis 1.13).
As this analysis included symptoms as well as exacerbations, which
were reduced among treatment groups, the analysis will tend
to underestimate the excess of non-COPD-related adverse events
occurring with PDE4 inhibitor treatment.
It is notable that treatment with roflumilast was associated with
an increased incidence of weight loss. Whether this was due to
anorexia from gastrointestinal adverse eKects or from another
eKect is not yet clear. Also not clear is whether cilomilast has the
same eKect, as this has not been studied. Weight loss may be a
beneficial eKect for people with COPD who are obese. In contrast,
low body mass in the later stages of COPD is associated with a worse
prognosis and is notoriously diKicult to reverse (GOLD 2020). This
adverse eKect warrants further investigation. It is reassuring that
there was no increase in serious adverse events nor in mortality,
although trials were of relatively short duration and analyses were
underpowered to report on the latter outcome.
Although the lower dose (250 μg) of roflumilast produced similar
improvements in FEV1 (Analysis 1.32) and was associated with
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slightly fewer adverse events than the larger dose (Analysis 1.14),
the lower dose was associated with a smaller reduction in rates
of exacerbation when compared with the higher dose in the
only trial that reported this (Roflumilast FK1 101). Moreover, data
on the lower dose were available from a limited number of
studies, and this has not been studied as add-on therapy to other
bronchodilators.
Awareness of the risk of psychiatric adverse events associated
with roflumilast treatment is growing (Analysis 1.25; Summary of
findings 1), in particular the increased likelihood of experiencing
sleep disturbances, anxiety, and depressed mood. It should be
noted that we found three reports of completed suicides and two of
suicide attempts among roflumilast-treated participants compared
to none in participants given placebo (roflumilast COPD safety
database).
Mortality
Mortality was a rare event, and there was no diKerence between
participants treated with a PDE4 inhibitor and those given placebo
(Analysis 1.30; Summary of findings 1).
Overall completeness and applicability of evidence
We have reviewed all known published and unpublished trials
identified through standard Cochrane searches, as well as those
obtained from the trials register for the National Institutes of Health
(NIH) and from pharmaceutical websites.
We have not been able to verify the pooled endpoint data
for psychiatric (treatment possibly harmful) and cardiovascular
adverse events (treatment possibly beneficial), as we obtained this
information from reports on the US Food and Drug Administration
(FDA) website and from White 2013, respectively.
To ensure that our Cochrane systematic review accurately reflects
all known outcomes of roflumilast therapy, for previous updates we
approached the manufacturer of roflumilast for study-level data on
each of the cardiovascular outcomes (cardiovascular death, non-
fatal myocardial infarction, and non-fatal stroke), as well as the
composite outcome, major adverse cardiovascular events (MACE).
This would have allowed us to perform comparisons both within
(i.e. between roflumilast and placebo groups) and among the
studies. Unfortunately, our request for individual trial data was
refused, with the following reasons cited.
• It is inappropriate from a statistical perspective to look into
individual trials with too small a sample size for this kind of
relatively rare endpoint.
• It was part of the retrospective analyses to evaluate the whole
data set with a suKiciently broad database and not to go into per-
study data that would comprise numbers in each treatment arm
that were too low for conclusive interpretation.
• In none of the studies was blinded adjudication of events
implemented as a prospective analysis, which would have
required a data release in terms of transparency for each
individual study (this is why it was not mentioned in the original
publications of individual trials).
In response to the statement by representatives of Takeda
Pharmaceuticals Limited, we have urged that these issues be
reconsidered for future studies, and that study data be made more
widely available. Finally, caution must be used when interpreting
associations between COPD exacerbations and MACE, because
although treatment groups were matched at baseline, it cannot be
assumed that these groups are equivalent when the focus is only
on groups of participants who experienced exacerbations. These
concerns could not be assessed in this review, as further study data
were not provided.
Certainty of the evidence
For the key outcomes of changes in lung function and quality
of life, greater beneficial eKects of PDE4 inhibitors were reported
in published than in unpublished studies, raising concerns about
publication bias. When investigating publication bias further for
each outcome, we found that eliminating from the analyses studies
with suspected publication bias did not significantly alter overall
eKect estimates or confidence intervals for lung function or quality
of life. Similarly, this was apparent when adverse events were
investigated.
We identified a moderate level of heterogeneity for both of the
primary outcomes for this review, which is not fully explained by
subgroup or sensitivity analyses according to study duration or
concomitant medication use. This suggests that unknown factors
that may impact eKect size have led us to downgrade the quality
of evidence and the certainty of our findings (Summary of findings
1). In contrast, the blinded design of studies comparing roflumilast
or cilomilast with placebo protected against detection bias in our
view. The certainty of evidence for a reduction in exacerbation was
therefore higher for this comparison. On balance, we believe the
true beneficial eKect of PDE4 inhibitors is likely to be no greater
than we have reported and is probably less; equally, the harms of
PDE4 treatment may have been understated (due in part to higher
withdrawal rates in active treatment arms). On the other hand,
as subgroup analyses for COPD severity are based on the mean
predicted lung function for the study group and not for individual
participants, we cannot rule out benefit for individuals of a specific
COPD phenotype.
Addition of new trials
The 2020 update of this review included four studies on roflumilast
500 µg and one study on tetomilast (Kavitha 2018; Liu 2018;
NCT00874497 (EMPHASIS); RO-2455-402-RD (ROBERT); Urban 2018
(ELASTIC)). Data from these new trials did not aKect the results
already yielded by analyses. Kavitha 2018 and Liu 2018 were not
included in the analyses for lung function, as the units for this
endpoint were unclear even though we contacted trial authors for
clarification. Data from Liu 2018 were not included in the meta-
analysis for SGRQ due to unclear data units in the publication.
Potential biases in the review process
Potential biases in the review process were minimised by double-
checking of data extraction and input. The review authors have no
conflicts of interest to declare.
Agreements and disagreements with other studies or
reviews
Several other meta analyses have been conducted, including
Luo 2016, Yuan 2016, and Shen 2018. Each of these included
fewer studies than the present review but presented findings and
conclusions that were similar. Our findings are also similar to those
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presented by Wedzicha 2016 and show eKects on exacerbations
similar to those described in Rabe 2017.
In a post hoc pooled analysis (n = 5595) of four trials in this
review (Rennard 2014), roflumilast was seen to improve transition
dyspnoea index (TDI) focal scores of breathlessness versus placebo
at week 52 (treatment diKerence 0.327; P < 0.0001). Roflumilast was
associated with more TDI responders and fewer TDI deteriorators
(≥ 1-unit increase or decrease from baseline, respectively) versus
placebo at week 52 (P < 0.01, both). Rates of MACE in COPD
participants treated with PDE4 inhibitors have been meta-analysed
and reported in White 2013. This review found that risk of
cardiovascular death, non-fatal myocardial infarction, or non-fatal
stroke, when combined into a composite outcome MACE, was
reduced in the roflumilast group compared with the placebo group
(hazard ratio 0.65, 95% CI 0.45 to 0.93; P = 0.019). On the other hand,
hazard ratios for treatment eKects for each of these types of events
individually were statistically diKerent. Cardiovascular events were
higher among participants with baseline cardiovascular risk factors
than among those without baseline cardiovascular risk (defined as
the presence of hypertension, diabetes mellitus, hyperlipidaemia,
and/or a history of heart disease). In addition, it was found that
the diKerence between treatment and placebo was statistically
significant only for the group of participants without baseline risk
factors. Event rates in a subgroup of trials that were one year in
duration show no significant diKerences between treatment and
placebo groups in the proportion of participants who reported a
MACE, even when divided into those who did or did not experience
a COPD exacerbation. Similarly, between participants with and
without MACE events, the proportions of participants experiencing
exacerbations were similar (43.2% and 42.1%, respectively).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Phosphodiesterase-4 (PDE4) inhibitors are oral medicines that may
be taken in combination with other standard chronic obstructive
pulmonary disease (COPD) treatments. Most evidence has been
gathered for roflumilast at a dose of 500 μg daily and cilomilast at
15 mg twice daily.
PDE4 inhibitors join an increasing list of treatments for COPD
that improve short-term lung function and reduce exacerbations,
but they have not been shown to increase life expectancy. Most
trials to date have been one year in duration (with the exception
of one study of nearly two years' duration). In contrast to long-
acting bronchodilators, PDE4 inhibitors have minimal benefit for
symptoms on a day-to-day basis, or for quality of life, and are oWen
associated with adverse eKects, especially gastrointestinal eKects
and headaches. Roflumilast is associated with greater weight
loss and increased psychiatric symptoms compared with placebo.
Findings of this review provide cautious support for the use of PDE4
inhibitors in COPD. In accordance with GOLD 2020 guidelines, PDE4
inhibitors may have a place as add-on therapy for a subgroup of
people with persistent symptoms or exacerbations despite optimal
COPD management (e.g. people who are not controlled on fixed-
dose long-acting beta2-agonist (LABA) and inhaled corticosteroid
(ICS) combinations).
Implications for research
This review has highlighted several possible topics for further study.
• EKects of PDE4 inhibitors on forced expiratory volume in
one second (FEV1) decline and mortality in studies of longer
duration.
• EKects of PDE4 inhibitors at shorter time points in longer-
duration studies on FEV1.
• Subgroup analysis of participants with/without chronic
bronchitis and with/without a history of exacerbations.
• EKects of PDE4 inhibitors among participants with frequent
exacerbations.
• EKects of PDE4 inhibitors on healthcare utilisation, including
hospitalisation (incidence and bed days).
• Direct comparison of PDE4 inhibitors and inhaled corticosteroids
(ICSs) when used as add-on therapies to tiotropium, to long-
acting beta2-agonists (LABA), or to all three (triple inhaled
therapies).
• Direct comparison of tiotropium or LABA, or both, as add-on
therapies to PDE4 inhibitors (± ICS).
• EKects of roflumilast on quality of life.
• Better characterisation of the weight loss seen with PDE4
inhibitors in COPD.
• Better description of the nature of eKects on exacerbations that
do occur.
• Use of PDE4 inhibitors in acute exacerbations.
• Cost-eKectiveness of PDE4 inhibitors.
• Increased exercise tolerance data for roflumilast.
• Increased data on tetomilast.
• Whether there is any benefit on cardiovascular outcomes for
PDE4 inhibitors in COPD.
• Use of eKects of PDE4 inhibitors to better understand the
pathophysiology of COPD.
• Further evaluation of roflumilast 250 µg versus 500 µg daily.
• Subgroup analysis of participants based on their weight.
• Use of CAT score as an outcome.
• Responder analyses (e.g. proportion of participants achieving a
minimum clinically important diKerence).
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: stated
Cilomilast 039 
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Participants Setting: 102 centres in Canada, Mexico, and the USA
Participants: 647 (15 mg cilomilast: 431, placebo: 216)
Baseline characteristics: mean age 65 years, 62% male, mean FEV1 % predicted 49.7%, mean smok-
ing history 59.9 pack-years for cilomilast and 56.1 pack-years for placebo, or current smokers (44% and
47%, respectively)
Inclusion criteria: FEV1/FVC ≤ 0.7, FEV1 30% to 70% with smoking history > 10 pack-years or current
smokers
Exclusion criteria: active tuberculosis, lung cancer, bronchiectasis
Total numbers of participant withdrawals: 137 (32%) and 52 (24%) from treatment and control
groups, respectively
Interventions Run-in: 4 weeks, single-blind. Placebo tablets to assess suitability
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: "the only other permitted medications for the treatment of airways dis-
ease were stable doses of Ipratropium, via a metered-dose inhaler, and mucolytic agents"
• SABA: "...the short-acting β2-agonist albuterol, which was administered via a metered-dose inhaler,
was supplied for the relief of acute respiratory symptoms"
• Corticosteroid: none
• LABA: none
Outcomes Primary outcomes: lung function; change in FEV1; SGRQ averaged over 24 weeks
Secondary outcomes: incidence rate of COPD exacerbations; adverse events; FVC at trough; 6MWT;
post-exercise dyspnoea
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Low risk The trial was double-blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk "The primary reasons for the withdrawal of subjects from the study prior to
randomisation were the failure to meet inclusion/exclusion criteria (15.4%)
and the presence of adverse effects, including COPD exacerbations (8.5%).
Cilomilast 039  (Continued)
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More subjects receiving cilomilast than placebo withdrew from the dou-
ble-blind phase of study (31.8% (n = 137) versus 24.1% (n = 52)"
Selective reporting (re-
porting bias)
Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website
Other bias Low risk Baseline anticholinergic, beta2-agonist, or corticosteroid use 54% in cilomi-
last, 58% placebo used ipratropium; 99% in cilomilast, 100% placebo used al-
buterol; 9% in cilomilast, 12% placebo used salmeterol; 7% in cilomilast, 8%






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: stated
Participants Setting: 98 centres in Australia and New Zealand, Germany, Spain, South Africa, and the UK
Participants: 700 (15 mg cilomilast: 474, placebo: 226)
Baseline characteristics: mean age 64.6 years, 80% male, mean FEV1 % predicted 49% with 5.1% re-
versibility, DLCO 71% predicted, also with higher rates of chronic bronchitis 80.1%. 45% active smokers
Inclusion criteria: aged 40 to 80 years, FEV1/FVC ≤ 0.7, FEV1 30% to 70% with smoking history > 10
pack-years
Exclusion criteria: active tuberculosis, lung cancer, bronchiectasis
Total numbers of participant withdrawals: 122 (26%) and 51 (23%) from treatment and control
groups, respectively
Interventions Run-in: 4 weeks, single-blind with placebo
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: 2% in cilomilast, 3% placebo used salbutamol; 3% in cilomilast, 1%
placebo used ipratropium
• SABA: "albuterol MDI was used as rescue medication"
• Corticosteroid: none
• LABA: none
Outcomes Primary outcomes: lung function; change in FEV1; SGRQ averaged over 24 weeks
Secondary outcomes: incidence rate of COPD exacerbations; summary symptom score; FVC at trough;
6MWT; post-exercise dyspnoea
Notes Funded by GlaxoSmithKline
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Low risk The trial was double-blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Total numbers of participants withdrawn 51 (23%) placebo, 122 (26%) cilomi-




Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 12 weeks
Analysis was done on per-protocol population
Participants Setting: not stated
Participants: 59 (15 mg cilomilast: 29, placebo: 30)
Baseline characteristics: mean age 61 to 62 years, 81% male, 53% active smokers, mean 46 pack-
years, 53% to 58% FEV1 predicted
Inclusion criteria: aged 40 to 80 years, fixed airflow obstruction, smoking history > 10 pack-years
Exclusion criteria: not stated
Total numbers of participant withdrawals: 4 (14%) and 2 (7%) from treatment and control groups,
respectively
Interventions Run-in: 4 weeks, single-blind with placebo
• Cilomilast 15 mg twice daily
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• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: "14 of 59 used ipratropium bromide at a constant dosage (8 in the place-
bo group, 6 in the cilomilast group)"
• SABA: "all patients were given albuterol for use as required"
• Corticosteroid: none
• LABA: none
Used alongside SABA (available to all) and anticholingeric drugs (offered to 24%)
Outcomes Primary outcome: change in neutrophil percentage in induced sputum
Secondary outcomes: FEV1; numbers of subepithelial CD8+ cells, CD 68+ cells, epithelial, and subep-
ithelial neutrophils
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Unclear risk The trial was double-blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk "One patient was lost to follow-up 3 days after randomisation and another
withdrawn for non-compliance 32 days after randomisation. Four patients
were withdrawn after adverse events"
Selective reporting (re-
porting bias)
Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
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Intention-to-treat analysis: stated
Participants Setting: 110 centres in Belgium, Finland, France, Italy, the Netherlands, Norway, Portugal, Spain, and
the UK
Participants: 711 (15 mg cilomilast: 469, placebo: 242)
Baseline characteristics: mean age 64.6 years, 86% male, mean FEV1 % predicted 53% with 5.0% re-
versibility, 38% active smokers
Inclusion criteria: FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years
Exclusion criteria: active tuberculosis, lung cancer, bronchiectasis
Total numbers of participant withdrawals: 121 (26%) and 63 (26%) from treatment and control
groups, respectively
Interventions Run-in: 4 weeks, single-blind with placebo
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: 0.9% in cilomilast, 4% placebo used salbutamol; 1% in cilomilast, 3%
placebo used ipratropium
• SABA: "albuterol MDI was used as rescue medication"
• Corticosteroid: none
• LABA: none
Outcomes Primary outcomes: lung function; change in FEV1; SGRQ averaged over 24 weeks
Secondary outcomes: incidence rate of COPD exacerbations; summary symptom score; FVC at trough;
6MWT; post-exercise dyspnoea
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Low risk The trial was double-blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Total numbers of participants withdrawn 63 (26%) placebo, 121 (26%) cilomi-
last, primarily due to adverse events, of which most were not due to COPD ex-
acerbations
Cilomilast 091  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk Outcomes were reported as planned. Trial information was reported on the
GSK website only






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: stated
Participants Setting: 103 centres in the USA
Participants: 613 (15 mg cilomilast: 296, placebo: 317)
Baseline characteristics: mean age 63.2 years placebo, 63.1 years cilomilast, 47% male placebo, 46%
male cilomilast. Mean FEV1 % predicted not available
Inclusion criteria: aged ≥ 40 years, FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years, ≤ 70% post-
albuterol reversibility, ≤ 15% or ≤ 200 mL (or both) post-albuterol FEV1 ≤ 70% of predicted normal, ≥ 1
COPD exacerbation within 12 months before screening
Exclusion criteria: not stated
Total numbers of participant withdrawals: 105 (35%) and 76 (24%) from treatment and control
groups, respectively
Interventions Run-in: not stated
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: no information available
• SABA: no information available
• Corticosteroid: no information available
• LABA: no information available
Outcomes Primary outcomes: change from baseline to endpoint in trough pre-bronchodilator FEV1; change in to-
tal SGRQ score averaged over 24 weeks
Secondary outcomes: changes from baseline in clinic trough FVC; time to first level 2 or level 3 COPD
exacerbation
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
Low risk Assumed that trialists used a robust method to carry out the randomisation
process because of pharmaceutical company sponsorship
Allocation concealment
(selection bias)
Low risk Assumed that trialists used a robust method to carry out the randomisation





Unclear risk The trial was double-blinded (participants and investigator). It is not clear if
the investigator was administering the treatment
Blinding of outcome as-
sessment (detection bias)
All outcomes








Low risk Outcomes were reported as planned. The trial was registered at clinicaltrial-
s.gov






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 12 weeks
Analysis was done on per-protocol population
Participants Setting: 10 centres in the USA
Participants: 65 (15 mg cilomilast: 31, placebo: 34)
Baseline characteristics: mean age 64.4 years placebo and 66.1 years cilomilast, 67% male placebo
and 84% male cilomilast, mean FEV1 % predicted not available
Inclusion criteria: aged 40 to 80 years, FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years, post-salbu-
tamol reversibility ≤ 15% or 200 mL, post-salbutamol FEV1 ≥ 1.0 L and between 30% and 70% predicted
Exclusion criteria: not stated
Total numbers of participant withdrawals: 1 (3%) and 1 (3%) from treatment and control groups, re-
spectively
Interventions Run-in: not stated
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
Cilomilast 110 
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• Short-acting anticholingeric: no information available
• SABA: no information available
• Corticosteroid: no information available
• LABA: no information available
Outcomes Primary outcome: change from baseline at endpoint in neutrophils as a percentage of total cells in in-
duced sputum
Secondary outcomes: FVC at trough; sputum macrophages, eosinophils, and lymphocytes as a per-
centage of total cells in induced sputum; total cell counts in induced sputum
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Assumed that trialists used a robust method to carry out the randomisation
process because of pharmaceutical sponsorship
Allocation concealment
(selection bias)
Low risk Assumed that trialists used a robust method to carry out the randomisation





Low risk The trial was double-blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Total numbers of participants withdrawn 1 (3%) placebo, 1 (3%) cilomilast
Selective reporting (re-
porting bias)
Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website only






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 12 weeks
Intention-to-treat analysis: stated
Participants Setting: 32 centres in the USA, Canada, and Australia
Participants: 156 (15 mg cilomilast: 79, placebo: 77)
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Baseline characteristics: mean age 64.2 years placebo and 65 years cilomilast, 66% male placebo and
65% male cilomilast, mean FEV1 % predicted not available
Inclusion criteria: aged 40 to 80 years, FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years, post-salbu-
tamol reversibility ≤ 15% or 200 mL, post-salbutamol FEV1 ≥ 1.0 L and between 30% and 70% predicted,
baseline RV (from plethysmography) ≥ 120% predicted RV
Exclusion criteria: not stated
Total numbers of participant withdrawals: 15 (19%) and 14 (18%) from treatment and control
groups, respectively
Interventions Run-in: not stated
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: no information available
• SABA: no information available
• Corticosteroid: no information available
• LABA: no information available
Outcomes Primary outcome: change from baseline to endpoint in volume of trapped gas (D)
Secondary outcomes: lung volume measurements, including SVC and RV; 6MWT; exertional dyspnoea
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Assumed that trialists used a robust method to carry out the randomisation
process because of pharmaceutical sponsorship
Allocation concealment
(selection bias)
Low risk Assumed that trialists used a robust method to carry out the allocation con-





Low risk The trial was double-blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes








Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website only
Other bias Unclear risk No information on baseline anticholinergic, beta2-agonist, or corticosteroid
use
Cilomilast 111  (Continued)
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Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: stated
Participants Setting: 22 centres in China
Participants: 1018 (15 mg cilomilast: 678, placebo: 340)
Baseline characteristics: mean age 63.9 years placebo and 64.6 years cilomilast, 91% male placebo
and 93% male cilomilast, mean FEV1 % predicted not available
Inclusion criteria: aged 40 to 75 years, FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years, docu-
mented history of COPD exacerbations each year for 3 years before screening, ≥ 1 exacerbation in the
last year that required oral corticosteroids or antibiotics, post-salbutamol reversibility ≤ 15% or 200
mL, post-salbutamol FEV1 ≥ 1.0 L and between 25% and 70% predicted, % predicted FRC ≥ 120% from
plethysmography
Exclusion criteria: not stated
Total numbers of participant withdrawals: 124 (18%) and 35 (10%) from treatment and control
groups, respectively
Interventions Run-in: not stated
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: no information available
• SABA: no information available
• Corticosteroid: no information available
• LABA: no information available
Outcomes Primary outcome: change from baseline to endpoint in trough pre-bronchodilator FEV1
Secondary outcomes: time to first level 2 or level 3 COPD exacerbation (level 2 is defined as acute
worsening of COPD that requires additional treatment or hospital outpatient visit; level 3 is hospital ad-
mission for treatment); change from baseline to endpoint RV and FRC; change from baseline total score
on SGRQ
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Assumed that trialists used a robust method to carry out the randomisation
process because of pharmaceutical company sponsorship
Allocation concealment
(selection bias)
Low risk Assumed that trialists used a robust method to carry out the allocation con-
cealment process because of pharmaceutical company sponsorship
Cilomilast 121 
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)














Low risk The trial was double-blind
Blinding of outcome as-
sessment (detection bias)
All outcomes








Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website only






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: stated
Participants Setting: 132 centres in USA and Canada
Participants: 825 (15 mg cilomilast: 418, placebo: 407)
Baseline characteristics: mean age 64.4 years placebo and 64.5 years cilomilast, 62% male placebo
and 56% male cilomilast, > 50% predicted FEV1 for both groups
Inclusion criteria: aged 40 to 80 years, FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years, post-salbu-
tamol reversibility ≤ 15% or 200 mL, post-salbutamol FEV1 ≥ 1.0 L and between 30% and 70% predicted
Exclusion criteria: not stated
Total numbers of participant withdrawals: 143 (34%) and 96 (24%) from treatment and control
groups, respectively
Interventions Run-in: not stated
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric 8.1% in cilomilast, 8.6% placebo used salbutamol; 1.7% in cilomilast, 2%
placebo used ipratropium bromide
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Outcomes Primary outcomes: change from baseline to endpoint in trough pre-bronchodilator FEV1; change in to-
tal SGRQ score averaged over 24 weeks
Secondary outcomes: post-exercise breathlessness; clinic trough FVC; time to first level 2 or level 3
COPD exacerbation
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk Patients and personnel did not know which treatment had been allocated
Blinding of outcome as-
sessment (detection bias)
All outcomes








Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website only






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 52 weeks
Intention-to-treat analysis: stated
Participants Setting: 137 centres from 18 countries
Participants: 907 (15 mg cilomilast: 455, placebo: 452)
Baseline characteristics: mean age 63.3 years placebo and 64.6 years cilomilast, 73% male placebo
and 78% male cilomilast, 42% current smokers
Inclusion criteria: aged 40 to 80 years, FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years, poor re-
versibility of airway obstruction defined by ≤ 10% predicted normal or ≤ 200 mL (or both) increase in
Cilomilast 157 
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FEV1 after administration of salbutamol 400 µg via MDI at screening, post-salbutamol FEV1 between
30% and 70% predicted normal at screening
Exclusion criteria: not stated
Total numbers of participant withdrawals: 167 (37%) and 121 (27%) from treatment and control
groups, respectively
Interventions Run-in: not stated
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: no information available
• SABA: no information available
• Corticosteroid: no information available
• LABA: no information available
Outcomes Primary outcomes: mean change from baseline in trough pre-bronchodilator FEV1 averaged over 52
weeks; incidence rate of level 2 (moderate) and level 3 (severe) COPD exacerbations during treatment
period
Secondary outcomes: time to first level 2 or level 3 COPD exacerbation; quality of life determined by
SGRQ
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation code was generated via the pharmaceutical company's coding
memo system in blocks
Allocation concealment
(selection bias)





Low risk Patients and investigator were blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes








Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website only
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Study characteristics
Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 12 weeks
Intention-to-treat analysis: not stated
Participants Setting: 42 centres in the USA
Participants: 306 (15 mg cilomilast: 203, placebo: 103)
Baseline characteristics: mean age 64.3 years placebo and 65.0 years cilomilast, 64% male placebo
and 70% male cilomilast
Inclusion criteria: pre-albuterol FEV1/FVC ≤ 0.7, post-albuterol FEV1 between 30% and 70% predicted
Exclusion criteria: not stated
Total numbers of participant withdrawals: 61 (30%) and 14 (14%) from treatment and control
groups, respectively
Interventions Run-in: not stated
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: no information available
• SABA: no information available
• Corticosteroid: no information available
• LABA: no information available
Outcomes Primary outcome: no primary efficacy or safety analyses defined; descriptive statistics of change from
baseline in minimum and maximum heart rate via 24-hour Holter monitoring reported
Secondary outcome: no secondary efficacy or safety analyses defined
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk The trial was double-blind
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Blinding of outcome as-
sessment (detection bias)
All outcomes








Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website only






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 18 weeks
Intention-to-treat analysis: stated
Participants Setting: 34 centres in the USA, Canada, and South America
Participants: 199 (15 mg cilomilast: 97, placebo: 102)
Baseline characteristics: mean age 64.7 years placebo and 63.7 years cilomilast, 76% male placebo
and 69% male cilomilast
Inclusion criteria: age ≥ 40 years, FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years, baseline FEV1 <
70% predicted normal, moderate to severe chronic dyspnoea defined by BDI focal score ≤ 7, evidence
of hyperinflation defined by RFRC ≥ 140% predicted, exercise limitation defined as peak symptom limit-
ed VO2 < 75%
Exclusion criteria: not stated
Total numbers of participant withdrawals: 24 (25%) and 13 (13%) from treatment and control
groups, respectively
Interventions Run-in: not stated
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: no information available
• SABA: no information available
• Corticosteroid: no information available
• LABA: no information available
Outcomes Primary outcome: change from baseline at endpoint in RFRC
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Secondary outcomes: change from baseline at endpoint in IC during exercise; exertional dyspnoea as
measured by the modified Borg Scale
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Patients were randomised via a call to the sponsor's medication ordering sys-
tem, during which the patient's subject number was confirmed and the patient
was provided with a 6-digit container number for identification of the initial
bottle of double-blind medication
Allocation concealment
(selection bias)





Low risk The trial was double blind. Cilomilast and matched placebo tablets were iden-
tical in appearance, and only the double-blind medication included the con-
tainer number
Blinding of outcome as-
sessment (detection bias)
All outcomes








Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website only






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 13 weeks
Analysis was done on the per-protocol population
Participants Setting: 27 centres in Australia, Canada, Finland, Ireland, Lithuania, Norway, Romania, Slovakia, Slove-
nia, South Africa, Sweden, and the UK
Participants: 127 (15 mg cilomilast: 65, placebo: 62)
Baseline characteristics: mean age 63.4 years placebo and 61.4 years cilomilast, 76% male placebo
and 72% male cilomilast
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Inclusion criteria: aged 40 to 80 years, FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years, post-bron-
chodilator FEV1 between 40% and 80% predicted normal, poor reversibility of ≤ 10% or 200 mL increase
in FEV1
Exclusion criteria: not stated
Total numbers of participant withdrawals: 8 (12%) and 6 (10%) from treatment and control groups,
respectively
Interventions Run-in: not stated
• Cilomilast 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: no information available
• SABA: no information available
• Corticosteroid: no information available
• LABA: no information available
Outcomes Primary outcomes: change from baseline at endpoint in CD68+ (macrophages) and CD8+ (cytotoxic T
lymphocytes) per unit area of tissue
Secondary outcomes: change from baseline in numbers of subepithelial cells per unit area in biopsy
for neutrophil elastase-positive (ne+) cells, CD4+, IL-8 mRNA-positive cells, TNF-alpha mRNA-positive
cells
Notes Funded by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A central randomisation schedule that was balanced at site level. An interac-










Low risk The trial was double-blind. Participants and personnel were blind to which
treatment they were assigned to. Cilomilast and matched placebo tablets were
identical in appearance, and only the double-blind medication included the
container number
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Total numbers of participants withdrawn 6 (10%) placebo, 8 (12%) cilomilast
Selective reporting (re-
porting bias)
Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website only
Other bias Low risk No information on baseline anticholinergic, beta2-agonist, or corticosteroid
use
Cilomilast 181  (Continued)
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Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 6 weeks
Intention-to-treat analysis: stated
Participants Setting: 60 centres in Austria, France, Germany, the Netherlands, and the UK
Participants: 424 (5 mg cilomilast: 109, 10 mg cilomilast: 102, 15 mg cilomilast: 107, placebo: 106)
Baseline characteristics: mean age 62 to 63 years, 75% to 78% male, mean FEV1 % predicted 46.8%,
mean smoking history 36 to 43 (SD 22.4) pack-years
Inclusion criteria: FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years
Exclusion criteria: asthma, poorly controlled COPD needing hospital visit 6 weeks before study, recent
COPD exacerbations, recent corticosteroid use
Total numbers of participant withdrawals: 18 (17%) and 17 (16%) from treatment and control
groups, respectively
Interventions Run-in: 2 weeks, single-blind, placebo tablets to assess compliance
• Cilomilast 5 mg, 10 mg, 15 mg twice daily
• Placebo twice daily
Concomitant medication
• Short-acting anticholingeric: 382 (90%) participants were given concomitant treatment for COPD dur-
ing the study; 267 (70%) salbutamol and 115 (30%) ipratropium bromide
• SABA: salbutamol used in 70%
• Corticosteroid: none
• LABA: none
Outcomes Primary outcomes: lung function: change in FEV1; SGRQ
Secondary outcomes: peak expiratory flow and FVC; first dose effect of active treatment on FEV1
Notes Post-bronchodilator results not given, so pre-bronchodilator values used in analysis. Funded by Glax-
oSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk The trial was double-blinded. Participants were not aware of which treatment
they were receiving because cilomilast and matched placebo tablets were
identical in appearance
Compton 2001 
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All outcomes
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk "14 patients (13%) taking cilomilast 15 mg had adverse events leading to pa-
tient withdrawal, as did 12 each in the 5 and 10 mg groups (11 and 12%, re-
spectively) and eight (8%) in the placebo group"
Selective reporting (re-
porting bias)
Unclear risk Unclear whether outcomes were assessed as planned; it was not possible to
find the trial in the GSK registry
Other bias Low risk 102 (24%) participants had been taking long-acting β2-agonists (e.g. salme-
terol, formoterol). 331 (78%) individuals had taken other medications for their
COPD, the most common being inhaled steroids; 229 (54%) took beclometha-





Methods 14 double-blind and placebo-controlled studies (Roflumilast FK1 101; Roflumilast FK1 103; Roflumilast
IN-108; Roflumilast M2-107; Roflumilast M2-110; Roflumilast M2-111; Roflumilast M2-112; Roflumilast
M2-118; Roflumilast M2-119; Roflumilast M2-121; Roflumilast M2-124; Roflumilast M2-125; Roflumilast
M2-127; Roflumilast M2-128)
Participants See individual studies
Interventions Roflumilast 500 µg once daily
















Low risk The trials were double-blind
Blinding of outcome as-
sessment (detection bias)
Unclear risk Assumed that this would be low risk; however, no available information
COPD safety pool 
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Unclear risk See individual studies
Selective reporting (re-
porting bias)
Unclear risk See individual studies





Methods Study design: parallel-group study
Randomisation: randomised controlled trial
Trial duration: 12 weeks
Intention-to-treat analysis: not stated
Participants Setting: 1 pulmonary medicine ward in India
Participants: 61 (intervention: 31; control: 30)
Baseline characteristics: mean age 58 years, mean FEV1 predicted 0.93, current smokers 33%
Inclusion criteria: Indian ethnicity, age ≥ 40 years with moderate to severe COPD, current or past
smokers, other co-existing conditions
Exclusion criteria: bronchial asthma, other lung diseases, lower respiratory tract infection, pregnant
or breastfeeding
Total numbers of participant withdrawals: not stated; assumed 1 person was not included in the
analysis
Interventions Run-in: not stated
• Roflumilast 500 µg once daily with 12 µg formoterol and 9 µg tiotropium combination metered-dose
inhaler once daily
• Formoterol 12 µg and 9 µg tiotropium combination metered-dose inhaler once daily
Concomitant medication
• All study participants were taking formoterol 12 µg and 9 µg tiotropium combination metered-dose
inhaler
Outcomes Primary outcomes: lung function (FEV1 and FVC); change in mean FEV1 after treatment
Secondary outcomes: adverse events in the roflumilast treatment group
Notes Funding not stated
Risk of bias
Bias Authors' judgement Support for judgement
Kavitha 2018 
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Random sequence genera-
tion (selection bias)
High risk Reported as a "randomised control study". No further information about ran-
domisation method. Also, groups are not balanced with regards to baseline









High risk Assumed that there was no blinding of participants or personnel
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Only 1 participant in the roflumilast group was lost; however, reasons for attri-
tion were not reported
Selective reporting (re-
porting bias)
High risk Outcomes not reported in the methods, so unclear whether outcomes report-
ed were what they intended to assess. Adverse event data were not report-
ed for the control group, so it is unclear whether there were no events in this
group. Outcome data for FEV1 were not clear, as no units were reported. If it
is assumed that trial authors reported litres, then those in the intervention
group improved by 660 mL, which is large in COPD terms, as it indicates 28%
improvement, yet in the discussion, trial authors mention that it is similar to
the 60 mL reported in the Fabbri study






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 52 weeks
Intention-to-treat analysis: stated
Participants Setting: single hospital in Yan'an, China
Participants: 120 (roflumilast 500 µg: 60, placebo: 60)
Baseline characteristics: COPD stage II to IV according to GOLD criteria, mean age 65 years, FEV1 %
predicted < 50%, 72% male, smoking history 37 pack-years, 66% current smokers
Inclusion criteria: aged ≥ 40 years, post-bronchodilator FEV1 < 50% predicted, FEV1:FVC ratio 70%,
post-bronchodilator FEV1 with 30% to 80% predicted, COPD history > 12 months, no medication change
for past 3 months
Exclusion criteria: asthma, other lung disease, systemic glucocorticosteroids, SABA 1 month before
study, severe mental disorder, pregnant or breastfeeding
Liu 2018 
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Total numbers of participant withdrawals: 5 (8%) and 6 (10%) from treatment and control groups,
respectively
Interventions Run-in: not stated
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
• Anticholingeric: 40% of participants were on anticholinergics
• β2-agonist: 34% of participants were on β2-agonists
• Corticosteroid: 18% of participants were on ICSs
• LABA: not stated
23% of participants were on home oxygen therapy
Outcomes Primary outcome: change from baseline in lung function (FEV1, FVC, and FEF25%-75%)
Secondary outcomes: quality of life (SGRQ); adverse events
Notes Funding not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was achieved via a computerised number programme generat-
ed by a statistician who was blinded to treatment allocation
Allocation concealment
(selection bias)
Unclear risk Unclear how the allocation sequence was concealed from patients (i.e. no





Low risk Participants were reported to be blinded to treatment allocation; investiga-
tors, data analysts, and outcome assessors were blinded to treatment alloca-
tion
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Participants were reported to be blinded to treatment allocation; investiga-





Low risk Overall, the number of withdrawals was 9%; however there was 1 more with-
drawal in the placebo group compared to the intervention group
Selective reporting (re-
porting bias)
High risk Reporting of outcome data for lung function and SGRQ is unclear. Data provid-
ed consist of mean difference and 95% CI when standard errors should be pro-
vided. A check of the data revealed discrepancies in the numbers. Data for ad-
verse events were also unclear. There was no reference to a protocol, so we do
not know whether outcomes were reported as planned. The paper includes
some confusing statements about follow-up at 12 weeks vs 12 months - prob-
ably 12 months - but then follow-up for another 3 months. Abstract states that
adverse events were increased, but this is not the same as the data in the pa-
per
Other bias Low risk No information on baseline anticholinergic, beta2-agonist, or corticosteroid
use
Liu 2018  (Continued)
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Methods Study design: parallel-group study
Randomisation: randomised, triple-blind, placebo-controlled trial
Trial duration: 104 weeks
Intention-to-treat analysis: stated
Participants Setting: 12 specialist centres across the USA
Participants: 84 (tetomilast 25 µg: 51, placebo: 33)
Baseline characteristics: mean age 58 years, 51% male
Inclusion criteria: aged 40 to 75 years, rating ≥ 1 on Goddart scale for emphysema, FEV1:FVC > 70% pre-
dicted, ≥ 1 COPD exacerbation in the past 12 months
Exclusion criteria: asthma, active tuberculosis/bronchiectasis, respiratory tract infection in past
month before screening, cancer in past 5 years, cardiovascular/endocrine blood/nervious system disor-
der, uncontrolled COPD exacerbation (level 2 or 3), recent systemic ICS or immunosuppressant, antico-
agulant
Total numbers of participant withdrawals: 28 (54%) and 18 (54%) from treatment and control
groups, respectively
Interventions Run-in: 25 µg dose tetomilast for 2 weeks
Intervention: 50 µg once daily
Comparator: placebo once daily
Concomitant medication
• Short-acting anticholingeric: not stated
• SABA: not stated
• Corticosteroid: not stated
• Long-acting beta2-agonist: not stated
Outcomes Primary outcomes: change in FEV1; rate of change in 20th percentile of lung voxels
Secondary outcomes: change in trough FEV1; density mask score based on lung density voxels; rate of
change in 20th percentile of lung density voxels expressed in HU units for whole lung; rate of change in
emphysema (observed); change in cumulative frequency of HU; change in computed tomography (de-
rived lung volumes); change in trough RV/TLC; change in trough inspiratory capacity; change in trough
functional residual capacity; change in carbon monoxide diffusion capacity; changes in mean specif-
ic airway resistance and specific conductance; change in 7-day average total symptom score for dysp-
noea, cough, and sputum; change in 7-day mean number of actuations of rescue medications; percent-
age of participants with COPD exacerbations by group; percentage of participants experiencing a COPD
exacerbation
Safety outcomes: adverse events; changes in laboratory parameters, blood pressure, heart rate, physi-
cal examination findings, body weight, and BMI
Notes Clinicaltrials.gov identifier: NCT00874497
Funded by Otsuka Pharmaceutical Development & Commercialization, Inc.
Risk of bias
NCT00874497 (EMPHASIS) 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Unclear risk The trial was double-blind; participants, care providers, and outcome asses-
sors were blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes





High risk 54% in each group did not complete treatment and discontinued the trial ear-
ly, but there were 5 more adverse events in the tetomilast group vs the place-
bo group. 4 more people in the intervention arm discontinued because of ear-
ly termination of the trial. Other factors included loss to follow-up, withdraw-




Low risk Outcomes were reported as planned. Trial information was reported on the
GSK website






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: stated
Participants Setting: 43 centres in mainland China, Hong Kong, and Singapore
Participants: 626 (500 µg roflumilast: 313, placebo: 313)
Baseline characteristics: mean age 64 years, 91% male, mean FEV1 % predicted 36%, mean smoking
history 37.2 pack-years for roflumilast and 37.5 pack-years for placebo or current smokers (24% and
29%, respectively)
Inclusion criteria: Chinese, Malaysian, or Indian ethnicity, age 40 to 80 years with severe or very severe
COPD, FEV1/FVC ≤ 0.7, post-bronchodilator FEV1 ≤ 50%. Current smokers or ex-smokers with smoking
history > 10 pack-years or current smokers; 12-month history of COPD and ≥ 14 puKs of rescue medica-
tion during the week before randomisation
Exclusion criteria: primary bronchiectasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer, in-
terstitial lung disease, active TB, lower respiratory tract infection, diagnosis of asthma at < 40 years of
age, α1-antitrypsin deficiency
RO-2455-301-RD (ACROSS) 
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Total numbers of participant withdrawals: 67 (21.4%) and 50 (16%) from treatment and control
groups, respectively
Interventions Run-in: 4 weeks, single-blind. Placebo tablets to assess suitability
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
Participants were allowed to continue taking fixed combinations of ICS plus LABA or LAMA monothera-
py (e.g. tiotropium) if taken at a stable dose for at least 6 months before the run-in period. SAMAs (e.g.
ipratropium) were allowed at a constant daily dose as concomitant medication if taken on a regular ba-
sis for at least 4 weeks before study inclusion. All other COPD treatments were not allowed
Outcomes Primary outcomes: lung function; change in pre-bronchodilator FEV1
Secondary outcomes: changes in post-bronchodilator FEV1, FVC, incidence rates of COPD exacerba-
tions, time to first COPD exacerbation, transition dyspnoea index, proportions of participants experi-
encing a COPD exacerbation, adverse events, changes in body weight, laboratory values, vital signs,
and physical examination findings
Notes Clinicaltrials.gov identifier: NCT01313494
Funded by AstraZeneca
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Investigators used an automated, interactive voice-response system to ran-
domly assign participants. The sponsor generated a list of participant num-
bers using a pseudo-random number generator
Allocation concealment
(selection bias)
Low risk The investigator or anyone at the study site was prevented from knowing the





Low risk The trial was double-blinded, and tablets were identical in appearance
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk The trial was double-blinded. The investigator or anyone at the study site was








Unclear risk Outcomes were reported as planned, and the trial was registered at the NCT
website
Other bias Low risk LAMA: 17.9% for placebo; 20.4% for roflumilast
SAMA: 18.2% for placebo; 17.3% for roflumilast
ICS/LABA: 55.9% for placebo; 59.7% for roflumilast
No information available. SABA allowed
RO-2455-301-RD (ACROSS)  (Continued)
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Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 16 weeks
Intention-to-treat analysis: stated
Participants Setting: 18 centres in Denmark, Germany, Poland, Sweden, and United Kingdom
Participants: 158 (500 µg roflumilast: 79; placebo: 79)
Baseline characteristics: mean age 63 years, 77% male, mean FEV1 predicted 60%, mean smoking his-
tory longer than 20 years or current smokers 54%
Inclusion criteria: post-bronchodilator 30% ≤ FEV1 ≤ 8% predicted, post-bronchodilator FEV1/FVC ra-
tio ≤ 70%, current/former smoker history ≥ 20 pack-years; aged 40 to 80 years with COPD diagnosed at
least 12 months before study inclusion, chronic productive cough for 3 months in each of previous 2
years
Exclusion criteria: recent COPD exacerbation, ongoing upper or lower respiratory tract infection, asth-
ma (with or without other lung disease), alpha-1-antitrypsin deficiency, bleeding disorder, concomitant
glucocorticosteroids, theophylline, lipoxygenase inhibitors, antiplatelet therapy, leukotriene antago-
nists
Total numbers of participant withdrawals: 3 (4%) and 6 (8%) from treatment and control groups, re-
spectively
Interventions Run-in: 6 weeks, single-blind with placebo to assess compliance. ICS and other non-allowed drugs
stopped
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholingeric: none
• SABA: none
• Corticosteroid: not permitted.
• Long-acting β2-agonist: 61% in the roflumilast group and 61% in the placebo group, respectively
Outcomes Primary outcome: change in numbers of CD8 inflammatory cells in bronchial biopsy samples
Secondary outcomes: change in numbers of inflammatory cells measured in submucosa, bronchial
epithelium, induced sputum; blood FEV1, FVC, and FEV1/FVC ratio
Safety outcomes: adverse events; changes in laboratory parameters, blood pressure, heart rate, physi-
cal examination findings, body weight, and BMI
Notes Funded by AstraZeneca
Risk of bias
Bias Authors' judgement Support for judgement
RO-2455-402-RD (ROBERT) 
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Random sequence genera-
tion (selection bias)




Low risk Both roflumilast and placebo were given as identical yellow, triangular tablets;






Low risk Participants and investigators were blinded to group assignment
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Overall the total % of participants who discontinued was 5.7%. In the roflumi-
last group, 3.7% discontinued compared to 7.59% in the placebo group. The
number of adverse events was the same in each group; the numbers not com-
pleting were 6 in the placebo group and 3 in the roflumilast group
Selective reporting (re-
porting bias)
Low risk Outcomes were reported as planned. Some of the outcome data were report-
ed in the NCT and EU clinical trials registers






Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 52 weeks
Intention-to-treat analysis: stated
Participants Setting: 203 centres in 21 countries (see online appendix)
Participants: 1945 (500 µg roflumilast: 969; placebo: 966)
Baseline characteristics: mean age 65 years, 75% male, mean FEV1 predicted 35%, mean smoking his-
tory 48 pack-years for roflumilast and 48 pack-years for placebo or current smokers (42% and 45%, re-
spectively)
Inclusion criteria: ≥ 40 years of age with a smoking history ≥ 20 pack-years and a diagnosis of COPD
with severe airflow limitation (confirmed by post-bronchodilator FEV1/FVC ratio < 0.70 and post-bron-
chodilator FEV1 ≤ 50% predicted), symptoms of chronic bronchitis, history of ≥ 2 exacerbations in the
previous year. Participants must have been taking an ICS–LABA combination for 12 months before
the study and a constant dose of an ICS–LABA fixed combination for at least 3 months before enrol-
ment, with placebo tablet compliance of 80% to 125% during the 4-week baseline observation period,
and with a total cough and sputum score ≥ 14 (in which the score was a sum of daily scores on 4-point
scales for cough and sputum) recorded in a daily diary during the week preceding the randomisation
visit
RO-2455-404-RD (REACT) 
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Exclusion criteria: COPD exacerbation that was ongoing during the baseline period, diagnosis of asth-
ma or other major lung disease
Total numbers of participant withdrawals: 269 (28%) and 192 (20%) from treatment and control
groups, respectively
Interventions Run-in: 4 weeks, single-blind. Placebo tablets to assess suitability
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
All participants used a fixed-dose ICS–LABA combination during baseline and treatment periods. If a
participant had an exacerbation that needed additional treatment during the study, the investigator
could give up to 40 mg prednisolone, administered systemically, per day for 7 to 14 days. In the case of
purulent sputum or suspected bacterial infection, additional antibiotic therapy was allowed. Use of the
following treatments was not allowed: oral and parenteral glucocorticosteroids (except to treat acute
exacerbations), LABA or ICS monotherapy, SAMA, and any SABA (with the exception of salbutamol) or
oral β2-agonists. Participants already taking inhaled tiotropium bromide (a LAMA) were allowed to con-
tinue this treatment
Outcomes Primary outcomes: rate of moderate or severe COPD exacerbations per patient per year
Secondary outcomes: change from baseline in post-bronchodilator FEV1, rate of severe COPD exac-
erbations per patient per year, rate of COPD exacerbations per patient per year (all categories), per-
centage of participants experiencing ≥ 1 COPD exacerbation, time to first COPD exacerbation (all cate-
gories), time to second moderate or severe COPD exacerbation, time to third moderate or severe COPD
exacerbation, number of participants needed to treat to avoid 1 moderate or severe COPD exacerba-
tion derived from exacerbation per patient per year, number of moderate or severe COPD exacerba-
tion days, duration of moderate or severe COPD exacerbations per participant, change from baseline
in post-bronchodilator FVC, change from baseline in post-bronchodilator FEF (25% to 75% vital capac-
ity), change from baseline in post-bronchodilator FEV6, change from baseline in post-bronchodilator
FEV1/FVC, change from baseline in rescue medication use, change from baseline in COPD symptom
score, percentage symptom-free days, percentage rescue medication-free days, change from baseline
in CAT total score, percentage participants with CAT score improvement, time to mortality (all-cause
and COPD exacerbation-related), time to withdrawal (all-cause and COPD exacerbation-related), per-
centage of participants with major adverse cardiovascular event, time to first major adverse cardio-
vascular event, percentage of participants with hospitalisation (all-cause), time to first hospitalisation,
time to withdrawal due to adverse event, percentage of participants experiencing ≥ 1 adverse event
(treatment-related), change from baseline in body weight, change from baseline in BMI
Notes Clinicaltrials.gov identifier: NCT01329029
Funded by AstraZeneca
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Enrolled participants were randomly assigned in a 1:1 ratio, with a block size
of 4, by a computerised central randomisation system, the Interactive Voice








Low risk Roflumilast and placebo were supplied as identical yellow triangular tablets
in wallet cards containing 40 tablets; all parties involved in the study were
masked to treatment assignment
RO-2455-404-RD (REACT)  (Continued)
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All outcomes
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 269 participants (28%) in the roflumilast group discontinued from the study
and 192 (20%) from the placebo group discontinued
Selective reporting (re-
porting bias)
Low risk Outcomes were reported as planned. The trial was registered at the NCT web-
site
Other bias Unclear risk LAMA: 69% for placebo; 70% for roflumilast. No group differences stated; how-
ever 1900 (98%) of 1935 participants were using a combination of ICS–LABA





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 12 weeks
Intention-to-treat analysis: stated
Participants Setting: single centre in USA
Participants: 27 (500 µg roflumilast: 11, placebo: 16)
Baseline characteristics: mean age 62 years, 64% male, mean FEV1 % predicted 45%, mean smoking
history 44 pack-years for roflumilast and 47 pack-years for placebo or current smokers (63% and 55%,
respectively)
Inclusion criteria: > 40 years old with a diagnosis of moderate to severe COPD as defined by GOLD cri-
teria, current or former cigarette smokers with more than 10 pack-years of total consumption, chronic
bronchitis defined by chronic cough and sputum production lasting ≥ 3 months for 2 consecutive years
Exclusion criteria: asthma as defined by ATS/ERS guidelines, clinically significant bronchiectasis,
known sensitivity to roflumilast, use of other methylxanthines (specifically theophylline) within 1
month of screening, changes to maintenance COPD therapy within 1 month of screening
Total numbers of participant withdrawals: 1 (9%) and 1 (6%) from treatment and control groups, re-
spectively
Interventions Run-in: no run-in
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
Allowed, except for theophylline. For roflumilast and placebo groups, respectively: LAMA was used by 8
(50%) and 6 (55%); ICS or LABA/ICS was used by 10 (63%) and 6 (55%)
Roflumilast DAL-MD-01 
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Outcomes Primary outcome: change in induced sputum AcPGP at 12 weeks post randomisation in an inten-
tion-to-treat analysis
Secondary outcomes: changes in plasma AcPGP, sputum neutrophil counts, additional sputum bio-
markers, 6MWT, Breathlessness Cough and Sputum Scale, SGRQ scores, changes in post-bronchodila-
tor FEV1 at 12-week visit
Notes Clinicaltrials.gov identifier NCT01572948. Funded by Forest Laboratories Inc., University of Alabama at
Birmingham
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The trial was reported as block randomised with a 1:1 allocation, stratified by









Low risk The trial was triple-blinded (participant, care provider, and investigator)
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk At follow-up, only 1 participant in each group was lost because of refusal to at-
tend the final visit or inability to be contacted for the final visit
Selective reporting (re-
porting bias)
Low risk Outomes were reported as planned; the trial was registered at clinicaltrial-
s.gov





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 26 weeks
Intention-to-treat analysis: stated
Participants Setting: not stated
Participants: 516 (roflumilast 250 µg: 175, roflumilast 500 µg: 169, placebo: 172)
Baseline characteristics: median age 61 to 62 years, 72% male, mean 38 to 63 pack-years, 53% current
smokers
Roflumilast FK1 101 
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Inclusion criteria: aged 40 to 75 years, FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years, reversibili-
ty < 12% or 200 mL, post-bronchodilator FEV1 35% to 75% predicted
Exclusion criteria: not stated
Total numbers of participant withdrawals: not stated
Interventions Run-in: 2 weeks with placebo
• Roflumilast 500 µg once daily
• Roflumilast 250 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholinergic: allowed at a constant daily dose for those treated before with anticholin-
ergics on a constant dosage
• SABA: salbutamol was allowed as rescue medication
• Corticosteroid: none
• LABA: none
Outcomes Primary outcomes: post-bronchodilator FEV1 and FEF between 25% and 75% of vital capacity
Secondary outcomes: numbers of moderate or severe COPD exacerbations that required treatment
with OCS
Notes Funding not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Reported as randomised. No further information
Allocation concealment
(selection bias)





Low risk Reported as double-blind
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk No available information
Selective reporting (re-
porting bias)
Unclear risk Unpublished study; no available information
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Study characteristics
Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: stated
Participants Setting: not stated
Participants: 518 (roflumilast 500 µg: 200, placebo: 186)
Baseline characteristics: mean age 60 years, 75% male, 62% current smokers, average 35 pack-years
Inclusion criteria: aged 40 to 75 years, FEV1/FVC ≤ 0.7, post-bronchodilator FEV1 35% to 75% predicted,
FEV1 reversibility ≤ 12% and ≤ 200 mL, pre-bronchodilator FEV1/FVC ≤ 70%
Exclusion criteria: not stated
Total numbers of participant withdrawals; not stated
Interventions Run-in: 2 weeks with placebo
• Roflumilast 500 µg once daily for 24 weeks
• Roflumilast 500 µg once daily for 12 weeks. Placebo once daily for following 12 weeks
Concomitant medication
• Short-acting anticholinergic: all medications were withdrawn except constant-dose short-acting an-
ticholinergics
• SABA: as rescue medication
• Corticosteroid: none
• LABA: none
Used alongside short-acting β2-agonists (available to all)
Outcomes Primary outcomes: results for 12/24-week post-bronchodilator FEV1
Notes Funding not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not stated
Allocation concealment
(selection bias)





Low risk The trial was double-blind
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk No information available
Roflumilast FK1 103 
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Unclear risk No information available
Selective reporting (re-
porting bias)
Unclear risk No information available





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 26 months
Intention-to-treat analysis: stated
Responder analysis for the most part
Participants Setting: 2 centres
Participants: 41 (500 µg roflumilast: 30, placebo: 11)
Baseline characteristics: not stated
Inclusion criteria: not stated
Exclusion criteria: not stated
Total numbers of participant withdrawals: not stated
Interventions Run-in: not stated
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication: not stated
Outcomes Primary outcomes: post bronchodilation: spirometry, body plethysmography, 6MWT, patient-reported
outcomes
Secondary outcomes: not stated
Notes Clinicaltrials.gov identifier NCT01480661
Funded by Takeda
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Reported as block randomised in a 3:1 ratio of roflumilast to placebo, respec-
tively; no further information about sequence generation
Roflumilast FLUI-2011-77 
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Allocation concealment
(selection bias)





Low risk The trial was reported as triple-blind (participant, care provider, and investiga-
tor)
Blinding of outcome as-
sessment (detection bias)
All outcomes





Unclear risk Assumed that this would be low risk; however, no available information
Selective reporting (re-
porting bias)
Low risk Outcomes reported as intended; trial registered at clinicaltrials.gov





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 12 weeks
Intention-to-treat analysis: not stated
Participants Setting: 5 centres in India
Participants: 118 recruited (roflumilast 500 µg: 47, roflumilast 200 µg: 46, placebo: 25)
Baseline characteristics: mean age 60 years, 98% male, 41% current smokers, post-bronchodilator
FEV1 57% to 61%, average 25 pack-years
Inclusion criteria: not stated
Exclusion criteria: not stated
Total numbers of participant withdrawals: roflumilast 500 µg: 13 (28%); roflumilast 200 µg: 7 (15%);
control 10 (40%)
Interventions Run-in: none
• Roflumilast 250 µg once daily
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholinergic: not stated
• SABA: not stated
• Corticosteroid: none
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• LABA: not stated
Outcomes Primary outcome: post-bronchodilator FEV1
Secondary outcomes: COPD exacerbations, adverse events
Notes Funded by Forest Laboratories
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Reported as randomised. No further information available
Allocation concealment
(selection bias)





Low risk The trial was reported as double-blind
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Data as above
Selective reporting (re-
porting bias)
Unclear risk No information available





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: not stated
Participants Setting: Japan
Participants: 600 (roflumilast 250 µg: 205, roflumilast 500 µg: 204, placebo: 191)
Baseline characteristics: mean age 70 years, 96% male, post-bronchodilator FEV1 not stated, average
56 pack-years, 37% current smokers
Inclusion criteria: not stated
Exclusion criteria: not stated
Roflumilast JP-706 
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Total numbers of participant withdrawals: not stated
Interventions Run-in: single-blind 4 weeks with placebo
• Roflumilast 500 µg once daily
• Roflumilast 250 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholinergic: used at a constant daily dose
• SABA: not stated
• Corticosteroid: not stated
• LABA: not stated
Outcomes Primary outcomes: pulmonary function (FEV1 pre-bronchodilator, FVC pre- and post-bronchodilator,
MMEF pre- and post-bronchodilator)
Secondary outcomes: number of COPD exacerbations, number of days to first COPD exacerbation, ad-
verse events (all-cause and drug-related), serious adverse events (all-cause and drug-related)
Notes Funded by Mitsubishi-Tanabe
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Reported as randomised; no further information about randomisation process
Allocation concealment
(selection bias)





Low risk The trial was reported as double-blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Not described
Selective reporting (re-
porting bias)
High risk No further information available about the trial. No trial registry information
found





Methods Study design: parallel-group study
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Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: stated
Participants Setting: 159 centres in Australia, Austria, Belgium, Canada, France, Germany, Hungary, Ireland, South
Africa, Spain, and the UK
Participants: 1411 (roflumilast 250 µg: 576, roflumilast 500 µg: 555, placebo: 280)
Baseline characteristics: median age 64 years, 74% male, post-bronchodilator FEV1 51% for both
groups, average 42 pack-years, 45% current smokers
Inclusion criteria: aged ≥ 40 with history of COPD > 12 months, FEV1 < 50% predicted, FEV1/FVC ≤ 0.7
with smoking history > 10 pack-years, reversibility < 12% or 200 mL, mean post-bronchodilator FEV1
30% to 80% predicted
Exclusion criteria: asthma, lung cancer or bronchiectasis, long-term oxygen treatment, recent exacer-
bation that required a course of systemic corticosteroids, emergency room treatment or hospital ad-
mission within 4 weeks before run-in period
Total numbers of participant withdrawals: 124 (22%) and 32 (11%) from treatment and control
groups, respectively
Interventions Run-in: 4 weeks with placebo
• Roflumilast 500 µg once daily
• Roflumilast 250 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholinergic: used at a constant daily dose
• SABA: salbutamol as rescue medication
• Corticosteroid: none
• LABA: none
Outcomes Primary outcomes: post-bronchodilator FEV1; SGRQ total score
Secondary outcomes: change from baseline in pre-bronchodilator FEV1; post-bronchodilator FVC;
post-bronchodilator FEV in 6 seconds and FVC; FEF rate between 25% and 75% of vital capacity; num-
ber of moderate or severe COPD exacerbations
Notes Funded by ALTANA Pharma AG
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The randomisation sequence was generated by the sponsor in a blind manner
Allocation concealment
(selection bias)
Unclear risk No information on allocation concealment method, but "no person involved in





Low risk The trial was double-blind. Roflumilast and placebo tablets and packaging
were identical, so neither participants nor study personnel were aware of ei-
ther medication allocation
Roflumilast M2-107  (Continued)
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Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk "No person involved in data analysis had knowledge of the randomisation se-
quence"
Roflumilast and placebo tablets and packaging were identical, so the investi-




Low risk 100 participants discontinued from the roflumilast 250 µg group, 124 from the
roflumilast 500 µg group, and 32 from the placebo group
Selective reporting (re-
porting bias)
High risk There was inconsistency in the quoting of statistical errors. Within the text and
in Table 2, data are quoted as "least squares means and SD"; however in Fig-
ures 2 and 3, SE bars are shown. It is more likely that results represented SE,
not SD. Trial registration was not found





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: not stated
Participants Setting: 36 centres in Argentina, Canada, Columbia, Mexico, Peru, and the USA
Participants: 909 participants randomised (roflumilast 500 µg: 449; placebo: 460)
Baseline characteristics: aged between 55 and 74 years (mean age 64.2 years in the roflumilast group
and 64.6 years in the placebo group), 88% participants were white, roflumilast group included 51%
males and the placebo group 55% males
Inclusion criteria: clinical diagnosis of COPD based on ATS criteria, post-bronchodilator FEV1/FVC ≤
70%, post-bronchodilator FEV1 ≥ 30% and ≤ 80% predicted, post-bronchodilator FEV1 increase ≤ 12% or
≤ 200 mL compared to pre-bronchodilator value, score grade ≥ 1 on the MRC Dyspnea Scale, currently
stable COPD with no change in COPD treatment in the prior 4 weeks
Exclusion criteria: clinical diagnosis of asthma, poorly controlled COPD, regular need for daily oxygen
therapy
Total numbers of participant withdrawals: roflumilast group: 15.4% withdrew due to adverse events,
10.5% withdrew consent, 2.9% withdrew due to lack of efficacy; placebo group: 7.6% withdrew due to
adverse events, 8.5% withdrew consent, 3% withdrew due to protocol violation
Interventions Run-in: 4-week single-blind period during which respiratory medication (including ICS, LABA, and long-
acting anticholinergics) was withdrawn
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholinergic: none
• SABA: none
Roflumilast M2-110 
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• Corticosteroid: none
• LABA: none
Outcomes Primary outcomes: pulmonary function tests (FEV1, FVC, FEF, PEF, FIV1, FVCin)
Secondary outcomes: exacerbation rate; quality of life; symptoms; use of rescue medication; safety
and tolerability
Notes ClinicalTrials.gov Identifier: NCT00062582. Funded by ALTANA Pharma AG
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Reported as randomised. Assumed that the randomisation method was ade-
quate due to pharmaceutical company sponsorship
Allocation concealment
(selection bias)






Low risk The trial was reported as double-blind
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Roflumilast group: 15.4% withdrew due to adverse events, 10.5% withdrew
consent, 2.9% withdrew due to lack of efficacy; placebo group: 7.6% withdrew










Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 52 weeks
Intention-to-treat analysis: stated
Participants Setting: M2-111 was conducted at 188 centres in 6 countries, and M2-112 at 159 centres in 14 countries
Participants: 1176 participants were randomised in this study (roflumilast: 500 µg: 568; placebo: 608)
Baseline characteristics: severe COPD according to GOLD criteria grades III and IV, mean age 64 to 65
years, 72% male
Inclusion criteria: aged ≥ 40 years, post-bronchodilator FEV1 < 50% predicted, reversibility < 15%,
mean post-bronchodilator FEV1 42%, FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years, 40% current
smokers, 60% ex-smokers, average 46 to 48 pack-years
Roflumilast M2-111 
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Exclusion criteria: history of asthma, lung cancer, or bronchiectasis; need for long-term oxygen thera-
py; known α1-antitrypsin deficiency, clinically significant cardiopulmonary comorbidity
Total numbers of participant withdrawals: data combined with M2-112 showing 433 (33%) and 348
(26%) from treatment and control groups, respectively
Interventions Run-in: 4 weeks with placebo
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholingeric: 891 patients on short-acting anticholinergics
• SABA: salbutamol as rescue medication
• Corticosteroid: 943 patients continued corticosteroid use
• LABA: none
Used alongside corticosteroids, anticholinergics, and rescue short-acting β2-agonists 54% overall
(available to all)
Outcomes Primary outcomes: change from baseline to endpoint in post-bronchodilator FEV1; number of moder-
ate or severe exacerbations per patient per year
Secondary outcomes: change from baseline in SGRQ total score; change from baseline in pre-
bronchial FEV1, post-bronchodilator FEV in 6 seconds and in FVC; FEF rate between 25% and 75% vital
capacity; number of moderate or severe COPD exacerbations requiring systemic corticosteroid treat-
ment per patient per year
Notes NCT00076089/BY217/M2-111. Funded by AstraZeneca
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The randomisation sequence was generated by a multiplicative congruent
pseudo-random numbers generator programme (programme RANDOM, based
on Fishman and Moore)
Allocation concealment
(selection bias)
Low risk "Each study participant who qualified was assigned a number in sequential or-
der. Code labelling prevented the investigator and the patient from knowing





Low risk The trial was double-blind
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Data combined with M2-112
Selective reporting (re-
porting bias)
Low risk Trial registered at clinicaltrials.gov; outcomes reported as planned. M2-111
and M2-112 data combined
Roflumilast M2-111  (Continued)
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk See individual trials
Allocation concealment
(selection bias)





Low risk See individual trials
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk See individual trials
Selective reporting (re-
porting bias)
Low risk See individual trials





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 52 weeks
Roflumilast M2-112 
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Intention-to-treat analysis: stated
Participants Setting: 159 centres in 14 countries
Participants: 1514 (roflumilast 500 µg: 761, placebo: 753)
Baseline characteristics: severe COPD according to GOLD criteria grades III and IV, mean age 65 years,
75% male
Inclusion criteria: aged ≥ 40 years, post-bronchodilator FEV1 < 50% predicted, reversibility < 15%,
mean post-bronchodilator FEV1 41%, FEV1/FVC ≤ 0.7 with smoking history > 10 pack-years, 37% current
smokers, 63% ex-smokers, average 44 pack-years
Exclusion criteria: history of asthma, lung cancer, or bronchiectasis; need for long-term oxygen thera-
py; known α1-antitrypsin deficiency or clinically significant cardiopulmonary comorbidity
Total numbers of participant withdrawals: 217 (29%) and 163 (22%) from treatment and control
groups, respectively
Interventions Run-in: 4 weeks with placebo
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholinergic: 891 participants on short-acting anticholinergics
• SABA: salbutamol as rescue medication
• Corticosteroid: 943 participants continued corticosteroid use
• LABA: none
Used alongside corticosteroids, anticholinergics, and rescue short-acting β2-agonists 54% overall
(available to all)
Outcomes Primary outcomes: change from baseline to endpoint in post-bronchodilator FEV1 and in the number
of moderate or severe exacerbations per patient per year
Secondary outcomes: change from baseline in SGRQ total score; change from baseline in pre-
bronchial FEV1; post-bronchodilator FEV in 6 seconds and FVC; FEF rate between 25% and 75% of vital
capacity; number of moderate or severe COPD exacerbations requiring systemic corticosteroid treat-
ment per patient per year
Notes NCT00430729/BY217/M2-112. Funded by AstraZeneca
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "The randomisation list was generated using a multiplicative congruent pseu-




Low risk "Each study participant who qualified was assigned a number in sequential or-
der. Code labelling prevented the investigator and the patient from knowing





Low risk The trial was double-blinded
Roflumilast M2-112  (Continued)
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Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk "Over 70% of patients completed the study. The reasons for withdrawal were
similar between groups except for adverse events, which occurred more fre-
quently with roflumilast"
"Withdrawal due to COPD exacerbations was reported in 3.5 and 3.2% of pa-









Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 12 weeks
Intention-to-treat analysis: stated
Participants Setting: 22 centres in 4 countries
Participants: 250 (roflumilast 500 µg: 127, placebo: 123)
Baseline characteristics: mean age 60 years, 73% (roflumilast) vs 84% (placebo) male, post-bron-
chodilator FEV1 55% predicted, average 41 pack-years, 53% current smokers
Inclusion criteria: clinically stable patients ≥ 40 years of age with smoking history > 10 pack-years and
12-month history of COPD. Other inclusion criteria included post-bronchodilator FEV1 30% to 80% pre-
dicted, FEV1/forced vital capacity (FVC) < 0.7, and set plethysmographic FRC and peak oxygen uptake
requirements
Exclusion criteria: asthma or lung disease other than COPD, α1-antitrypsin deficiency, participation in
pulmonary rehabilitation programme within 2 months, supplemental oxygen therapy, significant med-
ical comorbidity that may influence exercise tolerance
Total numbers of participant withdrawals: 16 (13%) and 12 (10%) from treatment and control
groups, respectively
Interventions Run-in: 2- to 3-week baseline period consisting of 2 familiarisation visits during which a symptom-lim-
ited constant work rate cycle exercise test was performed at 75% of maximum incremental work rate. If
a constant work rate endurance time was not produced within 2 minutes at both visits, a third visit was
performed. If reproducibility was not achieved at the third visit, the patient was not randomised
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholingeric: participants could use ipratropium bromide in regular stable doses as
needed
Roflumilast M2-118 
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• SABA: participants could use short-acting β2-agonists as needed
• Corticosteroid: ICSs were permitted throughout the study if taken at a constant dosage for > 3 months
before the start of the study
• LABA: none
Outcomes Primary outcomes: activity-related dyspnoea (TDI); spirometry and body plethysmography; symp-
tom-limited exercise tests
Notes Funded by Nycomed GmbH (Konstanz, Germany)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Reported as randomised. Assumed that the randomisation method was ade-
quate due to pharmaceutical company sponsorship
Allocation concealment
(selection bias)





Low risk Trial reported as double-blind
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Of 250 randomised participants, 16 from the roflumilast group and 12 from the
placebo group discontinued prematurely
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported, but no trial protocol found on trial registry websites





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 12 weeks
Intention-to-treat analysis: stated
Participants Setting: 32 centres in 5 countries
Participants: 410 (roflumilast 500 µg: 203, placebo: 207)
Baseline characteristics: mean age 68 years, 93% male, post-bronchodilator FEV1 50.5% predicted, av-
erage 44 pack-years, 69% current smokers
Roflumilast M2-119 
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Inclusion criteria: former or current smokers with pack-year history ≥ 10, aged ≥ 40 years, post-bron-
chodilator FEV1/FVC ≤ 0.7, FEV1 30% to 80% predicted, clinically stable COPD within 4 weeks before
baseline
Exclusion criteria: history of asthma or other relevant lung disease, COPD exacerbation within 4 weeks
before baseline, need for long-term oxygen therapy, known α1-antitrypsin deficiency, clinically signifi-
cant cardiopulmonary comorbidity
Total numbers of participant withdrawals: 40 (20%) and 18 (9%) from treatment and control groups,
respectively
Interventions Run-in: 4 weeks with placebo
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholingeric: "short-acting anticholinergics at a constant daily dosage as concomitant
medication if already taken on a regular basis at a constant dosage for at least 4 weeks prior to the
study"
• SABA: patients could use SABAs as needed
• Corticosteroid: none
• LABA: none
Outcomes Primary outcome: mean change in post-bronchodilator FEV1 from baseline
Secondary outcomes: mean change in pre-bronchodilator FEV1 from baseline; change in other lung
function measures, time to COPD exacerbation; proportion of participants experiencing exacerbations;
time to study withdrawal; adverse effects
Notes Clinicaltrials.gov identifier: NCT00242320; BY217/M2-119. Funded by Nycomed GmbH, Konstanz, Ger-
many
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation list used
Allocation concealment
(selection bias)






Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Of the 411 randomised participants, 41 from the roflumilast group and 18 from




Low risk Outcomes were reported as planned. The protocol was registered at clincaltri-
als.gov
Roflumilast M2-119  (Continued)
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Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 12 weeks
Intention-to-treat analysis: stated
Participants Setting: 16 centres in 6 countries
Participants: 600 participants (full analysis set; roflumilast 500 µg: 301, placebo: 299)
Baseline characteristics: median age 65 years, 74% male, FEV1 46% predicted, 48 mean pack-years
Inclusion criteria: history of COPD ≥ 12 months as defined by GOLD criteria, age ≥ 40 years, FEV1/FVC
ratio (post-bronchodilator) ≤ 70%, FEV1 (post-bronchodilator) ≤ 65% predicted, FRC (post-bronchodila-
tor) ≤ 120% predicted
Exclusion criteria: COPD exacerbation indicated by treatment with systemic glucocorticosteroids not
stopped ≥ 4 weeks before baseline visit; non-smoker, current smoker, or ex-smoker (smoking cessation
≥ 1 year ago) with smoking history < 10 pack-years; any concomitant disease that might interfere with
study procedures or evaluation
Total numbers of participant withdrawals: 32 participants withdrew due to COPD exacerbations
Interventions Run-in: 4-week single-blind placebo tablet once daily in the morning and all disallowed concomitant
medications withdrawn
• Roflumilast 500 µg once daily
• Placebo
Concomitant medication




Outcomes Primary outcome: lung function parameters indicative of hyperinflation in people with COPD
Secondary outcomes: mean change from randomisation to endpoint in additional pre- and post-bron-
chodilator spirometric and lung volume parameters; measurement of quality of life parameters; dysp-
noea
Notes ClinicalTrials.gov Identifier: NCT00108823; BY217/M2-121. Funded by AstraZeneca
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Reported as randomised. Assumed that the randomisation method was ade-
quate due to pharmaceutical company sponsorship
Roflumilast M2-121 
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Allocation concealment
(selection bias)





Low risk Trial reported as double-blind
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Of 600 randomised participants, 13 from the roflumilast group and 19 from the
placebo group withdrew due to exacerbations
Selective reporting (re-
porting bias)
Unclear risk A publication was not found for this trial; however, study results were obtained
from the trial registry website





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 52 weeks
Intention-to-treat analysis: stated
Participants Setting: 246 centres in 10 countries
Participants: 1513 (roflumilast 500 µg: 760, placebo: 753)
Baseline characteristics: mean age 64 years, 71% male, post-bronchodilator FEV1 37.6% predicted, av-
erage 47 pack-years, 48% current smokers
Inclusion criteria: former or current smokers with ≥ 20 pack-year history, aged ≥ 40 years, post-bron-
chodilator FEV1/FVC ≤ 0.7, chronic cough and sputum production, post-bronchodilator FEV1 < 50% pre-
dicted, ≥ 1 recorded COPD exacerbation requiring systemic glucocorticosteroids or treatment in hospi-
tal in previous year
Exclusion criteria: available in the online web appendix (p 11)
Total numbers of participant withdrawals: 264 (34%) and 234 (31%) from treatment and control
groups, respectively
Interventions Run-in: 4 weeks with placebo
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholingeric: 31% of those in the roflumilast group and 32% in the placebo group
• SABA: "patients could use short acting β2-agonists as needed"
Roflumilast M2-124 
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• Corticosteroid: none
• LABA: "eligible patients were stratified according to their use of long acting β2-agonists and smoking
status"; roflumilast 49%, placebo 51%
Outcomes Primary outcomes: mean change in pre-bronchodilator FEV1; mean rate of COPD exacerbations requir-
ing oral or parenteral glucocorticosteroids or requiring hospitalisation or leading to death (per patient
per year)
Secondary outcomes: mean change in post-bronchodilator FEV1; time to mortality for any reason; nat-
ural log-transformed CRP (mg/L); mean TDI focal score
Notes Clinicaltrials.gov identifier: NCT00297102. Funded by AstraZeneca
Adverse event data are pooled with numbers from study M2-125, which followed an identical study de-
sign
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A randomisation list was generated via a pseudo-random numbers generator,









Low risk "All individuals involved in the studies were unaware of treatment assignment.
Tablets were identical in appearance. The investigator or anyone at the study
site was prevented from knowing the allocation sequence with code labelling"
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 264 participants discontinued from the roflumilast group and 234 discontin-
ued from the placebo group
Selective reporting (re-
porting bias)
Low risk Outcomes reported as planned. Trial registered at clinicaltrials.gov
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk See individual studies
Allocation concealment
(selection bias)





Unclear risk See individual studies
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk See individual studies
Selective reporting (re-
porting bias)
Unclear risk See individual studies





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 52 weeks
Intention-to-treat analysis: stated
Participants Setting: 221 centres in 8 countries
Participants: 1571 (roflumilast 500 µg: 773, placebo: 798)
Baseline characteristics: mean age 64 years, 80% male, average 48 pack-years, 35% current smokers
Inclusion criteria: former or current smokers with pack-year history ≥ 20 years, aged ≥ 40 years, post-
bronchodilator FEV1/FVC ≤ 0.7, chronic cough and sputum production, post-bronchodilator FEV1 < 50%
predicted, ≥ 1 recorded COPD exacerbation requiring systemic glucocorticosteroids or treatment in
hospital in previous year
Exclusion criteria: available in the online web appendix (p 11)
Roflumilast M2-125 
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Total numbers of participant withdrawals: 246 (32%) and 248 (31%) from treatment and control
groups, respectively
Interventions Run-in: 4 weeks with placebo
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholingeric: 38% of those in the roflumilast group and 41% of the placebo group
• SABA: "patients could use short acting β2-agonists as needed"
• Corticosteroid: none
• LABA: "eligible patients were stratified according to their use of long acting β2-agonists and smoking
status"; roflumilast 48%, placebo 51%
Outcomes Primary outcomes: mean change in pre-bronchodilator FEV1; mean rate of COPD exacerbations (mod-
erate or severe) requiring oral or parenteral glucocorticosteroids or requiring hospitalisation or leading
to death (per patient per year)
Secondary outcomes: mean change in post-bronchodilator FEV1; time to mortality for any reason; nat-
ural log-transformed CRP (mg/L); mean TDI focal score during treatment period
Notes Clinicaltrials.gov identifier: NCT00297115; BY217/M2-125. Funded by AstraZeneca
Adverse event data are pooled with numbers from study M2-124, which followed an identical study de-
sign
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A randomisation list was generated via a pseudo-random numbers generator,









Unclear risk "All individuals involved in the studies were unaware of treatment assignment.
Tablets were identical in appearance. The investigator or anyone at the study
site was prevented from knowing the allocation sequence with code labelling"
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 246 patients discontinued from the roflumilast group and 248 discontinued
from the placebo group
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Study characteristics
Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: stated
Participants Setting: 135 centres in 10 countries
Participants: 1221 (roflumilast 500 µg: 467, placebo: 468)
Baseline characteristics: mean age 65 years, 71% male, post-bronchodilator FEV1 54.7% and 55.3%
predicted (roflumilast and placebo), average 43 pack-years, 39% current smokers
Inclusion criteria: former or current smokers with ≥ 1 year smoking cessation and a pack-year history ≥
10, aged ≥ 40 years, post-bronchodilator FEV1/FVC ≤ 0.7, post-bronchodilator FEV1 40% to 70% predict-
ed, partial reversibility to albuterol with increase from baseline FEV1 ≤ 12% or 200 mL
Exclusion criteria: available in the online web appendix (p 10)
Total numbers of participant withdrawals: 107 (23%) and 82 (18%) from treatment and control
groups, respectively
Interventions Run-in: 4 weeks with placebo once a day
• Roflumilast 500 µg and salmeterol once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholingeric: none
• SABA: participants used short-acting β2 as rescue medication
• Corticosteroid: none
• LABA: none
Outcomes Primary outcomes: change in mean pre-bronchodilator FEV1 from baseline to each post-randomisa-
tion visit
Secondary outcomes: post-bronchodilator FEV1 and FVC; TDI score; SOBQ; rate of COPD exacerba-
tions; use of rescue medication
Notes ClinicalTrials.gov identifier NCT00313209; BY217/M2-127; 2005-005080-28 (EudraCT Number). Funded
by Nycomed GmbH, Konstanz, Germany
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "The sponsor generated a randomisation list of patient random numbers using
a pseudo-random number generator. The investigator used an automated, in-
teractive voice response system to randomly assign patients"
Allocation concealment
(selection bias)




Low risk All individuals involved in the studies were unaware of treatment assignment
Roflumilast M2-127 
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All outcomes
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 107 participants discontinued from the roflumilast group and 82 discontinued
from the placebo group
Selective reporting (re-
porting bias)
Low risk Outcomes reported as planned. Trial registered at clincialtrials.gov





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: stated
Participants Setting: 85 centres in 7 countries
Participants: 910 (roflumilast 500 µg: 372, placebo: 372)
Baseline characteristics: mean age 64 years, 71% male, post-bronchodilator FEV1 56.0% and 56.2%
predicted (roflumilast and placebo), average 44 pack-years, 40% current smokers
Inclusion criteria: former or current smokers with ≥ 1 year smoking cessation and a pack-year history ≥
10, aged ≥ 40 years, post-bronchodilator FEV1/FVC ≤ 0.7, post-bronchodilator FEV1 40% to 70% predict-
ed, partial reversibility to albuterol with increase from baseline FEV1 ≤ 12% or 200 mL
Exclusion criteria: available in the online web appendix (p 10)
Total numbers of participant withdrawals: 62 (17%) and 39 (11%) from treatment and control
groups, respectively
Interventions Run-in: 4 weeks with placebo once a day
• Roflumilast 500 µg and tiotropium once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholingeric: none
• SABA: participants used short-acting β2 as rescue medication
• Corticosteroid: none
• LABA: none
Outcomes Primary outcomes: change in mean pre-bronchodilator FEV1 from baseline to each post-randomisa-
tion visit
Roflumilast M2-128 
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Secondary outcomes: post-bronchodilator FEV1 and FVC; TDI score; SOBQ; rate of COPD exacerba-
tions; use of rescue medication
Notes Clinicaltrials.gov identifier: NCT0042468; BY217/M2-128. Funded by Nycomed GmbH, Konstanz, Ger-
many
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "The sponsor generated a randomisation list of patient random numbers using
a pseudo-random number generator. The investigator used an automated, in-
teractive voice response system to randomly assign patients"
Allocation concealment
(selection bias)
Low risk The investigator or anyone at the study site was prevented from knowing the





Low risk "All individuals involved in the studies were unaware of treatment assignment.
The investigator or anyone at the study site was prevented from knowing the
allocation sequence with code labelling. Tablets were identical in appearance"
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk "All individuals involved in the studies were unaware of treatment assignment.
The investigator or anyone at the study site was prevented from knowing the




Low risk 62 participants discontinued from the roflumilast group and 39 discontinued
from the placebo group
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported as planned. Trial protocol registered at clincialtrials.gov
and at European trial registry





Methods Study design: parallel-group study
Randomisation: randomised, double-blind, placebo-controlled trial
Trial duration: 52 weeks
Intention-to-treat analysis: stated
Participants Setting: 338 locations across Australia, Argentina, Canada, Chile, Columbia, Italy, Malaysia, Peru,
Phillippines, Romania, Russia, Serbia, Spain, Taiwan, and Ukraine
Participants: 2354 (500 µg roflumilast: 1178; placebo: 1176)
Baseline characteristics: mean age 64 years, 68% male, mean FEV1 % predicted 33%, mean smoking
history 52.2 pack-years for roflumilast and 53.1 pack-years for placebo or current smokers (39% and
40%, respectively)
Roflumilast ROF-MD-07(RE2SPOND) 
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Inclusion criteria: ≥ 40 years with severe or very severe COPD, chronic bronchitis, ≥ 2 exacerbations
and/or hospitalisations in the previous year, receiving ICS/LABA with or without LAMA daily for ≥ 3
months
Exclusion criteria: within the 4 weeks before enrolment, had a moderate or severe COPD exacerbation
and/or a COPD exacerbation treated with antibiotics or systemic corticosteroids or a lower respiratory
tract infection. Other exclusionary criteria included diagnoses of other lung diseases, moderate to se-
vere liver impairment (Child-Pugh B or C), HIV or hepatitis infection, current diagnosis of asthma, can-
cer in the past 5 years, α1-antitrypsin deficiency, clinically significant cardiovascular condition, resting
QTc interval > 470 ms, BMI ≥ 45 kg/m2
Total numbers of participant withdrawals: 337 (29%) and 254 (21%) from treatment and control
groups, respectively
Interventions Run-in: 2 weeks, single-blind. Placebo tablets to assess suitability
• Roflumilast 500 µg once daily
• Placebo once daily
Concomitant medication
ICS/LABA FDC (fluticasone propionate/salmeterol, 250/50 mg (1 inhalation twice a day), or budes-
onide/formoterol, 160/4.5 mg (2 inhalations twice a day)). Participants taking fluticasone propi-
onate/salmeterol, 500/50 mg, at study entry were required to switch to the lower dosage (250/50 mg)
before entry. Up to 60% of participants were allowed concomitant LAMA (e.g. tiotropium) if adminis-
tered for ≥ 3 months before screening, with no dose change. Those not on LAMA were allowed a SAMA
Outcomes Primary outcome: rate of moderate or severe COPD exacerbations per patient per year
Secondary outcomes: rate of COPD exacerbations leading to hospitalisation or death (severe COPD ex-
acerbations); rate of moderate or severe exacerbations; rate of moderate or severe COPD exacerbations
or COPD exacerbations treated with antibiotics; rate of moderate or severe COPD exacerbations treated
with antibiotics during the treatment period; mean change in pre-dose FEV1; mean change in pre-dose
FEV1 from randomisation over 52 weeks; adverse events; mortality (all-cause); serious adverse events;
other adverse events (not including serious events)
Notes Clinicaltrials.gov identifier: NCT01443845. Funded by Astra Zeneca
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Reported as randomised. Assumed that the randomisation method was ade-
quate due to pharmaceutical company sponsorship
Allocation concealment
(selection bias)





Low risk Reported as triple-blind (participant, investigator and outcome assessor)
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk 337 participants (29%) discontinued from the roflumilast group and 254 (22%)
discontinued from the placebo group
Roflumilast ROF-MD-07(RE2SPOND)  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk Outcomes reported as planned. Trial registered at clinicaltrials.gov
Other bias Unclear risk 47% in each treatment group were taking LAMAs. Participants were also using
combined LABA/ICS. 65% in the placebo group were taking fluticasone propi-
onate/salmeterol FDC, and 65% in the roflumilast group. 35% of participants





Methods Study design: parallel-group study
Randomisation: randomised, triple-blind, placebo-controlled trial
Trial duration: 24 weeks
Intention-to-treat analysis: stated
Participants Setting: 1 specialist respiratory and critical care medicine centre at a hospital in Austria
Participants: 80 (roflumilast 500 µg: 40, placebo: 40)
Baseline characteristics: median age 64, 52% male, median 50 smoking pack-years
Inclusion criteria: 40 years of age and over, history of ≥ 2 COPD exacerbation requiring systemic corti-
costeroid treatment or hospitalisation in the last year
Exclusion criteria: inability to comply with study medication, history of acute exacerbation, alpha1-an-
titrypsin deficiency, asthma, acute/severe respiratory infection, lung cancer, bronchiectasis, ILD, acute
MI, systolic leW ventricular dysfunction, CHF, cardiac arrhythmia/heart valve deformation, peripheral
arterial occlusive disease, acute or chronic hepatic failure, autoimmune disease, active malignancy,
pregnant/breastfeeding, hypersensitivity to study medication or placebo, mental or neurological disor-
der, history of depression
Total numbers of participant withdrawals: 7 (17%) and 6 (15) in the roflumilast and placebo groups,
respectively
Interventions Run-in: 4 weeks
• Roflumilast 500 µg, once daily
• Placebo once daily
Concomitant medication
• Short-acting anticholinergic: not stated
• SABA: not stated
• Corticosteroid: not stated
• LABA: not stated
Outcomes Primary outcome: change in carotid femoral-pulse wave velocity
Secondary outcomes: change in reactive hyperaemia index; change in augmentation index; change
in matrix metalloproteinase-9; change in asymmetrical dimethylamine; change in tumour necrosis fac-
tor-alpha; change in FEV1; change in 6-minute walk test; change in COPD assessment test
Urban 2018 (ELASTIC) 
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Notes Clincaltrials.gov identifier: NCT01630200. Funded by Ludwig Boltzmann Institute for COPD and Respira-
tory Epidemiology
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Reported as randomised; no further information
Allocation concealment
(selection bias)





Low risk "All responsible persons, those administering interventions or assessing the
outcomes, and elementally all experimental and control patients were blinded
to group assignment"
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk "All responsible persons, those administering interventions or assessing the





Low risk 40 randomised in each group. In the roflumilast group 33/40 completed
(82.5%), in the placebo arm 34/40 completed (85%), so similar attrition. Simi-
lar numbers of non-fatal and serious fatal adverse events in each group
Selective reporting (re-
porting bias)
Low risk Study authors reported outcomes as planned; methods and results were pub-
lished on EU trials registry
Other bias Unclear risk Criteria for COPD not well defined apart from exacerbations
Urban 2018 (ELASTIC)  (Continued)
6MWT: 6-minute walk test; AcPGP: plasma acetyl-proline-glycine-proline; ATS: American Thoracic Society; BDI: Baseline Dyspnoea Index;
BMI: body mass index; BORG Scale: rating of perceived exertion; CAT: COPD Assessment Test; CHF: congestive heart failure; COPD: chronic
obstructive pulmonary disease; CRP: C-reactive protein; DLCO: diKusing capacity of the lung for carbon monoxide; EU: European Union;
ERS: European Respiratory Society; FDC: fixed dose combination; FEF: forced expiratory flow; FEV1: forced expiratory volume in one
second; FEV6: forced expiratory volume in six seconds; FIV1: forced expiratory volume in one second; FRC: functional residual capacity; FVC:
forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; HU: Hounsfield unit; HIV: human immunodeficiency
virus; IC: inspiratory capacity; ICS: inhaled corticosteroid; ILD: interstitial lung disease; LABA: long-acting beta2-agonist; LAMA:long-acting
muscarinic antagonist; MDI: metered-dose inhaler; MI: myocardial infarction; MMEF: maximal mid-expiratory flow; NCT: national clinical
trial; PEF: peak expiratory flow; QTc: corrected Q wave and T wave; RFRC: resting functional residual capacity; RV: residual volume;
SABA: short-acting beta2-agonist; SAMA: short-acting muscarinic antagonist; SD: standard deviation; SE: standard error; SGRQ: St George's
Respiratory Questionnaire; SOBQ: Shortness of Breath Questionnaire; SVC: slow vital capacity; TDI: transition dyspnoea index; TLC: total
lung capacity VO2: oxygen uptake.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Borker 2003 Insufficient data; only RR of QoL improvement provided
CTRI/2012/09/002961 No placebo group
CTRI/2014/01/004370 No placebo group
Ferguson 2003 Integrated results from four 24-week cilomilast trials
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Study Reason for exclusion
Fischer 2003 Analysis focused on participants with baseline SGRQ score ≥ median SGRQ score only
Grootendorst 2001 Endpoint: first dose bronchodilator effects only
Grootendorst 2002 Treatment Bayer BAY 19-8004; 11 participants; only 1 week in duration
Grootendorst 2003 Endpoint: first dose bronchodilator effects only
Grootendorst 2007 Cross-over design
GSK256066 Phase 2 trial; no primary outcome measure investigating lung function; only 1 trial to date
Kelsen 2002 No study ID or group numbers identified
Knobil 2003 No SD or SE given
Lim 2004 Combining results from 2 pivotal European phase 3 cilomilast trials
NCT00246935 Different regimens of roflumilast; no placebo group
NCT01849341 Different regimens of roflumilast; no placebo group
NCT01973998 Patients were diagnosed with AECOPD
NCT02018432 Different regimens of roflumilast; no placebo group
Nieman 1999 Study 038: insufficient data available for changes in lung function and exacerbation rates
Pascoe 2007 Treatment QAK423 (Novartis), discontinued. Only 1 trial available
Rabe 2017 Editorial letter
Reisner 2003 Combined results; individual studies already included in review
Rennard 2008 Systematic review; relevant individual studies already included in review
Roflumilast JP708 JP108 is an extension study of APTA-2217-06. After the key open of APTA-2217-06, administration
to placebo group would be terminated. Not all participants enrolled in JP106 continued onto the
JP108 study
Sadigov 2014 No placebo group
Sadigov 2015 Open-label; no placebo group
SB207499/040 Open-label study; men or women with COPD who successfully completed study 042 or 091 in which
participants received cilomilast 15 mg twice daily or placebo for 24 weeks in study 042 and 26
weeks in study 091 without tolerability problems. Concomitant COPD medication use allowed; giv-
en placebo or placebo/Ariflo during study period
SB207499/041 Open-label study; men or women with COPD who successfully completed study 039 in which par-
ticipants received cilomilast 15 mg twice daily or placebo for 24 weeks without tolerability prob-
lems. Concomitant COPD medication use allowed; given placebo or placebo/Ariflo during study pe-
riod
Song 2005 Abstract only; unable to contact study author
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Study Reason for exclusion
Spencer 2002 No study identification or group numbers identified
Vestbo 2007 Treatment UK-500,001 (Pfizer); discontinued
Vestbo 2009 Treatment UK-500,001 (Pfizer); discontinued
Wang 2005 Although quoted as significant, mean and SD figures not provided
Watz 2013 Inhaled therapy
Watz 2016 Different regimens of roflumilast
AECOPD: acute exacerbation of COPD; COPD: chronic obstructive pulmonary disease; QoL: quality of life; RR: risk ratio; SD: standard
deviation; SE: standard error; SGRQ: St George's Respiratory Questionnaire.
 
Characteristics of studies awaiting classification [ordered by study ID]
 
Methods international, 16-week, randomised, double-blind, placebo-controlled, parallel-group study in-
vestigating effects of roflumilast 500 µg once daily vs placebo on inflammatory parameters in
bronchial biopsy tissue specimens, sputum, and blood serum
Participants 150 participants with COPD and chronic bronchitis for at least 12 months will be recruited into the
study and randomised in a 1:1 ratio to receive either roflumilast or placebo
Interventions Roflumilast and placebo
Outcomes Primary endpoint will be number of CD8+ cells in bronchial biopsy tissue specimens (submucosa)
Key secondary endpoint will be number of CD68+ cells assessed by indirect immunohistochemistry




Methods Randomised controlled trial
Participants Participants with history of moderate to severe COPD for at least 12 months
Interventions Roflumilast and placebo
Outcomes Primary outcome variable will be mean change in post-bronchodilator FEV1 from baseline




Methods Single-blind, randomised, placebo-controlled study carried out in the Department of Respiratory
Medicine at National Institute of Diseases of the Chest and Hospital (NIDCH), Dhaka, Bangladesh
Mahmud 2013 
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Participants 130 participants were recruited initially and were randomly distributed into Group A, where they
received conventional therapy (inhaled salmeterol + fluticasone and tiotropium) and roflumilast
(0.5 mg once daily), and Group B, where participants were given placebo with conventional therapy
Study duration was 3 months
Interventions As above
Outcomes Primary outcome variable was change in mean FEV1
Secondary outcome variable was change in mean CAT score from baseline




Methods Multi-centre double-blind randomised controlled trial over 12 weeks across USA investigating the
safety and efficacy of various doses of oglemilast
Participants 427 participants with COPD, post-bronchodilator FEV1/FVC < 70%, post-bronchodilator FEV1 > 30%
and < 80%
Interventions Oglemilast and placebo
Outcomes Primary outcome variable will be pre-bronchodilator morning (trough) FEV1 at 12 weeks
Secondary endpoint will be pre-bronchodilator FVC at 12 weeks




Methods Single-centre, double-blind randomised controlled trial over 12 weeks in Spain
Participants 150 participants with a diagnosis of COPD, FEV1 < 70%; current and former smokers
Interventions Roflumilast and placebo
Outcomes Primary outcome variable will be endothelial function at 12 weeks
Secondary endpoints include arterial stiffness; serum and plasma inflammation markers; serum
oxidative stress markers; serum endothelial dysfunction markers at 12 weeks




Methods Triple-blind randomised controlled trial for 26 weeks investigating whether roflumilast could im-
prove metabolic profiles and reduce visceral adiposity in people with COPD
NCT01701934 
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Participants 14 participants with moderate to severe COPD, assigned to either 500 µg roflumilast or placebo for
26 weeks
Interventions Roflumilast and placebo
Outcomes Primary outcome variables will be change in body mass index; change in waist circumference;
change in hip-to-waist ratio; change in metabolic profiles; change in body composition; change in
subcutaneous adiposity; change in liver fat
Notes No data provided; awaiting results
NCT01701934  (Continued)
CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; FVC: forced vital
capacity.
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Evaluation of the effect of roflumilast in hyperinflated COPD patients using functional respiratory
imaging
Methods Parallel RCT
Participants 40 people who are stable on LABA/LAMA therapy and who are prone to dynamics hyperinflation
Interventions Roflumilast and placebo
Outcomes Radiological (CT) changes in airway measures
Changes in spirometry and body plethysmography
Starting date September 2015
Contact information University Hospital of Antwerp
Notes Other Study ID Numbers: FLUI-2014-134, EudraCT




Study name A multicenter randomised double-blind clinical study evaluated the safety, pharmacokinetic and
pharmacodynamic characteristics of roflumilast in COPD patients
Methods Parallel RCT
Participants People with COPD in China
Interventions Roflumilast and placebo
Outcomes Area under the plasma concentration after vs drug dose
Percentage of participants with adverse events of interest
Change in pre-bronchodilator FEV1 during the down-titration period
NCT02671942 2016 
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Starting date March 2016
Contact information Contact: Zheng Jinping
Notes Estimated enrolment: 120
Estimated study completion date: August 2017
NCT02671942 2016  (Continued)
COPD: chronic obstructive pulmonary disease; CT: computed tomography; FEV1: forced expiratory volume in one second; LABA: long-acting
beta2-agonist; LAMA:long-acting muscarinic antagonist; RCT: randomised controlled trial.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   PDE4 inhibitor versus placebo (2020 update)





Statistical method Effect size
1.1 FEV1 (by drug) 29 20815 Mean Difference (IV, Fixed, 95%
CI)
49.33 [44.17, 54.49]
1.1.1 Tetomilast 50 µg 1 76 Mean Difference (IV, Fixed, 95%
CI)
82.00 [-50.84, 214.84]
1.1.2 Roflumilast 500 μg 18 14384 Mean Difference (IV, Fixed, 95%
CI)
55.18 [48.65, 61.71]
1.1.3 Roflumilast 250 μg 3 1033 Mean Difference (IV, Fixed, 95%
CI)
56.88 [24.38, 89.38]
1.1.4 Cilomilast 15 mg 10 5322 Mean Difference (IV, Fixed, 95%
CI)
38.15 [29.41, 46.90]
1.2 FVC 17 22108 Mean Difference (IV, Fixed, 95%
CI)
86.98 [74.65, 99.31]
1.3 PEF 5 4245 Mean Difference (IV, Fixed, 95%
CI)
6.54 [3.95, 9.13]
1.3.1 Roflumilast 500 μg 4 3685 Mean Difference (IV, Fixed, 95%
CI)
5.46 [2.74, 8.17]
1.3.2 Roflumilast 250 μg 1 347 Mean Difference (IV, Fixed, 95%
CI)
7.00 [-4.05, 18.05]
1.3.3 Cilomilast 15 mg 1 213 Mean Difference (IV, Fixed, 95%
CI)
34.00 [20.14, 47.86]
1.4 SGRQ total score 11 7645 Mean Difference (IV, Fixed, 95%
CI)
-1.06 [-1.68, -0.43]
1.4.1 Roflumilast 500 μg 2 722 Mean Difference (IV, Fixed, 95%
CI)
-1.87 [-3.80, 0.06]
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Statistical method Effect size
1.4.2 Roflumilast 250 μg 2 2229 Mean Difference (IV, Fixed, 95%
CI)
-0.64 [-2.02, 0.74]
1.4.3 Cilomilast 15 mg 8 4694 Mean Difference (IV, Fixed, 95%
CI)
-1.06 [-1.81, -0.31]
1.5 SGRQ symptom score 2 1048 Mean Difference (IV, Fixed, 95%
CI)
-1.53 [-4.11, 1.06]
1.5.1 Roflumilast 1 835 Mean Difference (IV, Fixed, 95%
CI)
-1.00 [-3.78, 1.78]
1.5.2 Cilomilast 1 213 Mean Difference (IV, Fixed, 95%
CI)
-4.80 [-11.73, 2.13]
1.6 Number of participants with 1 or more
exacerbations (by drug)
27 20382 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.73, 0.84]
1.6.1 Roflumilast 500 μg 16 14778 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.73, 0.86]
1.6.2 Cilomilast 10 5528 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.67, 0.85]
1.6.3 Tetomilast 50 µg 1 76 Odds Ratio (M-H, Fixed, 95% CI) 2.45 [0.26, 23.13]
1.7 Exacerbation rate (inverse variance) 9   Rate Ratio (IV, Fixed, 95% CI) 0.88 [0.83, 0.93]
1.7.1 Roflumilast 8   Rate Ratio (IV, Fixed, 95% CI) 0.87 [0.82, 0.92]
1.7.2 Cilomilast 1   Rate Ratio (IV, Fixed, 95% CI) 0.95 [0.78, 1.17]
1.8 Borg Scale 6 2860 Mean Difference (IV, Fixed, 95%
CI)
-0.19 [-0.33, -0.05]
1.8.1 Cilomilast 6 2860 Mean Difference (IV, Fixed, 95%
CI)
-0.19 [-0.33, -0.05]
1.9 Shortness of Breath Questionnaire 2 1633 Mean Difference (IV, Fixed, 95%
CI)
-1.09 [-2.47, 0.28]
1.10 Summary symptom score 5 6186 Std. Mean Difference (IV, Fixed,
95% CI)
-0.02 [-0.07, 0.03]
1.10.1 Roflumilast 2 4287 Std. Mean Difference (IV, Fixed,
95% CI)
-0.02 [-0.08, 0.04]
1.10.2 Cilomilast 3 1899 Std. Mean Difference (IV, Fixed,
95% CI)
-0.04 [-0.13, 0.06]
1.11 Breathlessness Cough and Sputum
Scale (BCSS) (tetomilast 50 µg)
1   Mean Difference (IV, Fixed, 95%
CI)
Subtotals only
1.11.1 Breathlessness 1 22 Mean Difference (IV, Fixed, 95%
CI)
-0.07 [-0.77, 0.63]
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Statistical method Effect size
1.11.2 Cough 1 22 Mean Difference (IV, Fixed, 95%
CI)
0.23 [-0.54, 1.00]
1.11.3 Sputum 1 22 Mean Difference (IV, Fixed, 95%
CI)
-0.16 [-0.97, 0.65]
1.12 6-minute walk test 6 2055 Mean Difference (IV, Fixed, 95%
CI)
3.50 [-5.84, 12.85]
1.12.1 Roflumilast 2 107 Mean Difference (IV, Fixed, 95%
CI)
52.61 [-0.21, 105.42]
1.12.2 Cilomilast 4 1948 Mean Difference (IV, Fixed, 95%
CI)
1.92 [-7.58, 11.41]
1.13 Number of participants experiencing
an adverse event
30 21310 Odds Ratio (M-H, Fixed, 95% CI) 1.30 [1.22, 1.38]
1.13.1 Roflumilast 500 μg 15 14684 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [1.24, 1.43]
1.13.2 Cilomilast 15 mg 14 6542 Odds Ratio (M-H, Fixed, 95% CI) 1.21 [1.08, 1.36]
1.13.3 Tetomilast 50 µg 1 84 Odds Ratio (M-H, Fixed, 95% CI) 0.62 [0.25, 1.57]
1.14 Number of participants experiencing
an adverse event (roflumilast 500 μg vs
250 μg)
4 1977 Odds Ratio (M-H, Fixed, 95% CI) 1.21 [1.01, 1.46]
1.15 Diarrhoea 29 20623 Odds Ratio (M-H, Fixed, 95% CI) 3.10 [2.74, 3.50]
1.15.1 Roflumilast 14 13997 Odds Ratio (M-H, Fixed, 95% CI) 3.65 [3.10, 4.28]
1.15.2 Cilomilast 14 6542 Odds Ratio (M-H, Fixed, 95% CI) 2.47 [2.05, 2.98]
1.15.3 Tetomilast 1 84 Odds Ratio (M-H, Fixed, 95% CI) 1.68 [0.31, 9.24]
1.16 Nausea 27 20949 Odds Ratio (M-H, Fixed, 95% CI) 3.79 [3.24, 4.43]
1.16.1 Roflumilast 500 μg 12 13467 Odds Ratio (M-H, Fixed, 95% CI) 3.25 [2.60, 4.07]
1.16.2 Roflumilast 250 μg 1 856 Odds Ratio (M-H, Fixed, 95% CI) 3.97 [0.91, 17.39]
1.16.3 Cilomilast 15 mg 14 6542 Odds Ratio (M-H, Fixed, 95% CI) 4.37 [3.49, 5.47]
1.16.4 Tetomilast 50 µg 1 84 Odds Ratio (M-H, Fixed, 95% CI) 2.00 [0.20, 20.09]
1.17 Vomiting 12 5986 Odds Ratio (M-H, Fixed, 95% CI) 3.95 [2.78, 5.60]
1.17.1 Roflumilast 2 993 Odds Ratio (M-H, Fixed, 95% CI) 2.32 [0.53, 10.23]
1.17.2 Cilomilast 10 4993 Odds Ratio (M-H, Fixed, 95% CI) 4.06 [2.83, 5.82]
1.18 Dyspepsia 13 6247 Odds Ratio (M-H, Fixed, 95% CI) 3.17 [2.33, 4.30]
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1.18.1 Roflumilast 1 626 Odds Ratio (M-H, Fixed, 95% CI) 7.07 [0.36, 137.40]
1.18.2 Cilomilast 12 5621 Odds Ratio (M-H, Fixed, 95% CI) 3.13 [2.30, 4.27]
1.19 Weight loss 12 12462 Odds Ratio (M-H, Fixed, 95% CI) 3.72 [3.09, 4.47]
1.19.1 Roflumilast 11 12378 Odds Ratio (M-H, Fixed, 95% CI) 3.80 [3.15, 4.58]
1.19.2 Tetomilast 50 µg 1 84 Odds Ratio (M-H, Fixed, 95% CI) 0.12 [0.01, 2.63]
1.20 Withdrawals due to adverse events 31 21358 Odds Ratio (M-H, Fixed, 95% CI) 1.89 [1.73, 2.07]
1.20.1 Roflumilast 500 μg 16 14729 Odds Ratio (M-H, Fixed, 95% CI) 1.90 [1.70, 2.12]
1.20.2 Cilomilast 15 mg 14 6545 Odds Ratio (M-H, Fixed, 95% CI) 1.90 [1.61, 2.24]
1.20.3 Tetomilast 50 mg 1 84 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.20, 3.18]
1.21 Headache 23 19215 Odds Ratio (M-H, Fixed, 95% CI) 1.69 [1.46, 1.94]
1.21.1 Roflumilast 500 μg 12 13565 Odds Ratio (M-H, Fixed, 95% CI) 2.13 [1.74, 2.59]
1.21.2 Roflumilast 250 μg 1 347 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.24, 3.99]
1.21.3 Cilomilast 15 mg 11 5303 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [1.08, 1.62]
1.22 Abdominal pain 15 8329 Odds Ratio (M-H, Fixed, 95% CI) 2.02 [1.62, 2.52]
1.22.1 Roflumilast 3 2641 Odds Ratio (M-H, Fixed, 95% CI) 2.77 [1.38, 5.56]
1.22.2 Cilomilast 11 5604 Odds Ratio (M-H, Fixed, 95% CI) 1.97 [1.55, 2.49]
1.22.3 Tetomilast 50 µg 1 84 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.15, 6.13]
1.23 Influenza-like symptoms 9 11460 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.87, 1.36]
1.23.1 Roflumilast 500 μg 7 10147 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.87, 1.41]
1.23.2 Roflumilast 250 μg 1 347 Odds Ratio (M-H, Fixed, 95% CI) 1.98 [0.18, 22.00]
1.23.3 Cilomilast 15 mg 2 966 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.44, 1.75]
1.24 Upper respiratory tract infection 21 17022 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.81, 1.04]
1.24.1 Roflumilast 500 μg 11 11539 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.77, 1.09]
1.24.2 Roflumilast 250 μg 2 1203 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.54, 1.31]
1.24.3 Cilomilast 15 mg 10 4280 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.75, 1.13]
1.25 Psychiatric adverse events (roflumi-
last)
1   Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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1.25.1 Roflumilast 500 μg 1 11168 Odds Ratio (M-H, Fixed, 95% CI) 2.13 [1.79, 2.54]
1.25.2 Roflumilast 250 μg 1 6288 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.56, 1.33]
1.26 Anxiety or anxiety disorder (roflumi-
last)
1   Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.26.1 Roflumilast 500 μg 1 11168 Odds Ratio (M-H, Fixed, 95% CI) 1.81 [1.26, 2.62]
1.26.2 Roflumilast 250 μg 1 6288 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.40, 2.21]
1.27 Depression (roflumilast) 1   Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.27.1 Roflumilast 500 μg 1 11168 Odds Ratio (M-H, Fixed, 95% CI) 1.59 [1.11, 2.27]
1.27.2 Roflumilast 250 μg 1 6288 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.20, 1.56]
1.28 Insomnia and sleep disorders (roflu-
milast)
4   Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.28.1 Roflumilast 500 μg 4 15482 Odds Ratio (M-H, Fixed, 95% CI) 2.67 [2.11, 3.38]
1.28.2 Roflumilast 250 μg 1 6288 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.81, 2.70]
1.29 Serious adverse events 29 19191 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.91, 1.07]
1.29.1 Roflumilast 500 μg 14 12562 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.93, 1.12]
1.29.2 Cilomilast 15 mg 14 6545 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.72, 1.06]
1.29.3 Tetomilast 50 µg 1 84 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.23, 1.55]
1.30 Mortality 27 19786 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.77, 1.24]
1.30.1 Roflumilast 13 13370 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.79, 1.30]
1.30.2 Cilomilast 13 6332 Odds Ratio (M-H, Fixed, 95% CI) 0.70 [0.34, 1.45]
1.30.3 Tetomilast 1 84 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.31 FEV1 (by mean COPD severity) 22 16813 Mean Difference (IV, Fixed, 95%
CI)
52.78 [46.73, 58.83]
1.31.1 GOLD grade I + II (FEV1 ≥ 50% pre-
dicted)
10 4801 Mean Difference (IV, Fixed, 95%
CI)
51.82 [39.03, 64.60]
1.31.2 GOLD grade III + IV (FEV1 < 50% pre-
dicted)
12 12012 Mean Difference (IV, Fixed, 95%
CI)
53.06 [46.19, 59.92]
1.32 FEV1 (roflumilast 500 μg vs 250 μg) 3 1560 Mean Difference (IV, Fixed, 95%
CI)
22.61 [-5.95, 51.16]
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1.32.1 Roflumilast 250 ug 3 1560 Mean Difference (IV, Fixed, 95%
CI)
22.61 [-5.95, 51.16]
1.33 FEV1 (by study duration) 28 19939 Mean Difference (IV, Fixed, 95%
CI)
49.09 [43.86, 54.32]
1.33.1 Duration ≤ 12 weeks 8 1191 Mean Difference (IV, Fixed, 95%
CI)
101.71 [70.96, 132.46]
1.33.2 Duration 24 to 26 weeks 13 8086 Mean Difference (IV, Fixed, 95%
CI)
46.14 [38.44, 53.84]
1.33.3 Duration 52 weeks 7 10662 Mean Difference (IV, Fixed, 95%
CI)
48.77 [41.44, 56.10]
1.34 FEV1 (additional medication) 28 19719 Mean Difference (IV, Fixed, 95%
CI)
49.08 [43.85, 54.31]
1.34.1 Long-acting bronchodilator 2 1645 Mean Difference (IV, Fixed, 95%
CI)
60.52 [40.57, 80.46]
1.34.2 Corticosteroids 3 2904 Mean Difference (IV, Fixed, 95%
CI)
42.26 [25.46, 59.05]
1.34.3 PDE4i treatment only 20 10323 Mean Difference (IV, Fixed, 95%
CI)
44.80 [37.69, 51.91]
1.34.4 Various concomitant treatments 3 4847 Mean Difference (IV, Fixed, 95%
CI)
56.58 [46.91, 66.25]
1.35 FEV1 (random-effects model) 29 20015 Mean Difference (IV, Random,
95% CI)
51.49 [42.87, 60.10]
1.36 FEV1 (published vs unpublished) 29 20015 Mean Difference (IV, Fixed, 95%
CI)
49.28 [44.05, 54.51]
1.36.1 Published 20 15398 Mean Difference (IV, Fixed, 95%
CI)
55.75 [49.45, 62.06]
1.36.2 Unpublished 9 4617 Mean Difference (IV, Fixed, 95%
CI)
35.05 [25.70, 44.40]
1.37 SGRQ total score (by mean COPD
severity)
8 4851 Mean Difference (IV, Fixed, 95%
CI)
-1.56 [-2.39, -0.74]
1.37.1 GOLD grade I + II 3 2042 Mean Difference (IV, Fixed, 95%
CI)
-1.62 [-2.80, -0.44]
1.37.2 GOLD grade III + IV 5 2809 Mean Difference (IV, Fixed, 95%
CI)
-1.51 [-2.67, -0.34]
1.38 SGRQ total score (by duration) 11 7069 Mean Difference (IV, Fixed, 95%
CI)
-0.99 [-1.65, -0.33]
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1.38.1 Duration < 12 weeks 2 240 Mean Difference (IV, Fixed, 95%
CI)
-4.19 [-7.60, -0.78]
1.38.2 Duration 24 to 26 weeks 7 4600 Mean Difference (IV, Fixed, 95%
CI)
-1.18 [-1.94, -0.42]
1.38.3 Duration 52 weeks 2 2229 Mean Difference (IV, Fixed, 95%
CI)
0.26 [-1.18, 1.69]
1.39 SGRQ total score (by published vs
unpublished)
11 7069 Mean Difference (IV, Fixed, 95%
CI)
-1.00 [-1.65, -0.34]
1.39.1 Published 5 3079 Mean Difference (IV, Fixed, 95%
CI)
-1.98 [-3.07, -0.89]
1.39.2 Unpublished 6 3990 Mean Difference (IV, Fixed, 95%
CI)
-0.43 [-1.26, 0.40]
1.40 Number of participants on roflumi-
last with 1 or more exacerbations (addi-
tional medication)
15 14698 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.73, 0.85]
1.40.1 Long-acting bronchodilators 3 1834 Odds Ratio (M-H, Fixed, 95% CI) 0.69 [0.54, 0.88]
1.40.2 Corticosteroids 1 2686 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.70, 0.95]
1.40.3 Treatment only 7 5145 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.67, 0.93]
1.40.4 Various concomitant treatments 4 5033 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.72, 0.91]
1.41 FVC ML (roflumilast 500 µg, end-
point)
1 60 Mean Difference (IV, Fixed, 95%
CI)
0.52 [0.25, 0.79]
1.42 FEV1 (by unknown COPD severity) 1 76 Mean Difference (IV, Fixed, 95%
CI)
82.00 [-50.84, 214.84]
1.43 FEV1 (by duration, endpoint) 1 60 Mean Difference (IV, Fixed, 95%
CI)
0.52 [0.25, 0.79]
1.44 FEV1 (random-effects model, end-
point data)
1 60 Mean Difference (IV, Random,
95% CI)
0.43 [0.31, 0.55]
1.45 FEV1 (by moderate to severe COPD
severity, endpoint)
1 60 Mean Difference (IV, Fixed, 95%
CI)
0.52 [0.25, 0.79]
1.46 FEV1 (roflumilast 500 µg, endpoint) 1 60 Mean Difference (IV, Fixed, 95%
CI)
0.43 [0.31, 0.55]
1.47 FEV1 ML (additional medication
(PDE4i only) endpoint)
1 60 Mean Difference (IV, Fixed, 95%
CI)
0.52 [0.25, 0.79]
1.48 FEV1 (published, endpoint) 1 60 Mean Difference (IV, Fixed, 95%
CI)
0.52 [0.25, 0.79]
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1.49 FEV1 (roflumilast 500 μg by mean
COPD severity)
16 13896 Mean Difference (IV, Fixed, 95%
CI)
55.51 [48.88, 62.14]
1.49.1 GOLD grade I + II (FEV1 ≥ 50% pre-
dicted)
7 3341 Mean Difference (IV, Fixed, 95%
CI)
69.83 [53.34, 86.33]
1.49.2 GOLD grade III + IV (FEV1 < 50% pre-
dicted)
9 10555 Mean Difference (IV, Fixed, 95%
CI)
52.75 [45.52, 59.99]
1.50 FEV1 (unknown additional medica-
tion)
1 76 Mean Difference (IV, Fixed, 95%
CI)
82.00 [-50.84, 214.84]
1.51 FEV1 (by moderate to severe COPD
severity, roflumilast 500 µg endpoint)
1 60 Mean Difference (IV, Fixed, 95%
CI)
0.52 [0.25, 0.79]
1.52 FEV1 (by unknown COPD severity,
roflumilast 500 µg )
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Analysis 1.1.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome 1: FEV1 (by drug)
Study or Subgroup




Test for overall effect: Z = 1.21 (P = 0.23)




















Heterogeneity: Chi² = 21.53, df = 17 (P = 0.20); I² = 21%
Test for overall effect: Z = 16.56 (P < 0.00001)
1.1.3 Roflumilast 250 µg




Heterogeneity: Chi² = 1.08, df = 2 (P = 0.58); I² = 0%
Test for overall effect: Z = 3.43 (P = 0.0006)












Heterogeneity: Chi² = 23.75, df = 9 (P = 0.005); I² = 62%
Test for overall effect: Z = 8.55 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 56.15, df = 31 (P = 0.004); I² = 45%
Test for overall effect: Z = 18.73 (P < 0.00001)


























































































































































































































































IV, Fixed, 95% CI [mL]
82.00 [-50.84 , 214.84]
82.00 [-50.84 , 214.84]
71.00 [46.00 , 96.00]
63.00 [-208.97 , 334.97]
56.00 [38.26 , 73.74]
13.00 [-120.78 , 146.78]
52.00 [-9.00 , 113.00]
39.00 [-9.44 , 87.44]
125.00 [64.96 , 185.04]
152.00 [-64.52 , 368.52]
88.00 [48.83 , 127.17]
42.00 [21.08 , 62.92]
36.00 [5.52 , 66.48]
82.00 [8.34 , 155.66]
96.00 [37.74 , 154.26]
38.00 [15.86 , 60.14]
58.00 [38.59 , 77.41]
49.00 [24.07 , 73.93]
81.00 [47.75 , 114.25]
53.00 [40.00 , 66.00]
55.18 [48.65 , 61.71]
36.00 [-24.52 , 96.52]
137.00 [-79.38 , 353.38]
63.00 [23.84 , 102.16]
56.88 [24.38 , 89.38]
40.00 [12.30 , 67.70]
30.00 [-13.04 , 73.04]
20.00 [-90.83 , 130.83]
30.00 [-25.40 , 85.40]
44.00 [30.13 , 57.87]
70.00 [-40.92 , 180.92]
20.00 [-3.93 , 43.93]
24.00 [1.82 , 46.18]
34.00 [7.70 , 60.30]
160.00 [104.53 , 215.47]
38.15 [29.41 , 46.90]
49.33 [44.17 , 54.49]
Mean Difference
IV, Fixed, 95% CI [mL]
-200 -100 0 100 200
Favours placebo Favours PDE4i
Footnotes
(1) Units converted from L to mL, standard deviations obtained by imputing participant number in each group in the calculator from GIV analysis. Mean differences for each treatment group were not available, placebo imputed as zero, and roflumilast imputed as 0.063
(2) The participant number in the placebo group was halved to avoid double counting
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Heterogeneity: Chi² = 16.06, df = 16 (P = 0.45); I² = 0%
Test for overall effect: Z = 13.82 (P < 0.00001)





































































































































IV, Fixed, 95% CI [mL]
110.00 [39.29 , 180.71]
50.00 [-33.16 , 133.16]
50.00 [-47.95 , 147.95]
27.00 [-41.02 , 95.02]
60.00 [4.62 , 115.38]
195.00 [56.41 , 333.59]
109.00 [61.00 , 157.00]
64.00 [-44.19 , 172.19]
93.00 [61.81 , 124.19]
114.00 [46.93 , 181.07]
47.00 [-25.00 , 119.00]
151.00 [55.40 , 246.60]
101.00 [59.42 , 142.58]
103.00 [66.97 , 139.03]
57.00 [15.40 , 98.60]
101.00 [38.62 , 163.38]
83.00 [55.00 , 111.00]
86.98 [74.65 , 99.31]
Mean Difference
IV, Fixed, 95% CI [mL]
-500 -250 0 250 500
Favours placebo Favours PDE4i
Footnotes
(1) Imputed participant numbers and calculated SDs in RevMan calculator
 
 
Analysis 1.3.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome 3: PEF
Study or Subgroup






Heterogeneity: Chi² = 3.54, df = 3 (P = 0.32); I² = 15%
Test for overall effect: Z = 3.94 (P < 0.0001)




Test for overall effect: Z = 1.24 (P = 0.21)




Test for overall effect: Z = 4.81 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 19.24, df = 5 (P = 0.002); I² = 74%
Test for overall effect: Z = 4.95 (P < 0.00001)

































































IV, Fixed, 95% CI [L/min]
8.00 [-1.80 , 17.80]
16.25 [3.82 , 28.68]
4.21 [0.08 , 8.34]
5.07 [0.99 , 9.15]
5.46 [2.74 , 8.17]
7.00 [-4.05 , 18.05]
7.00 [-4.05 , 18.05]
34.00 [20.14 , 47.86]
34.00 [20.14 , 47.86]
6.54 [3.95 , 9.13]
Mean Difference
IV, Fixed, 95% CI [L/min]
-50 -25 0 25 50
Favours placebo Favours PDE4i
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Analysis 1.4.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome 4: SGRQ total score
Study or Subgroup




Heterogeneity: Chi² = 0.83, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 1.89 (P = 0.06)




Heterogeneity: Chi² = 1.82, df = 1 (P = 0.18); I² = 45%
Test for overall effect: Z = 0.91 (P = 0.36)










Heterogeneity: Chi² = 17.26, df = 7 (P = 0.02); I² = 59%
Test for overall effect: Z = 2.76 (P = 0.006)
Total (95% CI)
Heterogeneity: Chi² = 20.93, df = 11 (P = 0.03); I² = 47%
Test for overall effect: Z = 3.32 (P = 0.0009)











































































































IV, Fixed, 95% CI
-6.70 [-17.29 , 3.89]
-1.70 [-3.66 , 0.26]
-1.87 [-3.80 , 0.06]
-1.60 [-3.56 , 0.36]
0.30 [-1.64 , 2.24]
-0.64 [-2.02 , 0.74]
-4.10 [-6.18 , -2.02]
0.70 [-1.81 , 3.21]
-0.40 [-3.58 , 2.78]
0.04 [-1.57 , 1.65]
-0.30 [-2.31 , 1.71]
-1.90 [-3.57 , -0.23]
0.20 [-1.95 , 2.35]
-3.90 [-7.50 , -0.30]
-1.06 [-1.81 , -0.31]
-1.06 [-1.68 , -0.43]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PDE4i Favours placebo
 
 











Test for overall effect: Z = 1.36 (P = 0.17)
Total (95% CI)
Heterogeneity: Chi² = 0.99, df = 1 (P = 0.32); I² = 0%
Test for overall effect: Z = 1.16 (P = 0.25)


































IV, Fixed, 95% CI
-1.00 [-3.78 , 1.78]
-1.00 [-3.78 , 1.78]
-4.80 [-11.73 , 2.13]
-4.80 [-11.73 , 2.13]
-1.53 [-4.11 , 1.06]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PDE4i Favours placebo
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Analysis 1.6.   Comparison 1: PDE4 inhibitor versus placebo (2020 update),
Outcome 6: Number of participants with 1 or more exacerbations (by drug)
Study or Subgroup
















Urban 2018 (ELASTIC) (2)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 14.27, df = 15 (P = 0.51); I² = 0%














Heterogeneity: Chi² = 12.00, df = 9 (P = 0.21); I² = 25%
Test for overall effect: Z = 4.64 (P < 0.00001)





Test for overall effect: Z = 0.78 (P = 0.43)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 27.71, df = 26 (P = 0.37); I² = 6%
Test for overall effect: Z = 7.45 (P < 0.00001)




































































































































































M-H, Fixed, 95% CI
0.69 [0.21 , 2.30]
1.74 [0.68 , 4.49]
0.64 [0.22 , 1.89]
0.80 [0.67 , 0.96]
0.74 [0.39 , 1.41]
0.50 [0.09 , 2.68]
1.53 [0.79 , 2.96]
0.74 [0.55 , 1.01]
0.81 [0.70 , 0.95]
0.97 [0.52 , 1.81]
0.82 [0.59 , 1.15]
0.69 [0.51 , 0.93]
0.61 [0.44 , 0.84]
0.83 [0.56 , 1.22]
0.79 [0.67 , 0.93]
5.57 [0.62 , 50.03]
0.79 [0.73 , 0.86]
0.52 [0.36 , 0.75]
1.02 [0.73 , 1.41]
1.35 [0.33 , 5.64]
0.60 [0.44 , 0.82]
0.97 [0.44 , 2.15]
0.71 [0.55 , 0.92]
0.85 [0.63 , 1.14]
0.84 [0.65 , 1.09]
0.76 [0.40 , 1.44]
0.51 [0.12 , 2.10]
0.76 [0.67 , 0.85]
2.45 [0.26 , 23.13]
2.45 [0.26 , 23.13]
0.78 [0.73 , 0.84]
Odds Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favours PDE4i Favours placebo
Footnotes
(1) New study data added 2019
(2) New data added 2019
(3) New data 2019: level 2 or more; requiring physician visit or admission to hospital
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Analysis 1.7.   Comparison 1: PDE4 inhibitor versus placebo












Heterogeneity: Chi² = 2.71, df = 7 (P = 0.91); I² = 0%





Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI)
Heterogeneity: Chi² = 3.39, df = 8 (P = 0.91); I² = 0%
Test for overall effect: Z = 4.59 (P < 0.00001)



































IV, Fixed, 95% CI
0.87 [0.75 , 1.00]
0.86 [0.71 , 1.05]
0.93 [0.80 , 1.09]
0.85 [0.74 , 0.98]
0.82 [0.71 , 0.94]
0.79 [0.58 , 1.08]
0.84 [0.57 , 1.23]
0.92 [0.81 , 1.04]
0.87 [0.82 , 0.92]
0.95 [0.78 , 1.17]
0.95 [0.78 , 1.17]
0.88 [0.83 , 0.93]
Other
IV, Fixed, 95% CI
0.5 0.7 1 1.5 2
Favours PDE4i Favours placebo
 
 










Heterogeneity: Chi² = 1.62, df = 5 (P = 0.90); I² = 0%
Test for overall effect: Z = 2.68 (P = 0.007)
Total (95% CI)
Heterogeneity: Chi² = 1.62, df = 5 (P = 0.90); I² = 0%
Test for overall effect: Z = 2.68 (P = 0.007)



























































IV, Fixed, 95% CI
-0.32 [-0.62 , -0.02]
-0.18 [-0.51 , 0.15]
-0.18 [-0.58 , 0.22]
0.06 [-0.48 , 0.60]
-0.18 [-0.42 , 0.06]
-0.10 [-0.86 , 0.66]
-0.19 [-0.33 , -0.05]
-0.19 [-0.33 , -0.05]
Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours PDE4i Favours placebo
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Analysis 1.9.   Comparison 1: PDE4 inhibitor versus placebo





Heterogeneity: Chi² = 5.22, df = 1 (P = 0.02); I² = 81%
Test for overall effect: Z = 1.56 (P = 0.12)




























IV, Fixed, 95% CI
0.50 [-1.44 , 2.44]
-2.70 [-4.65 , -0.75]
-1.09 [-2.47 , 0.28]
Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours PDE4i Favours placebo
 
 






Heterogeneity: Chi² = 1.43, df = 1 (P = 0.23); I² = 30%






Heterogeneity: Chi² = 3.43, df = 2 (P = 0.18); I² = 42%
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI)
Heterogeneity: Chi² = 4.93, df = 4 (P = 0.29); I² = 19%
Test for overall effect: Z = 0.92 (P = 0.36)























































IV, Fixed, 95% CI
-0.06 [-0.15 , 0.03]
0.01 [-0.07 , 0.09]
-0.02 [-0.08 , 0.04]
-0.05 [-0.22 , 0.12]
0.08 [-0.08 , 0.25]
-0.13 [-0.29 , 0.03]
-0.04 [-0.13 , 0.06]
-0.02 [-0.07 , 0.03]
Std. Mean Difference
IV, Fixed, 95% CI
-0.2 -0.1 0 0.1 0.2
Favours PDE4i Favours placebo
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Analysis 1.11.   Comparison 1: PDE4 inhibitor versus placebo (2020 update),
















Test for overall effect: Z = 0.39 (P = 0.70)









































IV, Fixed, 95% CI
-0.07 [-0.77 , 0.63]
-0.07 [-0.77 , 0.63]
0.23 [-0.54 , 1.00]
0.23 [-0.54 , 1.00]
-0.16 [-0.97 , 0.65]
-0.16 [-0.97 , 0.65]
Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours roflumilast Favours placebo
 
 




Urban 2018 (ELASTIC) (1)
Subtotal (95% CI)
Heterogeneity: Chi² = 0.43, df = 1 (P = 0.51); I² = 0%







Heterogeneity: Chi² = 5.79, df = 3 (P = 0.12); I² = 48%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI)
Heterogeneity: Chi² = 9.64, df = 5 (P = 0.09); I² = 48%
Test for overall effect: Z = 0.74 (P = 0.46)






























































IV, Fixed, 95% CI
0.00 [-166.29 , 166.29]
58.51 [2.81 , 114.21]
52.61 [-0.21 , 105.42]
7.10 [-6.49 , 20.69]
-16.40 [-35.44 , 2.64]
0.80 [-24.47 , 26.07]
19.80 [-7.35 , 46.95]
1.92 [-7.58 , 11.41]
3.50 [-5.84 , 12.85]
Mean Difference
IV, Fixed, 95% CI
-200 -100 0 100 200
Favours placebo Favours PDE4i
Footnotes
(1) New data 2019
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Analysis 1.13.   Comparison 1: PDE4 inhibitor versus placebo (2020 update),
Outcome 13: Number of participants experiencing an adverse event
Study or Subgroup















Urban 2018 (ELASTIC) (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 64.11, df = 14 (P < 0.00001); I² = 78%
Test for overall effect: Z = 8.04 (P < 0.00001)

















Heterogeneity: Chi² = 12.53, df = 13 (P = 0.48); I² = 0%
Test for overall effect: Z = 3.19 (P = 0.001)





Test for overall effect: Z = 1.01 (P = 0.31)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 80.86, df = 29 (P < 0.00001); I² = 64%
Test for overall effect: Z = 8.45 (P < 0.00001)



















































































































































































M-H, Fixed, 95% CI
4.21 [2.43 , 7.30]
2.66 [1.17 , 6.08]
1.40 [1.16 , 1.68]
0.40 [0.08 , 2.06]
0.96 [0.63 , 1.48]
1.60 [0.56 , 4.57]
3.67 [2.40 , 5.60]
1.22 [0.90 , 1.64]
1.09 [0.90 , 1.32]
2.52 [1.69 , 3.77]
1.28 [1.11 , 1.49]
1.18 [0.91 , 1.54]
1.24 [0.93 , 1.66]
1.18 [0.99 , 1.40]
1.70 [0.68 , 4.22]
1.34 [1.24 , 1.43]
1.46 [0.94 , 2.27]
1.19 [0.84 , 1.67]
1.57 [0.50 , 4.91]
0.98 [0.70 , 1.37]
1.37 [0.94 , 1.99]
2.40 [0.81 , 7.10]
2.25 [1.10 , 4.62]
1.26 [0.93 , 1.69]
1.35 [0.92 , 1.99]
1.07 [0.79 , 1.46]
0.72 [0.43 , 1.22]
1.02 [0.56 , 1.83]
1.23 [0.60 , 2.52]
1.42 [0.82 , 2.45]
1.21 [1.08 , 1.36]
0.62 [0.25 , 1.57]
0.62 [0.25 , 1.57]
1.30 [1.22 , 1.38]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours PDE4i Favours placebo
Footnotes
(1) New study data added 2019
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Analysis 1.14.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome








Heterogeneity: Chi² = 13.28, df = 3 (P = 0.004); I² = 77%
Test for overall effect: Z = 2.08 (P = 0.04)


































M-H, Fixed, 95% CI
1.00 [0.65 , 1.52]
1.06 [0.46 , 2.45]
2.33 [1.57 , 3.46]
1.02 [0.79 , 1.30]
1.21 [1.01 , 1.46]
Odds Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours 500 µg Favours 250 µg
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Urban 2018 (ELASTIC) (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 19.96, df = 13 (P = 0.10); I² = 35%


















Heterogeneity: Chi² = 4.44, df = 13 (P = 0.99); I² = 0%






Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 31.97, df = 28 (P = 0.28); I² = 12%
Test for overall effect: Z = 18.13 (P < 0.00001)














































































































































































M-H, Fixed, 95% CI
1.38 [0.45 , 4.26]
6.68 [1.96 , 22.80]
3.03 [0.92 , 9.98]
3.03 [2.04 , 4.51]
4.71 [0.18 , 126.90]
4.52 [1.91 , 10.68]
4.67 [3.27 , 6.69]
26.32 [3.52 , 196.86]
2.50 [1.57 , 4.00]
3.14 [1.94 , 5.10]
2.50 [1.37 , 4.56]
17.76 [4.23 , 74.57]
3.36 [2.31 , 4.89]
7.56 [0.38 , 151.28]
3.65 [3.10 , 4.28]
2.21 [1.36 , 3.62]
2.38 [1.09 , 5.18]
1.70 [0.42 , 6.77]
2.58 [1.28 , 5.21]
3.01 [1.74 , 5.19]
2.37 [0.40 , 13.96]
5.31 [1.46 , 19.31]
2.58 [1.56 , 4.25]
2.01 [1.36 , 2.99]
2.64 [1.37 , 5.09]
2.19 [0.92 , 5.21]
3.38 [0.89 , 12.86]
2.50 [0.47 , 13.39]
4.83 [1.02 , 22.91]
2.47 [2.05 , 2.98]
1.68 [0.31 , 9.24]
1.68 [0.31 , 9.24]
3.10 [2.74 , 3.50]
Odds Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favours PDE4i Favours placebo
Footnotes
(1) New data 2019
(2) New study data 2019
 
 
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Analysis 1.16.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome 16: Nausea
Study or Subgroup












Urban 2018 (ELASTIC) (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 16.80, df = 11 (P = 0.11); I² = 35%
Test for overall effect: Z = 10.36 (P < 0.00001)





Test for overall effect: Z = 1.83 (P = 0.07)

















Heterogeneity: Chi² = 14.16, df = 13 (P = 0.36); I² = 8%
Test for overall effect: Z = 12.87 (P < 0.00001)





Test for overall effect: Z = 0.59 (P = 0.56)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 35.58, df = 27 (P = 0.12); I² = 24%
Test for overall effect: Z = 16.65 (P < 0.00001)














































































































































































M-H, Fixed, 95% CI
7.07 [0.36 , 137.40]
6.41 [0.75 , 54.54]
3.82 [2.14 , 6.82]
4.71 [0.18 , 126.90]
7.11 [1.68 , 30.11]
4.30 [2.62 , 7.05]
2.78 [1.52 , 5.06]
1.43 [0.73 , 2.80]
26.42 [3.56 , 195.79]
2.77 [0.87 , 8.76]
2.19 [1.41 , 3.41]
5.26 [0.24 , 113.11]
3.25 [2.60 , 4.07]
3.97 [0.91 , 17.39]
3.97 [0.91 , 17.39]
4.84 [2.46 , 9.54]
3.23 [1.57 , 6.65]
1.62 [0.25 , 10.45]
2.02 [0.95 , 4.29]
6.85 [3.61 , 13.00]
4.89 [0.52 , 46.36]
3.59 [1.12 , 11.57]
6.86 [2.10 , 22.35]
4.96 [3.17 , 7.76]
3.35 [1.81 , 6.20]
8.08 [1.89 , 34.63]
6.40 [1.38 , 29.65]
1.47 [0.40 , 5.50]
13.42 [1.71 , 105.19]
4.37 [3.49 , 5.47]
2.00 [0.20 , 20.09]
2.00 [0.20 , 20.09]
3.79 [3.24 , 4.43]
Odds Ratio
M-H, Fixed, 95% CI
0.001 0.1 1 10 1000
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Analysis 1.16.   (Continued)
Test for subgroup differences: Chi² = 3.64, df = 3 (P = 0.30), I² = 17.6%
Footnotes
(1) New data 2019
 
 







Heterogeneity: Chi² = 0.09, df = 1 (P = 0.77); I² = 0%














Heterogeneity: Chi² = 4.95, df = 9 (P = 0.84); I² = 0%
Test for overall effect: Z = 7.60 (P < 0.00001)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 5.39, df = 11 (P = 0.91); I² = 0%
Test for overall effect: Z = 7.68 (P < 0.00001)




















































































M-H, Fixed, 95% CI
2.60 [0.49 , 13.83]
1.52 [0.06 , 37.37]
2.32 [0.53 , 10.23]
3.29 [1.37 , 7.91]
17.33 [1.04 , 289.44]
10.76 [0.55 , 209.55]
15.28 [2.05 , 114.12]
4.02 [1.80 , 8.98]
3.09 [1.54 , 6.19]
2.69 [1.18 , 6.13]
4.73 [0.59 , 37.87]
4.34 [0.48 , 39.57]
5.08 [0.58 , 44.81]
4.06 [2.83 , 5.82]
3.95 [2.78 , 5.60]
Odds Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favours PDE4i Favours placebo
Footnotes
(1) New data 2019
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Heterogeneity: Chi² = 8.48, df = 11 (P = 0.67); I² = 0%
Test for overall effect: Z = 7.26 (P < 0.00001)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 8.80, df = 12 (P = 0.72); I² = 0%
Test for overall effect: Z = 7.37 (P < 0.00001)

























































































M-H, Fixed, 95% CI
7.07 [0.36 , 137.40]
7.07 [0.36 , 137.40]
2.81 [1.29 , 6.09]
1.78 [0.80 , 3.95]
6.04 [0.66 , 55.30]
3.09 [1.10 , 8.68]
11.29 [0.58 , 218.85]
5.43 [1.15 , 25.68]
5.27 [1.87 , 14.84]
3.97 [1.95 , 8.08]
3.06 [1.20 , 7.79]
1.29 [0.49 , 3.43]
4.34 [0.48 , 39.57]
7.00 [0.35 , 138.35]
3.13 [2.30 , 4.27]
3.17 [2.33 , 4.30]
Odds Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favours PDE4i Favours placebo
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Urban 2018 (ELASTIC) (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 9.92, df = 10 (P = 0.45); I² = 0%
Test for overall effect: Z = 14.00 (P < 0.00001)





Test for overall effect: Z = 1.34 (P = 0.18)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 14.56, df = 11 (P = 0.20); I² = 24%
Test for overall effect: Z = 13.88 (P < 0.00001)




















































































M-H, Fixed, 95% CI
4.21 [0.46 , 38.86]
3.48 [2.24 , 5.41]
4.71 [0.18 , 126.90]
2.83 [1.93 , 4.15]
11.80 [1.51 , 92.28]
4.14 [2.61 , 6.56]
3.51 [2.10 , 5.85]
8.68 [3.39 , 22.19]
10.92 [2.54 , 46.90]
3.43 [2.23 , 5.28]
15.26 [0.83 , 280.72]
3.80 [3.15 , 4.58]
0.12 [0.01 , 2.63]
0.12 [0.01 , 2.63]
3.72 [3.09 , 4.47]
Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
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Analysis 1.20.   Comparison 1: PDE4 inhibitor versus placebo
(2020 update), Outcome 20: Withdrawals due to adverse events
Study or Subgroup



















Heterogeneity: Chi² = 22.10, df = 14 (P = 0.08); I² = 37%
Test for overall effect: Z = 11.34 (P < 0.00001)

















Heterogeneity: Chi² = 11.81, df = 12 (P = 0.46); I² = 0%
Test for overall effect: Z = 7.72 (P < 0.00001)





Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 35.41, df = 28 (P = 0.16); I² = 21%
Test for overall effect: Z = 13.67 (P < 0.00001)






















































































































































































M-H, Fixed, 95% CI
1.53 [0.25 , 9.48]
3.31 [1.30 , 8.39]
1.00 [0.20 , 5.11]
2.11 [1.50 , 2.99]
Not estimable
1.24 [0.52 , 2.95]
0.17 [0.01 , 4.38]
4.59 [2.35 , 8.95]
1.99 [1.23 , 3.24]
1.94 [1.54 , 2.43]
3.12 [1.29 , 7.56]
1.61 [1.18 , 2.18]
1.29 [0.95 , 1.76]
1.86 [1.25 , 2.75]
1.72 [0.97 , 3.05]
2.30 [1.69 , 3.13]
1.90 [1.70 , 2.12]
1.44 [0.94 , 2.21]
1.63 [0.98 , 2.71]
10.76 [0.55 , 209.55]
1.31 [0.84 , 2.04]
3.24 [1.81 , 5.79]
Not estimable
1.86 [0.73 , 4.72]
3.23 [1.51 , 6.91]
2.06 [1.38 , 3.07]
1.88 [1.28 , 2.78]
2.56 [1.14 , 5.73]
1.64 [0.56 , 4.78]
2.00 [0.48 , 8.38]
1.84 [0.74 , 4.60]
1.90 [1.61 , 2.24]
0.79 [0.20 , 3.18]
0.79 [0.20 , 3.18]
1.89 [1.73 , 2.07]
Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours PDE4i Favours placebo
Footnotes
(1) New data added 2019
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Analysis 1.21.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome 21: Headache
Study or Subgroup















Heterogeneity: Chi² = 10.85, df = 11 (P = 0.46); I² = 0%
Test for overall effect: Z = 7.46 (P < 0.00001)





Test for overall effect: Z = 0.02 (P = 0.98)














Heterogeneity: Chi² = 8.82, df = 10 (P = 0.55); I² = 0%
Test for overall effect: Z = 2.69 (P = 0.007)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 29.69, df = 23 (P = 0.16); I² = 23%
Test for overall effect: Z = 7.28 (P < 0.00001)





















































































































































M-H, Fixed, 95% CI
0.74 [0.16 , 3.42]
1.94 [1.14 , 3.32]
1.55 [0.43 , 5.58]
5.12 [0.65 , 40.19]
2.39 [1.64 , 3.49]
7.36 [0.90 , 60.34]
1.52 [0.82 , 2.82]
3.25 [1.45 , 7.24]
2.86 [1.02 , 8.01]
17.14 [0.99 , 298.03]
1.71 [1.18 , 2.47]
5.26 [0.24 , 113.11]
2.13 [1.74 , 2.59]
0.98 [0.24 , 3.99]
0.98 [0.24 , 3.99]
1.32 [0.69 , 2.49]
1.55 [0.83 , 2.89]
6.04 [0.66 , 55.30]
0.71 [0.36 , 1.40]
1.57 [0.98 , 2.51]
1.40 [0.88 , 2.24]
1.63 [0.94 , 2.82]
1.02 [0.30 , 3.45]
1.24 [0.57 , 2.70]
0.67 [0.26 , 1.72]
1.00 [0.34 , 2.96]
1.32 [1.08 , 1.62]
1.69 [1.46 , 1.94]
Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours PDE4i Favours placebo
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Urban 2018 (ELASTIC) (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 0.44, df = 2 (P = 0.80); I² = 0%















Heterogeneity: Chi² = 9.58, df = 10 (P = 0.48); I² = 0%
Test for overall effect: Z = 5.63 (P < 0.00001)





Test for overall effect: Z = 0.03 (P = 0.97)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 11.50, df = 14 (P = 0.65); I² = 0%
Test for overall effect: Z = 6.22 (P < 0.00001)








































































































M-H, Fixed, 95% CI
7.07 [0.36 , 137.40]
2.54 [1.21 , 5.31]
3.08 [0.12 , 77.80]
2.77 [1.38 , 5.56]
1.62 [0.95 , 2.76]
1.83 [0.89 , 3.75]
8.06 [0.40 , 163.21]
3.73 [1.81 , 7.65]
3.54 [0.35 , 35.93]
13.71 [0.76 , 247.65]
1.85 [0.91 , 3.78]
1.38 [0.89 , 2.15]
2.63 [0.93 , 7.44]
1.67 [0.65 , 4.32]
2.80 [0.72 , 10.88]
1.97 [1.55 , 2.49]
0.97 [0.15 , 6.13]
0.97 [0.15 , 6.13]
2.02 [1.62 , 2.52]
Odds Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favours PDE4i Favours placebo
Footnotes
(1) New data added 2019
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Analysis 1.23.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome 23: Influenza-like symptoms
Study or Subgroup










Heterogeneity: Chi² = 8.77, df = 6 (P = 0.19); I² = 32%
Test for overall effect: Z = 0.85 (P = 0.39)





Test for overall effect: Z = 0.55 (P = 0.58)





Heterogeneity: Chi² = 0.55, df = 1 (P = 0.46); I² = 0%
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 9.89, df = 9 (P = 0.36); I² = 9%
Test for overall effect: Z = 0.74 (P = 0.46)















































































M-H, Fixed, 95% CI
7.39 [0.90 , 60.72]
1.10 [0.76 , 1.61]
1.49 [0.81 , 2.73]
0.60 [0.29 , 1.24]
0.82 [0.34 , 1.99]
6.96 [0.36 , 135.26]
1.03 [0.62 , 1.71]
1.11 [0.87 , 1.41]
1.98 [0.18 , 22.00]
1.98 [0.18 , 22.00]
2.15 [0.18 , 25.07]
0.81 [0.40 , 1.67]
0.88 [0.44 , 1.75]
1.09 [0.87 , 1.36]
Odds Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favours PDE4i Favours placebo
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Analysis 1.24.   Comparison 1: PDE4 inhibitor versus placebo
(2020 update), Outcome 24: Upper respiratory tract infection
Study or Subgroup














Heterogeneity: Chi² = 13.93, df = 10 (P = 0.18); I² = 28%
Test for overall effect: Z = 0.96 (P = 0.34)





Heterogeneity: Chi² = 0.17, df = 1 (P = 0.68); I² = 0%
Test for overall effect: Z = 0.76 (P = 0.45)













Heterogeneity: Chi² = 12.11, df = 9 (P = 0.21); I² = 26%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 26.33, df = 22 (P = 0.24); I² = 16%
Test for overall effect: Z = 1.40 (P = 0.16)
















































































































































M-H, Fixed, 95% CI
2.09 [0.77 , 5.69]
0.70 [0.06 , 8.82]
0.98 [0.54 , 1.75]
0.82 [0.42 , 1.62]
0.85 [0.62 , 1.17]
3.26 [1.27 , 8.39]
0.74 [0.38 , 1.43]
0.88 [0.54 , 1.41]
0.46 [0.21 , 1.04]
1.98 [0.36 , 10.90]
0.90 [0.63 , 1.29]
0.92 [0.77 , 1.09]
0.77 [0.42 , 1.42]
0.93 [0.48 , 1.81]
0.84 [0.54 , 1.31]
1.04 [0.66 , 1.63]
1.27 [0.62 , 2.60]
4.64 [0.49 , 44.27]
1.03 [0.41 , 2.59]
1.16 [0.76 , 1.78]
0.80 [0.17 , 3.91]
1.62 [0.51 , 5.20]
0.70 [0.47 , 1.06]
0.46 [0.23 , 0.93]
0.34 [0.07 , 1.71]
0.92 [0.75 , 1.13]
0.91 [0.81 , 1.04]
Odds Ratio
M-H, Fixed, 95% CI
0.02 0.1 1 10 50
Favours PDE4i Favours placebo
Footnotes
(1) New data added 2019
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Analysis 1.25.   Comparison 1: PDE4 inhibitor versus placebo (2020
update), Outcome 25: Psychiatric adverse events (roflumilast)
Study or Subgroup





Test for overall effect: Z = 8.40 (P < 0.00001)





Test for overall effect: Z = 0.65 (P = 0.51)





























M-H, Fixed, 95% CI
2.13 [1.79 , 2.54]
2.13 [1.79 , 2.54]
0.87 [0.56 , 1.33]
0.87 [0.56 , 1.33]
Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours roflumilast Favours placebo
 
 
Analysis 1.26.   Comparison 1: PDE4 inhibitor versus placebo (2020
update), Outcome 26: Anxiety or anxiety disorder (roflumilast)
Study or Subgroup





Test for overall effect: Z = 3.17 (P = 0.002)





Test for overall effect: Z = 0.14 (P = 0.89)





























M-H, Fixed, 95% CI
1.81 [1.26 , 2.62]
1.81 [1.26 , 2.62]
0.94 [0.40 , 2.21]
0.94 [0.40 , 2.21]
Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours roflumilast Favours placebo
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Analysis 1.27.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome 27: Depression (roflumilast)
Study or Subgroup





Test for overall effect: Z = 2.53 (P = 0.01)





Test for overall effect: Z = 1.11 (P = 0.27)





























M-H, Fixed, 95% CI
1.59 [1.11 , 2.27]
1.59 [1.11 , 2.27]
0.56 [0.20 , 1.56]
0.56 [0.20 , 1.56]
Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours roflumilast Favours placebo
 
 
Analysis 1.28.   Comparison 1: PDE4 inhibitor versus placebo (2020
update), Outcome 28: Insomnia and sleep disorders (roflumilast)
Study or Subgroup







Heterogeneity: Chi² = 2.31, df = 3 (P = 0.51); I² = 0%
Test for overall effect: Z = 8.23 (P < 0.00001)





Test for overall effect: Z = 1.26 (P = 0.21)












































M-H, Fixed, 95% CI
2.88 [2.15 , 3.86]
1.96 [1.04 , 3.68]
0.45 [0.02 , 12.06]
2.69 [1.62 , 4.48]
2.67 [2.11 , 3.38]
1.48 [0.81 , 2.70]
1.48 [0.81 , 2.70]
Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours roflumilast Favours placebo
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Analysis 1.29.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome 29: Serious adverse events
Study or Subgroup














Urban 2018 (ELASTIC) (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 31.35, df = 10 (P = 0.0005); I² = 68%
Test for overall effect: Z = 0.43 (P = 0.66)

















Heterogeneity: Chi² = 19.12, df = 13 (P = 0.12); I² = 32%
Test for overall effect: Z = 1.34 (P = 0.18)





Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 54.01, df = 25 (P = 0.0007); I² = 54%
Test for overall effect: Z = 0.25 (P = 0.80)











































































































































































M-H, Fixed, 95% CI
Not estimable
Not estimable
1.67 [0.52 , 5.34]
0.83 [0.68 , 1.01]
Not estimable
0.82 [0.33 , 2.04]
0.52 [0.03 , 8.71]
1.62 [0.77 , 3.41]
1.30 [0.77 , 2.21]
1.03 [0.85 , 1.24]
2.52 [1.69 , 3.77]
0.88 [0.74 , 1.05]
1.13 [0.90 , 1.42]
1.52 [0.54 , 4.29]
1.02 [0.93 , 1.12]
0.45 [0.25 , 0.81]
1.03 [0.52 , 2.03]
2.15 [0.18 , 25.07]
0.61 [0.32 , 1.13]
0.78 [0.41 , 1.48]
3.39 [0.13 , 86.43]
4.23 [0.87 , 20.58]
1.96 [0.96 , 3.98]
0.62 [0.37 , 1.04]
0.95 [0.64 , 1.42]
0.88 [0.25 , 3.09]
0.89 [0.29 , 2.76]
1.94 [0.17 , 21.91]
1.33 [0.29 , 6.11]
0.87 [0.72 , 1.06]
0.60 [0.23 , 1.55]
0.60 [0.23 , 1.55]
0.99 [0.91 , 1.07]
Odds Ratio
M-H, Fixed, 95% CI
0.002 0.1 1 10 500
Favours PDE4i Favours placebo
Footnotes
(1) New study data added 2019
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Urban 2018 (ELASTIC) (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 4.84, df = 9 (P = 0.85); I² = 0%

















Heterogeneity: Chi² = 4.08, df = 5 (P = 0.54); I² = 0%






Test for overall effect: Not applicable
Total (95% CI)
Total events:
Heterogeneity: Chi² = 10.18, df = 15 (P = 0.81); I² = 0%
Test for overall effect: Z = 0.20 (P = 0.84)
























































































































































M-H, Fixed, 95% CI
Not estimable
Not estimable
0.94 [0.48 , 1.84]
Not estimable
1.26 [0.24 , 6.55]
0.70 [0.40 , 1.21]
5.15 [0.25 , 107.91]
0.99 [0.50 , 1.96]
1.03 [0.59 , 1.81]
1.26 [0.34 , 4.70]
4.96 [0.24 , 103.66]
1.20 [0.70 , 2.05]
2.05 [0.18 , 23.59]
1.01 [0.79 , 1.30]
0.50 [0.07 , 3.57]
0.47 [0.07 , 3.39]
Not estimable
3.64 [0.19 , 70.73]
Not estimable
Not estimable
5.00 [0.24 , 105.86]
0.25 [0.02 , 2.76]
Not estimable




0.70 [0.34 , 1.45]
Not estimable
Not estimable
0.98 [0.77 , 1.24]
Odds Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favour PDE4i Favours placebo
Footnotes
(1) New study data added 2019
(2) New data added 2019
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Analysis 1.31.   Comparison 1: PDE4 inhibitor versus placebo
(2020 update), Outcome 31: FEV1 (by mean COPD severity)
Study or Subgroup












Heterogeneity: Chi² = 16.91, df = 9 (P = 0.05); I² = 47%
Test for overall effect: Z = 7.94 (P < 0.00001)














Heterogeneity: Chi² = 28.44, df = 11 (P = 0.003); I² = 61%
Test for overall effect: Z = 15.15 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 45.39, df = 21 (P = 0.002); I² = 54%
Test for overall effect: Z = 17.11 (P < 0.00001)














































































































































































IV, Fixed, 95% CI
20.00 [-90.83 , 130.83]
30.00 [-25.47 , 85.47]
24.00 [1.82 , 46.18]
63.00 [-208.97 , 334.97]
152.00 [-64.35 , 368.35]
88.00 [48.76 , 127.24]
82.00 [8.34 , 155.66]
96.00 [37.74 , 154.26]
49.00 [24.07 , 73.93]
81.00 [47.75 , 114.25]
51.82 [39.03 , 64.60]
40.00 [12.30 , 67.70]
30.00 [-13.84 , 73.84]
160.00 [104.53 , 215.47]
71.00 [46.00 , 96.00]
56.00 [38.26 , 73.74]
13.00 [-120.78 , 146.78]
125.00 [64.96 , 185.04]
42.00 [21.08 , 62.92]
36.00 [5.52 , 66.48]
38.00 [15.86 , 60.14]
58.00 [38.59 , 77.41]
53.00 [40.00 , 66.00]
53.06 [46.19 , 59.92]
52.78 [46.73 , 58.83]
Mean Difference
IV, Fixed, 95% CI
-200 -100 0 100 200
Favours placebo Favours PDE4i
 
 
Analysis 1.32.   Comparison 1: PDE4 inhibitor versus placebo
(2020 update), Outcome 32: FEV1 (roflumilast 500 μg vs 250 μg)
Study or Subgroup





Heterogeneity: Chi² = 0.08, df = 2 (P = 0.96); I² = 0%
Test for overall effect: Z = 1.55 (P = 0.12)
Total (95% CI)
Heterogeneity: Chi² = 0.08, df = 2 (P = 0.96); I² = 0%
Test for overall effect: Z = 1.55 (P = 0.12)






































IV, Fixed, 95% CI
16.00 [-41.71 , 73.71]
15.00 [-192.91 , 222.91]
25.00 [-8.28 , 58.28]
22.61 [-5.95 , 51.16]
22.61 [-5.95 , 51.16]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours 250 µg Favours 500 µg
 
 
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Analysis 1.33.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome 33: FEV1 (by study duration)
Study or Subgroup










Heterogeneity: Chi² = 8.93, df = 7 (P = 0.26); I² = 22%
Test for overall effect: Z = 6.48 (P < 0.00001)















Heterogeneity: Chi² = 28.73, df = 12 (P = 0.004); I² = 58%
Test for overall effect: Z = 11.74 (P < 0.00001)









Heterogeneity: Chi² = 5.11, df = 6 (P = 0.53); I² = 0%
Test for overall effect: Z = 13.03 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 54.59, df = 27 (P = 0.001); I² = 51%
Test for overall effect: Z = 18.39 (P < 0.00001)



























































































































































































































IV, Fixed, 95% CI
20.00 [-90.83 , 130.83]
70.00 [-40.92 , 180.92]
160.00 [104.53 , 215.47]
63.00 [-208.97 , 334.97]
13.00 [-120.78 , 146.78]
152.00 [-64.35 , 368.35]
82.00 [8.34 , 155.66]
96.00 [37.74 , 154.26]
101.71 [70.96 , 132.46]
40.00 [12.30 , 67.70]
30.00 [-13.84 , 73.84]
30.00 [-25.40 , 85.40]
44.00 [30.13 , 57.87]
20.00 [-3.93 , 43.93]
24.00 [1.82 , 46.18]
71.00 [46.00 , 96.00]
52.00 [-9.08 , 113.08]
39.00 [-9.44 , 87.44]
125.00 [64.96 , 185.04]
88.00 [48.76 , 127.24]
49.00 [24.07 , 73.93]
81.00 [47.75 , 114.25]
46.14 [38.44 , 53.84]
34.00 [7.70 , 60.30]
56.00 [38.26 , 73.74]
42.00 [21.08 , 62.92]
36.00 [5.52 , 66.48]
38.00 [15.86 , 60.14]
58.00 [38.59 , 77.41]
53.00 [40.00 , 66.00]
48.77 [41.44 , 56.10]
49.09 [43.86 , 54.32]
Mean Difference
IV, Fixed, 95% CI
-200 -100 0 100 200
Favours placebo Favours PDE4i
Footnotes
(1) Converted L to mL, SDs obtained from imputing participants in each group, mean for each group obtained from difference in mean between roflumilast and placebo and standard error reported in publication
 
 
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Analysis 1.34.   Comparison 1: PDE4 inhibitor versus placebo






Heterogeneity: Chi² = 2.28, df = 1 (P = 0.13); I² = 56%






Heterogeneity: Chi² = 1.28, df = 2 (P = 0.53); I² = 0%
Test for overall effect: Z = 4.93 (P < 0.00001)






















Heterogeneity: Chi² = 43.89, df = 19 (P = 0.0010); I² = 57%
Test for overall effect: Z = 12.35 (P < 0.00001)





Heterogeneity: Chi² = 1.57, df = 2 (P = 0.46); I² = 0%
Test for overall effect: Z = 11.47 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 54.63, df = 27 (P = 0.001); I² = 51%
Test for overall effect: Z = 18.39 (P < 0.00001)






























































































































































































































IV, Fixed, 95% CI
49.00 [24.07 , 73.93]
81.00 [47.75 , 114.25]
60.52 [40.57 , 80.46]
42.00 [21.08 , 62.92]
36.00 [5.52 , 66.48]
82.00 [8.34 , 155.66]
42.26 [25.46 , 59.05]
40.00 [12.30 , 67.70]
30.00 [-13.04 , 73.04]
20.00 [-90.83 , 130.83]
30.00 [-25.40 , 85.40]
44.00 [30.13 , 57.87]
70.00 [-40.92 , 180.92]
20.00 [-3.93 , 43.93]
24.00 [1.82 , 46.18]
34.00 [7.70 , 60.30]
160.00 [104.53 , 215.47]
63.00 [-208.97 , 334.97]
13.00 [-120.78 , 146.78]
52.00 [-9.00 , 113.00]
39.00 [-9.44 , 87.44]
125.00 [64.96 , 185.04]
152.00 [-64.35 , 368.35]
88.00 [48.83 , 127.17]
96.00 [37.74 , 154.26]
38.00 [15.86 , 60.14]
58.00 [38.59 , 77.41]
44.80 [37.69 , 51.91]
71.00 [46.00 , 96.00]
56.00 [38.26 , 73.74]
53.00 [40.00 , 66.00]
56.58 [46.91 , 66.25]
49.08 [43.85 , 54.31]
Mean Difference
IV, Fixed, 95% CI
-200 -100 0 100 200
Favours placebo Favours PDE4i
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Analysis 1.35.   Comparison 1: PDE4 inhibitor versus placebo
































Heterogeneity: Tau² = 207.68; Chi² = 54.82, df = 28 (P = 0.002); I² = 49%
Test for overall effect: Z = 11.72 (P < 0.00001)

























































































































































































































IV, Random, 95% CI
40.00 [12.30 , 67.70]
30.00 [-13.84 , 73.84]
20.00 [-90.83 , 130.83]
30.00 [-25.40 , 85.40]
44.00 [30.13 , 57.87]
70.00 [-40.92 , 180.92]
20.00 [-3.93 , 43.93]
24.00 [1.82 , 46.18]
34.00 [7.70 , 60.30]
160.00 [104.53 , 215.47]
82.00 [-50.84 , 214.84]
71.00 [46.00 , 96.00]
63.00 [-208.97 , 334.97]
56.00 [38.26 , 73.74]
13.00 [-120.78 , 146.78]
52.00 [-9.08 , 113.08]
39.00 [-9.44 , 87.44]
125.00 [64.96 , 185.04]
152.00 [-64.35 , 368.35]
88.00 [48.76 , 127.24]
42.00 [21.08 , 62.92]
36.00 [5.52 , 66.48]
82.00 [8.34 , 155.66]
96.00 [37.74 , 154.26]
38.00 [15.86 , 60.14]
58.00 [38.59 , 77.41]
49.00 [24.07 , 73.93]
81.00 [47.75 , 114.25]
53.00 [40.00 , 66.00]
51.49 [42.87 , 60.10]
Mean Difference
IV, Random, 95% CI
-200 -100 0 100 200
Favours placebo Favours PDE4i
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Analysis 1.36.   Comparison 1: PDE4 inhibitor versus placebo
























Heterogeneity: Chi² = 37.45, df = 19 (P = 0.007); I² = 49%












Heterogeneity: Chi² = 6.15, df = 8 (P = 0.63); I² = 0%
Test for overall effect: Z = 7.34 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 56.53, df = 28 (P = 0.001); I² = 50%
Test for overall effect: Z = 18.47 (P < 0.00001)































































































































































































































IV, Fixed, 95% CI
40.00 [12.30 , 67.70]
20.00 [-90.83 , 130.83]
160.00 [104.53 , 215.47]
71.00 [46.00 , 96.00]
63.00 [-208.97 , 334.97]
56.00 [38.26 , 73.74]
13.00 [-120.78 , 146.78]
52.00 [-9.08 , 113.08]
39.00 [-9.44 , 87.44]
125.00 [64.96 , 185.04]
96.00 [56.76 , 135.24]
42.00 [21.08 , 62.92]
36.00 [5.52 , 66.48]
82.00 [8.34 , 155.66]
96.00 [37.74 , 154.26]
38.00 [15.86 , 60.14]
58.00 [38.59 , 77.41]
49.00 [24.07 , 73.93]
81.00 [47.75 , 114.25]
53.00 [40.00 , 66.00]
55.75 [49.45 , 62.06]
30.00 [-13.84 , 73.84]
30.00 [-25.40 , 85.40]
44.00 [30.13 , 57.87]
70.00 [-40.92 , 180.92]
20.00 [-3.93 , 43.93]
24.00 [1.82 , 46.18]
34.00 [7.70 , 60.30]
82.00 [-50.84 , 214.84]
152.00 [-64.35 , 368.35]
35.05 [25.70 , 44.40]
49.28 [44.05 , 54.51]
Mean Difference
IV, Fixed, 95% CI
-200 -100 0 100 200
Favours placebo Favours PDE4i
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Analysis 1.37.   Comparison 1: PDE4 inhibitor versus placebo (2020
update), Outcome 37: SGRQ total score (by mean COPD severity)
Study or Subgroup





Heterogeneity: Chi² = 0.68, df = 2 (P = 0.71); I² = 0%
Test for overall effect: Z = 2.70 (P = 0.007)







Heterogeneity: Chi² = 14.87, df = 4 (P = 0.005); I² = 73%
Test for overall effect: Z = 2.54 (P = 0.01)
Total (95% CI)
Heterogeneity: Chi² = 15.57, df = 7 (P = 0.03); I² = 55%
Test for overall effect: Z = 3.70 (P = 0.0002)












































































IV, Fixed, 95% CI
-0.40 [-3.58 , 2.78]
-1.90 [-3.57 , -0.23]
-1.70 [-3.66 , 0.26]
-1.62 [-2.80 , -0.44]
-4.10 [-6.18 , -2.02]
0.70 [-1.81 , 3.21]
-3.90 [-7.50 , -0.30]
-6.70 [-17.29 , 3.89]
0.30 [-1.64 , 2.24]
-1.51 [-2.67 , -0.34]
-1.56 [-2.39 , -0.74]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PDE4i Favours placebo
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Analysis 1.38.   Comparison 1: PDE4 inhibitor versus placebo
(2020 update), Outcome 38: SGRQ total score (by duration)
Study or Subgroup




Heterogeneity: Chi² = 0.24, df = 1 (P = 0.62); I² = 0%
Test for overall effect: Z = 2.41 (P = 0.02)









Heterogeneity: Chi² = 13.81, df = 6 (P = 0.03); I² = 57%
Test for overall effect: Z = 3.05 (P = 0.002)




Heterogeneity: Chi² = 0.00, df = 1 (P = 0.95); I² = 0%
Test for overall effect: Z = 0.35 (P = 0.73)
Total (95% CI)
Heterogeneity: Chi² = 20.56, df = 10 (P = 0.02); I² = 51%
Test for overall effect: Z = 2.96 (P = 0.003)




































































































IV, Fixed, 95% CI
-3.90 [-7.50 , -0.30]
-6.70 [-17.29 , 3.89]
-4.19 [-7.60 , -0.78]
-4.10 [-6.18 , -2.02]
0.70 [-1.81 , 3.21]
-0.40 [-3.58 , 2.78]
0.04 [-1.57 , 1.65]
-0.30 [-2.31 , 1.71]
-1.88 [-3.55 , -0.21]
-1.70 [-3.66 , 0.26]
-1.18 [-1.94 , -0.42]
0.20 [-1.95 , 2.35]
0.30 [-1.64 , 2.24]
0.26 [-1.18 , 1.69]
-0.99 [-1.65 , -0.33]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PDE4i Favours placebo
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Analysis 1.39.   Comparison 1: PDE4 inhibitor versus placebo (2020









Heterogeneity: Chi² = 11.22, df = 4 (P = 0.02); I² = 64%









Heterogeneity: Chi² = 4.44, df = 5 (P = 0.49); I² = 0%
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI)
Heterogeneity: Chi² = 20.61, df = 10 (P = 0.02); I² = 51%
Test for overall effect: Z = 2.96 (P = 0.003)

































































































IV, Fixed, 95% CI
-4.10 [-6.18 , -2.02]
-3.90 [-7.50 , -0.30]
-6.70 [-17.29 , 3.89]
-1.70 [-3.66 , 0.26]
0.30 [-1.64 , 2.24]
-1.98 [-3.07 , -0.89]
0.70 [-1.81 , 3.21]
-0.40 [-3.58 , 2.78]
0.04 [-1.57 , 1.65]
-0.30 [-2.31 , 1.71]
-1.90 [-3.57 , -0.23]
0.20 [-1.95 , 2.35]
-0.43 [-1.26 , 0.40]
-1.00 [-1.65 , -0.34]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PDE4i Favours placebo
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Analysis 1.40.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome 40:








Heterogeneity: Chi² = 1.48, df = 2 (P = 0.48); I² = 0%

















Heterogeneity: Chi² = 5.59, df = 6 (P = 0.47); I² = 0%
Test for overall effect: Z = 2.89 (P = 0.004)







Heterogeneity: Chi² = 2.66, df = 3 (P = 0.45); I² = 0%
Test for overall effect: Z = 3.55 (P = 0.0004)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 11.23, df = 14 (P = 0.67); I² = 0%
Test for overall effect: Z = 5.98 (P < 0.00001)













































































































M-H, Fixed, 95% CI
0.64 [0.22 , 1.89]
0.61 [0.44 , 0.84]
0.83 [0.56 , 1.22]
0.69 [0.54 , 0.88]
0.81 [0.70 , 0.95]
0.81 [0.70 , 0.95]
0.74 [0.39 , 1.41]
0.50 [0.09 , 2.68]
1.53 [0.79 , 2.96]
0.74 [0.55 , 1.01]
0.97 [0.52 , 1.81]
0.82 [0.59 , 1.15]
0.69 [0.51 , 0.93]
0.79 [0.67 , 0.93]
0.69 [0.21 , 2.30]
1.74 [0.68 , 4.49]
0.80 [0.67 , 0.96]
0.80 [0.68 , 0.94]
0.81 [0.72 , 0.91]
0.79 [0.73 , 0.85]
Odds Ratio
M-H, Fixed, 95% CI
0.5 0.7 1 1.5 2
Favours PDE4i Favours placebo
Footnotes
(1) New study data added 2019
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Analysis 1.41.   Comparison 1: PDE4 inhibitor versus placebo (2020





Test for overall effect: Z = 3.79 (P = 0.0002)





















IV, Fixed, 95% CI
0.52 [0.25 , 0.79]
0.52 [0.25 , 0.79]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours Placebo Favours Roflumilast
 
 
Analysis 1.42.   Comparison 1: PDE4 inhibitor versus placebo





Test for overall effect: Z = 1.21 (P = 0.23)





















IV, Fixed, 95% CI
82.00 [-50.84 , 214.84]
82.00 [-50.84 , 214.84]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours placebo Favours roflumilast
 
 
Analysis 1.43.   Comparison 1: PDE4 inhibitor versus placebo





Test for overall effect: Z = 3.79 (P = 0.0002)





















IV, Fixed, 95% CI
0.52 [0.25 , 0.79]
0.52 [0.25 , 0.79]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours placebo Favours roflumilast
Footnotes
(1) Roflumilast 500 µg, duration 12 weeks
 
 
Analysis 1.44.   Comparison 1: PDE4 inhibitor versus placebo (2020





Test for overall effect: Z = 7.10 (P < 0.00001)





















IV, Random, 95% CI
0.43 [0.31 , 0.55]
0.43 [0.31 , 0.55]
Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours placebo Favours roflumilast
Footnotes
(1) Roflumilast 500 µg
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Analysis 1.45.   Comparison 1: PDE4 inhibitor versus placebo (2020 update),





Test for overall effect: Z = 3.79 (P = 0.0002)





















IV, Fixed, 95% CI
0.52 [0.25 , 0.79]
0.52 [0.25 , 0.79]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours placebo Favours roflumilast
Footnotes
(1) Roflumilast 500 µg, duration 12 weeks
 
 
Analysis 1.46.   Comparison 1: PDE4 inhibitor versus placebo





Test for overall effect: Z = 7.10 (P < 0.00001)





















IV, Fixed, 95% CI
0.43 [0.31 , 0.55]
0.43 [0.31 , 0.55]
Mean Difference
IV, Fixed, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours Placebo Favours Roflumilast
 
 
Analysis 1.47.   Comparison 1: PDE4 inhibitor versus placebo (2020 update),





Test for overall effect: Z = 3.79 (P = 0.0002)





















IV, Fixed, 95% CI
0.52 [0.25 , 0.79]
0.52 [0.25 , 0.79]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours placebo Favours roflumilast
Footnotes
(1) Roflumilast 500 µg only
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Test for overall effect: Z = 3.79 (P = 0.0002)





















IV, Fixed, 95% CI
0.52 [0.25 , 0.79]
0.52 [0.25 , 0.79]
Mean Difference
IV, Fixed, 95% CI
-200 -100 0 100 200
Favours placebo Favours PDE4i
Footnotes
(1) Roflumilast 500 µg, duration 12 weeks
 
 
Analysis 1.49.   Comparison 1: PDE4 inhibitor versus placebo (2020
update), Outcome 49: FEV1 (roflumilast 500 μg by mean COPD severity)
Study or Subgroup









Heterogeneity: Chi² = 5.38, df = 6 (P = 0.50); I² = 0%
Test for overall effect: Z = 8.30 (P < 0.00001)











Heterogeneity: Chi² = 12.24, df = 8 (P = 0.14); I² = 35%
Test for overall effect: Z = 14.28 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 21.07, df = 15 (P = 0.13); I² = 29%
Test for overall effect: Z = 16.41 (P < 0.00001)




































































































































IV, Fixed, 95% CI
63.00 [-208.97 , 334.97]
152.00 [-64.35 , 368.35]
88.00 [48.76 , 127.24]
82.00 [8.34 , 155.66]
96.00 [37.74 , 154.26]
49.00 [24.07 , 73.93]
81.00 [47.75 , 114.25]
69.83 [53.34 , 86.33]
71.00 [46.00 , 96.00]
56.00 [38.26 , 73.74]
13.00 [-120.78 , 146.78]
125.00 [64.96 , 185.04]
42.00 [21.08 , 62.92]
36.00 [5.52 , 66.48]
38.00 [15.86 , 60.14]
58.00 [38.59 , 77.41]
53.00 [40.00 , 66.00]
52.75 [45.52 , 59.99]
55.51 [48.88 , 62.14]
Mean Difference
IV, Fixed, 95% CI
-200 -100 0 100 200
Favours placebo Favours PDE4i
 
 
Analysis 1.50.   Comparison 1: PDE4 inhibitor versus placebo (2020





Test for overall effect: Z = 1.21 (P = 0.23)





















IV, Fixed, 95% CI
82.00 [-50.84 , 214.84]
82.00 [-50.84 , 214.84]
Mean Difference
IV, Fixed, 95% CI
-500 -250 0 250 500
Favours placebo Favours PDE4i
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Analysis 1.51.   Comparison 1: PDE4 inhibitor versus placebo (2020 update), Outcome





Test for overall effect: Z = 3.79 (P = 0.0002)





















IV, Fixed, 95% CI
0.52 [0.25 , 0.79]
0.52 [0.25 , 0.79]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours placebo Favours roflumilast
Footnotes
(1) Roflumilast 500 µg, duration 12 weeks
 
 
Analysis 1.52.   Comparison 1: PDE4 inhibitor versus placebo (2020 update),





Test for overall effect: Z = 1.21 (P = 0.23)





















IV, Fixed, 95% CI
82.00 [-50.84 , 214.84]
82.00 [-50.84 , 214.84]
Mean Difference
IV, Fixed, 95% CI
-500 -250 0 250 500
Favours placebo Favours roflumilast
 
 
A D D I T I O N A L   T A B L E S
 







Table 1.   Number of references for which we sought full text 
 
 
Study ID Percentage reduction
(treatment vs placebo)
Rate ratio (95% CI) P value
Cilomilast 039 45 - 0.001
Table 2.   Studies reporting severe exacerbation rates per patient per year 
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RO-2455-404-RD (REACT) 24.3 0.757 (0.601 to 0.952) 0.0175
Roflumilast M2-124+M2-125 17 0.82 (0.63 to 1.06) 0.163
Roflumilast ROF-MD-07(RE2SPOND) 8.5 0.95 (0.75 to 1.19) 0.635
Table 2.   Studies reporting severe exacerbation rates per patient per year  (Continued)
 
 
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Trials Register
Electronic searches: core databases
 
Database Frequency of search
CENTRAL (The Cochrane Library) Monthly
MEDLINE (Ovid SP) ALL Weekly
Embase (Ovid SP) Weekly





Handsearches: core respiratory conference abstracts
 
Conference Years searched
American Academy of Allergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International Primary Care Respiratory Group Congress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
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MEDLINE search strategy used to identify trials for the Cochrane Airways Trials Register
COPD  search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.






Filter to identify RCTs
1. exp "clinical trial [publication type]"/









11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
Appendix 2. Search strategy to identify relevant trials from the Cochrane Airways Trials Register
#1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All
#2 MeSH DESCRIPTOR Bronchitis, Chronic
#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#4 COPD:MISC1
#5 (COPD OR COAD OR COBD):TI,AB,KW
#6 #1 OR #2 OR #3 OR #4 OR #5
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#22 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21
#23 #6 and #22
Appendix 3. Airways Group Trials Register search strategy (sensitive search)
PDE* or phosphodiesterase* or isoenzyme* or theophylline or rolipram or pentoxifylline or papaverine or milrinone or etazolate or
etazolate or dyphylline or dipyridamole or caKeine or amrinone or aminophylline or isobutylxanthine or cilomilast or ariflo or cilostazol
or enoximone or milrinone or olprinone or roflumilast or sb207499 or zardaverine or cilostamide or enoximone or trequinsin or Telomilast
or IC485 or Oglemilast or QAK423 or GRC-3886 or Arofylline or AWD12-281
W H A T ' S   N E W
 
Date Event Description
9 March 2020 New citation required but conclusions
have not changed
The 2020 update of this review includes 4 new trials of roflumi-
last - Kavitha 2018; Liu 2018; RO-2455-402-RD (ROBERT); Urban
2018 (ELASTIC) - and 1 new trial of tetomilast - NCT00874497
(EMPHASIS). Two new review authors (SJ and RF) were added,
and 2 review authors (JC and BL) stepped down
9 March 2020 New search has been performed Literature search was run
 
H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 5, 2011
 
Date Event Description
11 October 2016 New search has been performed New literature search was run
11 October 2016 New citation required but conclusions
have not changed
Five new eligible studies of roflumilast 500 μg were included
- RO-2455-301-RD (ACROSS); RO-2455-404-RD (REACT); Roflu-
milast DAL-MD-01; Roflumilast FLUI-2011-77; Roflumilast ROF-
MD-07(RE2SPOND). No substantive changes were made to re-
view findings
17 December 2013 Amended Typo in plain language summary title was amended
4 November 2013 Amended Risk of bias for Cilomilast 076 was added
6 June 2013 New search has been performed New literature search was run
6 June 2013 New citation required and conclusions
have changed
We included 7 new studies in this update and excluded 1 cross-
over trial. FDA report on psychiatric adverse events and suicides
was included
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Date Event Description
Text was revised to take account of Cochrane reporting stan-
dards
'Summary of findings' table was added
 
C O N T R I B U T I O N S   O F   A U T H O R S
Phillippa Poole: protocol initiation and development, checking of content of current update, corresponding author.
Sadia Janjua: screening, data extraction, risk of bias assessment, and write-up of the 2020 review update.
Rebecca Fortescue: data extraction and risk of bias assessment.
Contributions of editorial team
Chris Cates (Co-ordinating Editor): checked data entry before the full write-up of the review, edited the protocol, advised on methods, and
approved the updated review prior to publication.
Emma Dennett (Managing Editor): co-ordinated the editorial process, advised on interpretation and content, and edited the review.
Emma Jackson (Assistant Managing Editor): conducted peer review and edited various sections and references in the protocol and in the
review.
Elizabeth Stovold (Information Specialist): designed the search strategy, ran the searches, and edited the search methods section.
D E C L A R A T I O N S   O F   I N T E R E S T
Phillippa Poole: none known.
Sadia Janjua is funded full-time as a systematic reviewer by a National Institute for Health Research (NIHR) Programme Grant to complete
work on this review.
Rebecca Fortescue is Co-ordinating Editor for Cochrane Airways.
S O U R C E S   O F   S U P P O R T
Internal sources
• University of Auckland provided salary support for Professor Phillippa Poole, New Zealand
External sources
• The authors declare that no such funding was received for this systematic review, Other
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We added the comparison between published and unpublished results when we discovered the large number of unpublished studies but
before we extracted data from the studies and carried out the analysis.
We excluded cross-over trials, as carry-over eKects and disease progression cannot be adequately controlled for in people with COPD.
We updated the methods section in accordance with MECIR standards.
We separated mortality from non-fatal serious adverse events in the methods section for clarity of presentation in the 'Summary of findings'
table and in other sections of the review.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Administration, Oral;  Aminopyridines  [*administration & dosage]  [adverse eKects];  Benzamides  [*administration & dosage]  [adverse
eKects];  Cyclohexanecarboxylic Acids  [*administration & dosage]  [adverse eKects];  Cyclopropanes  [administration & dosage]
 [adverse eKects];  Disease Progression;  Forced Expiratory Volume  [drug eKects];  Nitriles  [*administration & dosage]  [adverse eKects]; 
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Phosphodiesterase 4 Inhibitors  [*administration & dosage]  [adverse eKects];  Pulmonary Disease, Chronic Obstructive  [*drug therapy]; 
Quality of Life;  Randomized Controlled Trials as Topic
MeSH check words
Humans
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